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Summary 
Orally disintegrating Tablets (ODTs), also known as fast-disintegrating, fast-melt or fast-dissolving 
tablets, are a relatively novel dosage technology that involves the rapid disintegration or dissolution of the 
dosage form into a solution or suspension in the mouth without the need for water. The solution 
containing the active ingredients is swallowed, and the active ingredients are then absorbed through the 
gastrointestinal epithelium to reach the target and produce the desired effect. Formulation of ODTs was 
originally developed to address swallowing difficulties of conventional solid oral dosage forms (tablets 
and capsules) experienced by wide range of patient population, especially children and elderly. 
  
The current work investigates the formulation and development of ODTs prepared by freeze drying.  
Initial studies focused on formulation parameters that influence the manufacturing process and 
performance of lyophilised tablets based on excipients used in commercial products (gelatin and 
saccharides). The second phase of the work was followed up by comprehensive studies to address the 
essential need to create saccharide free ODTs using naturally accruing amino acids individually or in 
combinations. Furthermore, a factorial design study was carried out to investigate the feasibility of 
delivering multiparticulate systems of challenging drugs using a novel formulation that exploited the 
electrostatic associative interaction between gelatin and carrageenan. Finally, studies aimed to replace 
gelatin with ethically and morally accepted components to the end users were performed and the selected 
binder was used in factorial design studies to investigate and optimise ODT formulations that 
incorporated drugs with varies physicochemical properties. 
 
Our results show that formulation of elegant lyophilised ODTs with instant disintegration and adequate 
mechanical strength requires carful optimisation of gelatin concentration and bloom strength in addition 
to saccharide type and concentration. Successful formulation of saccharides free lyophilised ODTs 
requires amino acids that crystallise in the frozen state or display relatively high Tg', interact and integrate 
completely with the binder and, also, display short wetting time with the disintegrating medium.  
The use of an optimised mixture of gelatin, carrageenan and alanine was able to create viscous solutions 
to suspend multiparticulate systems and at the same time provide tablets with short disintegration times 
and adequate mechanical properties. On the other hand, gum arabic showed an outstanding potential for 
use as a binder in the formulation of lyophilised ODTs. Compared to gelatin formulations, the use of gum 
arabic simplified the formulation stages, shortened the freeze drying cycles and produced tablets with 
superior performance in terms of the disintegration time and mechanical strength. Furthermore, 
formulation of lyophilised ODTs based on gum arabic showed capability to deliver diverse range of drugs 
with advantages over commercial products.  
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Introduction   
 
1.1. Project scope and significance 
The gastro intestinal tract (GIT) is a highly specialized system in the body that is involved in 
secretion, digestion and absorption. All food nutrients required by the body must be ingested 
orally, processed by the GIT and absorbed into the bloodstream. Also, the GIT is responsible 
for preventing noxious materials from causing local irritation or systemic toxicity. Therefore 
the unique GIT physiology creates many barriers that face the systemic delivery of drug 
molecules. The major barriers include the presence of degradative enzymes and extreme pH 
conditions throughout the GIT, absorption efflux mechanisms (such as P-glycoprotein), first 
pass metabolism (hepatic), in addition to a number of hydrophilic/ lipophilic barriers. To 
address these barriers, while improving patient compliance, researchers have developed oral 
dosage forms (delivery systems) by combining drugs (active ingredients) with a variety of inert 
substances (excipients). Suitable oral delivery systems can be designed, depending on the 
physicochemical and pharmacokinetics characteristics of drugs, to provide control and 
accuracy of dosing, elegancy and stability in shelf and GIT, and to improve the dissolution and 
absorption profile of the drugs. Traditionally, oral delivery systems refer to tablets, capsules, 
solutions and suspensions that administered orally, swallowed and then transiting the 
gastrointestinal tract (GIT) to achieve the required drug release and absorption.   
Despite phenomenal advances in the injectable, inhalable, transdermal, nasal, and other 
delivery systems, the oral route is still considered the most preferable for both patients and 
industry. Being natural, noninvasive, and safe method of drug delivery, oral delivery is, always, 
associated with high degree of patient compliance (Li and Robinson, 1987; Sastry et al., 1997; 
Fasano, 1998). On the other hand, oral delivery systems are able to accommodate various 
physicochemical properties of drugs, do not require strict sterile conditions and, therefore, less 
expensive to manufacture. Thus, even small improvements in oral drug delivery technology 
can make significant difference in enhancing patient compliance and drug delivery fields in 
general. Over the past decades, several novel technologies for oral delivery have been 
developed, examples include; oral rapid disintegrating (dissolving) tablets (segar, 1998), 
mucoadhesive buccal dosage forms (Poertero et al., 2006), site specific drug delivery (Liu et al 
2003) and novel controlled release dosage forms (Dashevsky et al., 2004; Liu and Xu, 2007). 
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The launch of new technologies has expanded the market of oral drug delivery product 
significantly to generate $35 billion sales in 2004 with an expected annual growth of 10%. The 
main driver of this market growth is the rapid dissolve dosage forms and OTC market segment 
(Ghosh and Pfister, 2005). The worldwide market of rapid dissolved products was estimated of 
about $ 1.4 billion in 2005 (IMS data) (Muir, 2007).  
Oral rapid disintegrating (dissolve) tablets (ODTs) are solid dosage forms that are placed in the 
mouth, rapidly disintegrate/dissolve when in contact with the saliva and then easily swallowed 
without the need for water (European pharmacopoeia, 2002). The basic idea behind the ODTs 
is to combine the benefit of solid (stable and easy to handle) and liquid (ingestible) oral dosage 
forms. ODTs provide practical solution for wide range of people who experience difficulty in 
swallowing (dysphasia). This includes paediatric and geriatric patients, as well as hospitalised 
or bedridden patients suffering from a variety of disorders like stroke, thyroid disorders, 
Parkinson’s disease and other neurological disorders like multiple sclerosis and cerebral palsy 
(Sastry et al., 2000). It is estimated that 50% of the population is affected by this problem, 
which results in a high incidence of non-compliance and ineffective therapy (Segar, 1998). The 
convenience and ease of using ODTs is also important with normal consumers (Jeong and Park, 
2008), as it offers convenient and practical dosage all the time especially in case of no access 
to water (Mizumoto et al., 2005). In addition to improving patient compliance, ODTs have been 
investigated for their potential in increasing the bioavailability of poorly water soluble drug, 
through enhancing the dissolution profile of the drug (Corveleyn and Remon., 1998; Ahmed 
and Aboul-Einien, 2007), and providing rapid onset of action, by avoiding the need for gastric 
disintegration and facilitating pre-gastric absorption (through the buccal and oesophageal 
mucosa) (Segar, 1998). Moreover, pharmaceutical companies also have commercial reasons 
for formulating ODTs. As a drug reaches the end of its patent, the development and 
formulation of the drug into new dosage forms allows pharmaceutical companies to extend 
the patent life and market exclusivity (Biradar et al., 2006). 
 
1.2. Recent patents and trends in the formulation of ODTs  
Patent databases are among the most important and up-to-date sources of technological 
information as every patent must contain an element of novelty. Hence, analysing and 
summarising patents of ODTs in one article is extremely important in building an overall 
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picture of latest developments and achievements in this field, which will be helpful for the art 
specialists and pharmaceutical companies who are interested in developing and patenting new 
technologies in ODTs. Accordingly, this article will present a review of recent advances in ODT 
formulations that have been patented over the last decade. The analysis of the patent 
documents has been carried out by searching in the free online patent worldwide database 
(http://www.freepatentsonline.com) of granted patents in orally disintegrating tablets and 
related fields. The manufacturing steps in addition to the excipients and active ingredients 
used in each patents were summarised in tables, whereas the motivations, major claims, 
inventive steps and significances were highlighted in the text according to the manufacturing 
approach. 
Searching in the free online patent worldwide database (http://www.freepatentsonline.com) 
for ODTs patents resulted in finding 81 published patents over the period from 1999 to 
2010.Quantitative analysis of these patents revealed various technologies that have been 
applied to manufacture ODTs namely compression based technologies, freeze drying, 
moulding, tablet loading and pulverisation. Figure 1.1 shows the percentage of each approach 
from the total number of the analysed patents. Direct compression technologies have been 
most widely used over this period, and up to 85% of the filed patents utilised direct 
compression to manufacture ODTs. On the other hand, moulding technologies accounted for 
9% in manufacturing ODTs, 4% for freeze drying, whilst only 2% of patents utilised tablet 
loading and pulverisation technologies.   
Applications were filed from different countries including Japan, India, Canada, Great Britain, 
France, Belgium, Netherlands, Italy, Denmark, Germany, Korea, Portugal and USA. From the 81 
patents studied, USA and Canada contributed the most (up to 44%) followed by Asia (37%) and 
Europe (19%), See Figure 1.2.  
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Figure 1.1 Various technologies used in manufacturing ODTs in the period 1999 to 2010.  
 
Trend analysis of the number of patents published in each year was evaluated as well. Figure 
1.3 shows that only 2 patents were published in 1999 and the number of applications started 
to increase steadily between 2001 and 2007. Despite a minor decline in 2008 the following 
year (2009) witnessed the highest number of patent applications over the decade with up to 
15 published patents in this year, which represents 18.5% of the total number of patents 
analysed. It is interesting to note that within the first quarter of the current year (2010) three 
patents were already published, indicating that this year might witness a high number of patents to be 
released. 
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Figure 1.2 Geographical distribution of ODTs patents between 1999 & 2010. 
 
 
 
 
Figure 1.3 Number of patent applications filed in the period between 1999 to 2010. 
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1.2.1. Conventional tablet press  
Manufacturing of ODTs using conventional tableting and packaging equipments is the simplest 
and most cost effective among other available techniques. Analysis of recent patents of ODTs 
produced by conventional tablet press methods, as shown in Tables 1.1, 1.2 and 1.3, revealed 
that the inventions were driven by two major motivations. Firstly, the need of innovative 
formulation strategies to modify the standard tableting procedure to provide tablets which 
disintegrate rapidly in the mouth with pleasant mouth feel and adequate mechanical 
properties. The second motivation is to extend the application of ODTs to more challenging 
drugs by overcoming some restrictions imposed by the nature of these drugs, such as their 
unpleasant taste, gastric acid sensitivity and instability during or after the manufacturing 
process, which limits their formulation in ODT dosage forms. Accordingly, the patents are 
discussed in detail below, based on the motivation of the invention and the employed 
formulation strategy. 
 
1.2.1.1. Direct compression 
Table 1.1 summarises patents that formulate ODTs by lightly compressing mixtures of active 
ingredients and excipients into tablets. These patents were based on using appropriate 
combinations of carefully selected excipients as the main components, without the need of 
further processing. The selected excipients provide rapid disintegration profile, pleasant 
mouth feel and adequate physical strength. All patents on direct compression have stated the 
necessity to use one or combinations of disintegrants to achieve fast disintegration with most 
of the work was dictated to the use of superdisintegrants which swell in contact with water 
and hence force the tablet to disintegrate. Sugars or sugar alcohols have been reported almost 
in all patents based on direct compression as they are highly water-soluble excipients which, in 
addition to their sweet taste, enhance the wettability of the tablet with water and 
consequently facilitates the disintegration (Chandrasekhar et al., 2009). 
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Table 1.1 Summary of patents that produced ODTs by direct compression. 
Patent no. Manufacturing Steps Excipients Drug Comments Reference 
1 Involves; mixing the ingredients 
and meloxicam for 30 mins, 
followed by the addition of the 
lubricant. Blending again for 5 
minutes then compression to form 
the tablets. 
- Starch (20-50% w/w). 
- Glidants. 
- Water soluble excipient 
(40-80%) (ex. lactose). 
Meloxicam or its 
pharmaceutically 
acceptable salts, such as 
meglumin, sodium, or 
potassium (1-25 mg/tablet). 
Other auxiliary agents such as 
lubricants, sweeteners, souring and 
flavouring agents could be added. 
Ohki et al., 
2004 
2 Involves; blending the active drug 
with excipients. Mixing the 
lubricant with the blend. And 
finally compression to form the 
tablets. 
- Fillers (calcium sulfates). 
- Carbohydrates (Mannitol). 
- Starch clays (kaolin). 
- PEG (10-95% w/w). 
Cox-2 inhibitors such as 
celecoxib and rofecixib. 
Other conventional techniques 
such as wet, dry granulation and 
specialized techniques could be 
used but direct compression is used 
herein because of low cost. 
Murpani et 
al., 2003 
3 Involves; mixing of the ingredients, 
followed by direct compression to 
form the tablets. 
- Soluble excipients (ex. 
sugar alcohol). 
- Lubricants. 
- Surfactants. 
- Liquefying solids (low 
melting point glycerides). 
Poorly bioavailable drugs 
which degrade by enzymes 
or acid upon passing 
through GIT (ex. estrogens, 
progestins). 
Very fast delivery of drugs giving 
blood levels similar to parenteral 
administration. 
McCarty, 
1999 
4 Involves; sieving & mixing of all 
components (apart from the 
lubricant). Followed by direct 
compression to form the tablets.  
- Spray dried mannitol. 
- Microcrystalline cellulose. 
- Humidity absorbing agents 
(syloid
®
) 0.1-0.5%. 
- Disintegration promoter 
(14-18.5%). 
 Spray dried mannitol is used 
because it is highly soluble in water, 
highly compressible, high dilution 
capacities and chemically stable. 
Ferran, 
2006 
5 Involves; blending a mixture of a 
drug and excipients. Followed by 
compression to form the tablets. 
- Binder (ex. starch). 
-Water-soluble excipient 
(ex. mannitol or lactose). 
Any active ingredient or 
medicament. 
A tablet preparation showing good 
sensory acceptability and yet 
having an adequate strength. 
Nishii et al., 
2003 
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6 Involves; mixing the drug with 
excipients. 
Followed by direct compression to 
form the tablets. 
- Calcium carbonate 
(disintegrating agent and 
dental abrasive). 
- Sugar alcohol (ex. 
mannitol). 
Therapeutic agents used for 
the prevention and 
treatment of dental caries 
and periodontal disease. 
Friability of less than about 2% and 
disintegrates in less than about 60 
seconds when immersed in water. 
Withiam et 
al., 2005 
7 Involves; mixing all formulation 
ingredients using a blender, adding 
the lubricant to the powder 
mixture, and finally 
direct compression to form the 
tablets. 
- Titanium dioxide (water 
insoluble substance). 
- Sugar alcohol (ex. 
mannitol). 
- Superdisintegrant (ex. 
sodium starch glycolate). 
Wide range of drugs 
suitable for ODT 
formulation. 
The inclusion of titanium dioxide 
has dual functionality: 
Enabling rapid tablet disintegration, 
and 
providing tooth cleaning effect. 
Mehra et 
al., 2005 
8 Involves; dry mixing all formulation 
ingredients using a blender, adding 
the lubricant to the powder 
mixture, and finally 
direct compression to form the 
tablets. 
- Filler (ex. microcrystalline 
cellulose). 
- Disintegrant (ex. low 
substituted hydroxypropyl- 
cellulose). 
 
Epinephrine The tablets are designed for buccal 
or sublingual absorption. 
Rawas-
Qalaji et al., 
2007 
9 Involves; mixing the compression 
blend, adding microcapsules and 
mixing. Followed by the addition of 
the lubricant to the final mixture, 
and finally 
compressing into tablets. 
- Disintegrants (ex. starch). - 
Water insoluble inorganic 
excipient (ex. dibasic 
calcium phosphate). 
- Water-soluble filler (ex. 
lactose). 
- Surfactants. 
Wide range of drugs 
suitable for ODT 
formulation. 
Orally disintegrating tablets of 
microcapsules. 
Dobetti, 
2003 
10 Involves; mixing the drug with the 
compression blend. Followed by 
the addition of a lubricant, and 
finally compressing into tablets. 
- Disintegrants (ex. 
crospovidone). 
- Sugar alcohol (ex. 
mannitol). 
- Hydrophilic polymer (ex. 
Ondansetron  Ahmed et 
al., 2008 
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microcrystalline cellulose). 
11 Involves; mixing the drug with 
excipients. Followed by direct 
compression to form the tablets. 
- Low surface area silica 
material (ex. Zeo
®
 49). 
- Sugar alcohol (ex. 
mannitol). 
Pharmaceutical, 
nutraceutical or oral care 
active ingredients. 
The inclusion of a low surface area 
silica material encourages quick 
disintegration in the oral cavity. 
Withiam et 
al., 2007a 
12 Involves; mixing the drug with 
excipients. Followed by direct 
compression to form the tablets. 
- Low surface area titanium 
dioxide.  
- Sugar alcohol (ex. 
mannitol). 
- Disintegrant (ex. 
crospovidone). 
Pharmaceutical, 
nutraceutical or oral care 
active ingredients. 
The inclusion of a low surface area 
silica material encourages quick 
disintegration in the oral cavity. 
Withiam et 
al., 2007b 
13 Involves; mixing the drug with 
excipients. Followed by direct 
compression to form the tablets. 
- Low surface area calcium 
carbonate. 
- Sugar alcohol (ex. 
mannitol). 
- Disintegrant (ex. 
crospovidone). 
Pharmaceutical, 
nutraceutical or oral care 
active ingredients. 
The inclusion of a low surface area 
silica material encourages quick 
disintegration in the oral cavity. 
Withiam et 
al., 2007c 
14 Involves; blending the active 
ingredients with the excipients. 
Followed by direct compression to 
form the tablets. 
- Silicified microcrystalline 
cellulose. 
- Sweetening agent, 
flavouring agents, glidants. 
Antibiotics (ex. amoxicillin 
alone or in combination 
with clavulonic acid). 
 
Silicified microcrystalline cellulose 
allows the manufacture of high 
dose of amoxicillin/ clavulonic acid. 
Skulji et al., 
2006 
15 Involves; separate mixing of two 
compressible mixtures. Followed 
by pre-compression of one 
mixture, and finally 
compressing of at least two layers. 
- Binders (ex. PEG 8000). 
- Other inactive excipients 
(salivating agents, 
surfactants, super-
disintegrants, and bulking 
agents). 
Any drug which can be 
incorporated into the multi-
layered ODT. 
Multi-layered ODT (designed to 
avoid the limitations of mono-
layered ODT associated with 
storage and handling). 
Cherukuri, 
2008 
16 Involves; direct compression or 
granulating a mixture of a drug and 
excipients. Followed by 
- Bitterness-reducing 
ingredient composed of an 
essential oil (ex. mint oil). 
Bitter tasting drugs, namely 
Acetaminophen. 
A tablet exhibiting little bitterness, 
when a bitter-tasting drug is 
comprised in the tablet. 
Ohmri et al., 
2003 
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compression to form the tablets. 
 
- High sweetness-sweetener 
(ex. stevia or aspartame). 
- Acidic phospholipid (ex. 
soybean lecithin). 
17 Involves; dry blending; of the drug, 
carrier, disintegrant, and lubricant. 
Followed by direct compression to 
form the tablets. 
- Carrier: spray dried 
mixture of lactose 
monohydrate and 
microcrystalline cellulose. 
Galanthamine 
hydrobromide 
 Gilis and De 
Conde, 
2002 
 
 
Chapter 1 – Introduction   
35 
 
In addition to these two main mechanisms, some patents add another factor to promote the 
disintegration by inclusion of water insoluble excipients, such as microcrystalline cellulose 
(Ferran, 2006; Rawas-Qalaji et al., 2007; Ahmed et al., 2008) dibasic calcium phosphate 
(Dobetti, 2003) and titanium dioxide (Mehra et al., 2005), to generate repulsive forces with the 
readily soluble materials inside the tablet (Fukami et al., 2005). Humidity absorbing agents 
(permeabilizing agents) such as Syloid® have been used in directly compressed ODT to 
promote the disintegration by forming hydrophilic networks inside the tablet and hence 
facilitate saliva penetration (Ferran, 2006).  Also, low surface area materials such as silica 
(Withiam et al., 2007a), titanium dioxide (Withiam et al., 2007b) and calcium carbonate 
(Withiam et al., 2007c) have been disclosed in patents to promote the quick disintegration 
properties of directly compressed ODTs. These materials must exhibit sufficiently low surface 
areas in order to improve the ability of the tablets to disintegrate quickly when placed in the 
oral cavity.  
In distinction to the commonsensical use of superdisintegrants and saccharides as essential 
components to facilitate the rapid disintegration of directly compressed ODTs, Skulj et al 
(2006) used silicifed microcrystalline cellulose as a single component that can be mixed with 
high doses of active drugs and directly compressed the mixture into ODTs, suggesting that 
silicifed microcrystalline cellulose has multiple roles in the formulation, as a disintegrant, 
wicking agent, binder and filler (Skulji et al., 2006). 
Other standard excipients are also included in all the patents to enhance the formulation 
process and the taste such as diluents, lubricants, glidants, binders, sweeteners, flavouring 
agents, preservatives and colorants. The claimed advantage of the direct compression 
approach is its low manufacturing costs due to the limited number of production steps (simple 
mixing and compressing). 
 
1.2.1.2. Compression and preparation of rapidly dispersible granules  
Granulation is any process which involves size enlargement (agglomeration) which converts 
small particles into physically stronger and larger aggregates. Methods available to granulate 
pharmaceutical powders can be broadly classified into wet and dry granulation, each having 
different strengths and weaknesses. Wet granulation, which is the most widely used process of 
granulation in the pharmaceutical industry, involves wet massing of the powder blend with a 
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granulating liquid, wet sizing and drying. There are various technologies available to merge all 
these steps into single and reproducible process, including high shear mixing granulation, fluid 
bed granulation, extrusion/ spheronisation, and spray drying granulation. 
The process of granulation is traditionally applied in the pharmaceutical industry to enhance 
powder flow and cohesion properties of drugs and excipients that experience poor flowability 
and/or poor compactibility. Moreover, granulation prevents segregation of components, 
improves dissolution rate of hydrophobic drugs and leads to low dust generation, which results 
in decreasing cross contamination and airborne exposure. Hence, the development of rapidly 
dispersible granules suitable for the formulation of ODTs has received a great interest (Okuda 
et al., 2009).   
Patents on ODTs that included granulation in their production methods as the inventive step, 
account for about 45% of compressed ODT patents, are summarised in Table 1.2. These 
patents have applied various procedures and materials in order to distinct their formulations. 
To achieve quick disintegration profile in the mouth, some patents (no. 18-27) dry mix highly 
hydrophilic excipients and disintegrants with the active ingredients and then carry out wet 
granulation on the mixture to produce rapidly dispersible granules that can be compressed to 
produce ODTs. Due to the presence of highly water-soluble excipients and superdisintegrants 
in these formulations, the mechanism of disintegration of such tablets is probably a 
combination of the wicking effect of hydrophilic components and swelling of disintegrants. 
Upon contact with water, the hydrophilic components dissolve quickly, allowing more water to 
penetrate into the tablets which causes the disintegrants to swell and consequently break the 
tablets into small particles. In addition to the standard ODT excipients such as sugars, sugar 
alcohols, disintegrants and flavours, various hydrophilic materials have been reported as main 
excipients, as shown in Table 1.2.   
Ohta et al (2005) developed ODTs containing a large quantity of amino acids, by granulating a 
mixture of an amino acid and a disintegrant with an aqueous solution of saccharide, drying the 
granules and compressing the granules into tablets. 
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 Table 1.2 Summary of patents that produced ODTs by compression of rapidly dispersible granules.  
Patent no. Manufacturing Steps Excipients Drug Comments Reference 
18 Involves; wet granulation of ODT 
components with water or ethanol. 
Followed by 
drying and mixing with a lubricant, and 
finally 
compression to form the tablets. 
- Sugar alcohol (D-mannitol). 
- Saccharrides (lactose). 
- Disintegrants (ex. crospovidone). 
 
Wide range of 
pharmaceutically active 
ingredients. 
Both with average 
particle diameter not 
more than 30µm. 
 
Ohta et al., 2001 
19 Involves; mixing the drug with 
components 1 and 2. Followed by; wet 
granulating, sieving, and drying, and 
finally compression at low pressure to 
form the tablets. 
- Component 1: highly plastic 
materials (ex. fructose, 
maltodexrin). 
-Component 2: water penetration 
enhancers (ex. carbohydrates). 
- Binder polymers. 
Wide range of active 
ingredients can be used 
such as loratidine, 
aspirin, and 
acetaminoph en. 
Patent claims high 
plasticity of the tablets, 
and therefore only 
small force is necessary 
to reach the plastic 
deformation stage 
during compression. 
 
Fu et al., 2005 
20 Involves; granulating a mixture of an 
active drug with excipients. Followed by 
compression to form the tablets. 
Corn starch, lactose, crystalline 
cellulose, hydroxypropyl-cellulose, 
and light anhydrous silicic acid. 
 
Micronised AS-3201 Patent claims an 
improvement in the 
dissolution 
characteristics and 
bioavailability of AS-
3201. 
 
Ohashi  et al., 
2006 
21 Involves; granulating a mixture of a drug 
and excipients. Followed by compression 
to form the tablets. 
 
- Saccharides (D-mannitol). 
- Filler (crystalline cellulose). 
Applies to any 
pharmaceutic-ally 
effective drug of choice. 
  
Higuchi et al., 
2009 
22 Involves; granulation of a mixture of 
amino acids and excipients. Followed by 
compression to form the tablets. 
- Disintegrating agent (ex. 
crospovidone). 
- Binder (ex. lactose or mannitol). 
Amino acid and/or 
amino acid derivative. 
ODTs containing an 
amino acid as a 
principal agent. 
 
Ohta et al., 2004 
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23 Involves; granulating a mixture of a drug 
and excipients. Followed by 
compression to form the tablets.  
 
- Saccharide having low 
mouldability (ex. maltiol). 
N –acetylglucosamine, 
β-carotene and/or 
vitamin A. 
N -acetylglucosamine 
based tablets, with 
excellent disintegration 
property in the oral 
cavity and adequate 
hardness. 
 
Kamisono et al., 
2007 
24 Involves; granulating a mixture of a drug 
and excipients. Followed by  
compression to form the tablets. 
 
- Sugar alcohols (ex. mannitol). 
- Flow agent (ex. silicon dioxide). 
 
An active ingredient or a 
pharmaceutically 
acceptable salt. 
The ODT has a non-
filamentous 
microstructure of at 
least two sugar 
alcohols. 
 
Amin et al., 2008 
25 Involves; granulating a mixture of a drug 
and excipients. Followed by  
compression to form the tablet. 
- Matrix forming agent (Silicified 
micro-crystalline cellulose). 
Simvastatin Improved tablet 
stability by using a non-
alkaline lubricant. 
 
Jansen , 2007 
26 Involves; granulating a mixture of a drug 
and excipients. Followed by 
compression to form the tablet.  
 
- Binder (ex. cellulose-based 
polymer). 
- Lower critical solution 
temperature (LCST) modifier (ex. 
an electrolyte). 
An organic or inorganic 
compound that is 
physiologically or 
pharmacologically 
active. 
Ensuring fast 
disintegration by using 
a lower LCST modifier 
to reduce the LCST of 
the polymer below or 
about 37ºC. 
 
Dong, 2010 
27 Involves; granulating a mixture of a drug 
and excipients. Followed by 
compression to form the tablets, and 
finally  aging is performed on the tablets. 
- Saccharide (ex. glucose). 
- Water-soluble binder (ex. 
polyvinylpyrrolidone). 
- Additional excipient (ex. 
mannitol). 
Any medicament which 
can be formulated by a 
conventional wet 
granulation process. 
A simple method for 
producing intrabuccally 
disintegrating tablets in 
large scale. 
 
Shirai et al., 2002 
28 Involves; sieving and mixing of the active 
ingredient and excipients. Followed by 
wet granulation of the active ingredient, 
starch and effervescent base. Followed by 
the addition of an effervescent acid and 
- Effervescent couple: effervescent 
base (sodium carbonate) and 
effervescent acid (malic acid). 
- Lubricant, bulking & 
disintegrating agent. 
Preferably antacids such 
as calcium carbonate 
and magnesium 
hydroxide at 25-50% 
w/w. 
An effervescent couple 
generates a gas 
evolving reaction when 
in contact with saliva, 
which enhances tablet 
 
Ouali, 1998 
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lubricant, and finally compression is 
performed to form the tablets. 
disintegration. 
A high concentration of 
corn starch synergises 
ODT disintegration. 
29 Involves; granulation of the active drug 
with the excipients. Followed by 
compression to form the tablet.   
 
- Low density alkali earth metal 
salts (ex. calcium carbonate). 
- Water-soluble carbohydrates (ex. 
sorbitol). 
Wide range of 
pharmaceutically active 
ingredients. 
Spray drying or pre-
compaction of low 
density alkali earth 
metal salts or water 
soluble carbohydrates 
enhances their 
compressibility. 
Eoga and Valia, 
1999 
30 Involves; dry blending the drug with a; 
disintegrant, diluent and glidant. 
Followed by compressing the resultant 
mixture in the dry state to form the 
tablets. 
Tablet film coating can be applied at the 
end. 
- Spray dried mixture of lactose 
monohydrate & microcrystalline 
cellulose (75:25). 
- Disintegrant. 
- Film forming polymer. 
Galanthamine 
hydrobromide (1:1) 2-
10%. 
 
Film coated tablets are 
easier to swallow, but 
their weight should 
range between 3-8% in 
order not to adversely 
affect the 
disintegration time. 
Gilis and De 
Conde, 2002 
31 Involves; mixing of the components, 
followed by direct compression to form 
the tablets. 
Pre-treatments such as wet granulation 
and coating may be applied. 
- Silicified microcrystalline 
cellulose. 
 
Pharmaceutically active 
agent, 
nutrient, 
nutraceutical or 
cosmetic. 
 
Other auxiliary 
excipients are not 
necessary but may be 
used (ex. disintegrants, 
lubricants, masking 
agents and sugars). 
Platteeuw and 
Heuvel, 2004 
32 Involves; wet granulation of the active 
drug and excipients. Followed by drying 
the resultant wet granules, and finally 
compression to form the tablets. 
- Carbohydrates (ex. spray dried 
mannitol). 
- Water insoluble filler (ex. 
microcrystalline cellulose). 
Any suitable ingredients 
which could be 
pharmaceutically active. 
 Grimshaw et al., 
2007 
33 Involves; granulating a mixture of the 
drug and excipients. Followed by 
- Dissolution retardant (ex. 
polymethacrylate). 
Valdecoxib Useful in the treatment 
or prophylaxis of 
Le et al., 2003 
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compression to form the tablets. 
 
- Rapid dissolution excipient (ex. 
mannitol). 
 
cyclooxygenase-2 
mediated conditions 
and disorders. 
34 Involves; spray drying a homogenised 
aqueous mixture of water soluble and 
insoluble excipients. 
Followed by the addition of an active 
ingredient (powder, granules, pellets or 
beads) and the compression blend. 
Finally, direct compression is performed 
to form the tablets. 
- Water insoluble excipient 
(calcium silicate). 
- Water-soluble excipient (ex. 
carbohydrate). 
- Compression blend: binders, 
disintegrants, diluents, salivating 
agents, sweeteners, lubricants and 
stabilizers. 
Wide range of drugs 
suitable for ODT 
formulation. 
The patent covers any 
method that produces 
particles with intimate 
contact of water-
soluble and insoluble 
excipients (for e.g. wet 
mixing, spray 
congealing, and 
precipitation). 
Gandhi et al., 
2009 
35 Involves; heating an aqueous solution of 
carbohydrate. Followed by the addition of 
calcium silicate with continuous stirring. 
Drying the mixture in a heated air stream 
is then performed, followed by the 
addition of an active ingredient (powder, 
granules, pellets or beads) and the 
compression blend. Finally, direct 
compression is performed to form the 
tablets. 
- Calcium silicate. 
- Carbohydrate (ex. mannitol). 
- Compression blend: binders, 
disintegrants, diluents, salivating 
agents, sweeteners, lubricants and 
stabilizers. 
Wide range of drugs 
suitable for ODT 
formulation. 
Any process that 
ensures the complete 
coating of calcium 
silicate with the 
carbohydrate can be 
employed (for e.g. 
spray drying and 
fluidized bed process). 
Pilgaonkar et al., 
2009 
36 Involves; wet-granulating a mixture of 
water-soluble and insoluble excipients 
with a drug. Drying the wet granules is 
then performed, followed by the addition 
of disintegrants, lubricants, water-soluble 
and insoluble fillers, and the addition of 
other excipients. Finally, compression is 
carried out to form the tablets. 
- Water-soluble carbohydrate (ex. 
mannitol). 
-Water insoluble filler (ex. 
microcrystalline cellulose). 
-Disintegrant (ex. sodium 
carboxymethyl-cellulose). 
- Other excipients: flavouring 
agents sweeteners, preservatives 
Pharmaceutically active, 
nutraceutically active, 
or breath fresheners. 
 Grimshaw et al., 
2008 
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and colorants. 
37 Involves; blending the excipients 
together. Followed by co-processing the 
mixture (milling or wet granulation), and 
the addition of a lubricant. Finally, 
compression is performed to form the 
tablets. 
- Compression excipients; 
ethylcellulose (water insoluble 
binder), disintegrants, fillers, and 
flow aids. 
 
Wide variety of active 
ingredients. 
This patent relates to 
the use of 
ethylcellulose in orally 
disintegrating tablets. 
Durig, 2008 
38 Involves; preparing agglomerates of one 
or more superdisintegrants. Followed by 
mixing the prepared agglomerates with 
the active ingredient and the excipients. 
Finally, compression is performed to form 
the tablets. 
- Superdisintegrants (ex. sodium 
starch glycolate and 
croscarmellose cellulose). 
Wide range of 
pharmaceutically active 
ingredients. 
It was demonstrated 
that disintegration 
time of the tablets 
containing 
agglomerates is faster 
than tablets prepared 
by dry blending. 
Tian et al. 2005 
 
39 Involves; melt-granulation of low melting 
point and water soluble ingredients. 
Followed by congealing using spray 
drying, milling, or mixing. Finally, 
compression to form the tablets is carried 
out. 
- Low melting point compounds 
(ex. polyethylene glycol, 
monoglycerides). 
- Water-soluble excipients (ex. 
saccharides, amino acids). 
Wide range of 
pharmaceutically active 
ingredients. 
 Abu-Izza et al. 
2002 
40 Involves; granulating a mixture of the 
excipients. Followed by mixing the 
granules with the active drug, and finally, 
compression is performed to form the 
tablets. 
- Microcrystalline cellulose. 
- Saccheride (D-mannitol). 
- Binder (maize starch gum). 
Domperidone Convenient 
administration and the 
delivery of 
Domperidone for 
gastrokinetic and 
antiemetic activity. 
Ramalho et al. 
2005 
41 Involves; granulation of a mixture of a 
medicament and sugar (the core). 
Followed by granulating the core with a 
disintegrating agent, and finally 
- Sugar (ex. mannitol). 
- Disintegrating agent (ex. 
crystalline cellulose). 
The medicament is not 
particularly limited. 
The tablets are 
produced by tableting 
drug cores coated with 
a pharmaceutical 
Suga and Nakano, 
2006 
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compression is performed to form the 
tablets. 
disintegrating agent. 
42 Involves; preparing microgranules from a 
drug, a sugar alcohol and an ODT binder. 
Followed by preparing rapidly dispersing 
microgranules from saccharides and a 
disintegrant. Blending of the drug 
microgranules and rapidly dispersing 
microgranules is then performed, and 
finally direct compression is carried out to 
form the tablets. 
- ODT binder (ex. PVP, HPMC, corn 
starch). 
- Sugar alcohol (ex. mannitol). 
- Disintegrant (ex. crospovidone). 
- Other excipients: flavouring 
agents, preservatives, wetting 
agents, coloring agent, and taste-
masking agents. 
 
 
Wide range of drugs 
suitable for ODT 
formulation. 
 Venkatesh et al. 
2009a 
43 Involves; preparing granules of a 
disintegrant with a sugar alcohol and/or a 
saccharide. Followed by coating the 
granules with a disintegrant and mixing 
the coated granules with an active 
ingredient and other excipients. Finally, 
compression is carried out to form the 
tablets. 
- Disintegrant (ex. crospovidone). 
- Sugar alcohol and/or a saccharide 
(ex. mannitol). 
- Coating polymer (ex. 
crospovidone solution). 
- Other excipients: lubricants, 
taste-masking agents, and 
sweeteners. 
Wide range of drugs 
suitable for the direct 
compression process. 
The granule comprises 
a disintegrant inside 
and coated outside. 
The active drug is 
added during granule 
preparation and/or 
during the mixing step. 
Akutagawa and 
Narasaki, 2009 
44 Involves; wet-granulating a mixture of a 
disintegrant and a sugar alcohol. Followed 
by coating the granules with a 
disintegrant and mixing the coated 
granules with an active ingredient and 
other excipients. Finally, direct 
compression is performed to form the 
tablets. 
 
 
- Disintegrant (ex. crospovidone). 
- Sugar alcohol (mannitol or 
erythritol). 
- Other excipients: lubricants, 
taste-masking agents, sweeteners, 
colorants, and binders. 
Wide variety of active 
ingredients. 
The granule comprises 
a disintegrant inside 
and coated outside. 
To insure rapid 
disintegration, the 
active drug is 
preferably added to 
the outside of the 
coated granules. 
Akutagawa and 
Narasaki, 2010 
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45 Involves; mixing the unsuppressed bitter 
tasting drug granules, granules containing 
water-soluble excipients, and 
compression blend excipients. Followed 
by compression to form the tablets. 
Finally, an alcohol based solvent is applied 
to the compressed tablets and allowed to 
evaporate. 
- Drug granules: drug and fillers. 
- Water-soluble granules: a 
saccharide (ex. mannitol) and a 
binder which is soluble in water 
and in alcohol solvent (ex. polyvinyl 
pyrrolidone). 
 
Drugs with a bitter 
taste. 
Treating the tablets 
with an alcohol based 
solvent after 
compression enhances 
their hardness. 
Uemura et al., 
2009 
46 Involves; preparing a microporous binder. 
Followed by mixing the microporous 
binder with a drug and other excipients 
using a blender. Finally, compression is 
carried out to form the tablets. 
- Microporous binders: ionisable or 
non-ionisable cellulosic polymer 
(ex. hydroxypropyl-methyl- 
cellulose phthalate) and wicking 
agent (ex. sugar alcohol, 
saccharide). 
- Other excipients: diluents, 
lubricants, glidants, binders, 
sweeteners, preservatives and 
colorants. 
Wide variety of active 
ingredients. 
The microporous 
binder is prepared by 
causing liquid-liquid or 
solid-liquid phase 
separation for a single 
phase solution of the 
polymer and wicking 
agent, prior to drying 
to the solid particle. 
Ray et al., 2008 
47 Involves; granulating a mixture of a cyclic 
GMP phosphodiesterase inhibitor and the 
excipients. Followed by compression-
moulding to form the tablets. 
- Filler (ex. crystalline cellulose). 
- Surfactant (ex. sodium lauryl 
sulphate). 
- Water soluble polymer (ex. 
methylcellulose). 
- Saccharides (ex. mannitol). 
Cyclic GMP 
Phosphodieste-rase 
Inhibitors. 
The ODT can be easily 
taken, swallowed and 
handled, with an 
improvement in 
solubility of the drug 
Grenier et al., 
2007 
48 Involves; granulating a mixture of a drug 
and excipients. Followed by compression 
to form the tablets. 
 
- Disintegration agents (ex. type-c 
methacrylic acid copolymers and 
crospovidone). 
- Diluent (ex. mannitol). 
The medicament is not 
particularly limited. 
Using combinations of 
the disintegrants 
produces ODTs that 
disintegrate in less 
than 30 seconds. 
Furitsu et al., 
2004 
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Fu et al (2005) described a method of preparing highly plastic granules that can be compressed 
into ODTs, which involves granulating a mixture of a porous, plastic substance (ex. LYCATAB®, 
MALTRIN®, GLUCIDEX®), a water penetration enhancer (saccharides), active ingredients and a 
binder, sieving and/or drying the granules and lightly compressing into tablets that are 
characterised by fast disintegration and low friability profiles.  
Kamisono et al (2007) described a method of incorporating high doses of  
N-acetylglucosamine into ODT dosage forms, by preparing granules from a mixture of  
N-acetylglucosamine and a low mouldable saccharide, mixing the granules with a high 
mouldable saccharide, and compressing into tablets. 
Other patents add effervescent agents to the mixture before the granulation process in order 
to synergise the fast disintegration profile by generating a gas evolving reaction when in 
contact with saliva which enhances tablet disintegration (Ouali, 1998 ; Eoga and Valia, 1999). 
In contrary to the conventional concepts of using highly water-soluble excipients to formulate 
rapidly dispersible granules, the use of water insoluble excipients have also been cited in a 
number of patents as the main excipients (patents no. 30 -37). Various water insoluble 
materials are disclosed in ODTs patents, including calcium silicate (Gandhi et al., 2009; 
Pilgaonkar et al., 2009), microcrystalline cellulose (Shirai et al., 2002; Le et al., 2003), silicified 
microcrystalline cellulose (Platteeuw and Heuvel, 2004), ethylcellulose (Durig, 2008) and 
polymethacrylate (Suga and Nakano, 2006). The granules are produced by granulating a 
homogenous mixture of the water insoluble component, a highly water soluble excipient (for 
example a saccharide or sugar alcohol) in addition to the active drug and other auxiliary ODT 
excipients. The presence of highly water-soluble excipients in close proximity with the 
insoluble materials is crucial to allow rapid disintegration, which, as mentioned earlier, 
generates repulsive forces between the two excipients inside the granules and consequently 
breaks down the tablets. 
Additional disintegration factors are usually employed to promote disintegration by inclusion 
of superdisintegrants in the formulation. However, granules manufactured from silicified 
microcrystalline cellulose (SMCC) do not require the inclusion of highly water-soluble 
excipients or disintegrants to display rapid disintegration (Jansen , 2007; Platteeuw and 
Heuvel, 2004), possibly due to its intrinsic ability to absorb water that can initiate self 
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subsequent swelling activity (Kachrimanis et al., 2003) which results in complete disintegration 
of the tablet.  
Alternative approaches, where the active drug and auxiliary excipients are not included in the 
granulation mixture and are added to the rapidly dispersing granules just before the 
compression step, have been also patented (no. 38-40). Ramalho et al (2005) described a 
method of manufacturing  ODTs of domperidone by lightly compressing a mixture of the drug 
with pre-prepared rapidly dispersing granules, which comprises of mannitol and maize starch 
gum (a binder). Tian et al (2005) prepared agglomerates, comprising of one or more 
superdisintegrants which can be mixed with active drugs and other auxiliary excipients and 
then compressed into ODTs. Abu-Izza et al (2002) mixed the active drug with fast dissolving 
granules, comprising a low melting point compound such as polyethylene glycol, hydrogenated 
oil (Wecobee M) and a water-soluble excipient such as a sugar alcohol (mannitol).      
Furthermore, other patents have employed complicated procedures to formulate ODTs by 
compressing granules (no. 41-45). Suga and Nakano (2006) developed a method to produce 
ODTs which involves secondary granulation or coating of disintegrating agents 
(superdisintegrants) on the primary granules (cores), which comprises an active drug and a 
saccharide. A similar method, but where the active drug is added during granules preparation 
and/or during the compression moulding stage, are patented elsewhere (Akutagawa and 
Narasaki, 2009; Akutagawa and Narasaki, 2010. Venkatesh et al (2009) formulated ODTs of 
temazepam by compressing a mixture of two groups of granules, in which one contains the 
active drug (temazepam) with a saccharide and an ODT binder (drug microgranules), while the 
second comprises saccharides and disintegrants (rapidly dispersed microgranules). A similar 
method of compressing a mixture of two separately prepared granules of a drug and water-
soluble saccharide was applied to suppress the bitter taste of a drug when prepared as ODTs 
(Uemura et al., 2009). Ray et al (2008) described a method of preparing fast disintegrating 
microporous binder particles that can be mixed with active drugs and compressed into highly 
porous ODTs. The microporous binder, which comprises an aqueous soluble cellulosic polymer 
and a wicking agent, is prepared by causing liquid-liquid or solid-liquid phase separation of a 
single phase solution of the polymer and wicking agent prior to drying the solid particle.    
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1.2.1.3. Compression of multiparticulates into ODTs 
As mentioned earlier, the fast disintegrating behaviour of the ODT in the mouth limits the 
number of active drugs that can be incorporated, due to their bad taste, slow onset of action, 
short half life and/or instability in gastric fluids. Tableting of multiparticulates into ODTs has 
attracted scientists to overcome these limitations and widen the application of ODTs. The basic 
idea is to prepare ODTs that disintegrate rapidly in the mouth into easily swallowing small 
particles that mask and protect the active drugs until released at appropriate sites in the 
gastrointestinal tract. Recent patents have described several approaches of preparing 
multiparticulate systems that can be compressed into ODTs, see Table 1.3. 
Tableting of coated drug particles is the most common technique cited in recent patents to 
mask the bad taste of active drugs in ODT formulations (patents no. 49-55 in Table 1.3). 
Mimura et al. (2009) formulated ODTs of the bitter-tasting mitiglinide calcium hydrate by 
simple coating of the drug granules with water insoluble polymers such as ethyl acrylate-
methylmethacrylate copolymer or acid-soluble polymers such as aminoalkyl methacrylate 
copolymer E that delays the dissolution of the drug in the mouth. Whereas, other patents have 
described coating the drug particles with a mixture of water insoluble polymer such as 
ethylcellulose and gastro-soluble pore-former such as calcium carbonate to prevent their bad 
taste from developing in the mouth, while ensuring complete release in the stomach (patents 
no. 50-53, in Table 1.3). In distinction with polymeric materials, lipids have been used to coat 
drug particles and hence mask their unpleasant taste (Szamosi et al., 2007; Harland, 2003).       
Moreover, multilayer coating has been developed to overcome formulation and stability issues 
associated with tableting of conventional coated granules into ODTs. For instance, oxycodone 
was formulated into ODTs as taste masked granules by applying a subcoat of a gastric-soluble 
compound such as polyvinyl alcohol before coating with a conventional taste-masking polymer 
(for e.g. Eudragit®). The subcoat was applied to prevent possible interaction between the 
taste-masking polymer and oxycodone that leads to oxidatitive degradation of the drug. 
Another advantage of the multilayer coating system is the ability to incorporate 
acetaminophen along with oxycodone within the ODT, which is usually difficult as their direct 
contact promotes the degradation of oxycodone (Hoarau, 2009; Oury et al., 2009).  
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Table 1.3 Summary of patents that disclosed the compression of multiparticulates into ODTs. 
Patent no. Manufacturing Steps Excipients Drug Comments Reference 
49 Involves; granulating a mixture of a 
drug and excipients. Followed by 
coating with taste masking polymer 
and mixing with the excipients. 
Compression is then carried out to 
form the tablets. 
- Microcrystalline cellulose. 
- Masking agent (ex. aminoalkyl 
methacrylate copolymer E). 
- Sugar or sugar alcohol (ex. 
lactose). 
Mitiglinide calcium 
hydrate 
A bitterness-masked 
tablet. 
Mimura et al., 
2009 
50 Involves; coating drug particles 
with the first coat. Followed by 
second coating with flavouring 
agents or sweeteners and mixing 
with the compression blend. 
Finally, direct compression is 
performed to form the tablets. 
- First coat: water insoluble 
polymer (ex. ethylcellulose) and 
gastrosoluble pore-former (ex. 
maltodextrins). 
- Compression blend: saccharide 
and/or sugar alcohol granules with 
a disintegrant. 
Ranitidine salt, 
solvate or ester. 
Orally disintegrating 
tablets of taste-masked 
microcapsules. 
Venkatesh  et al,. 
2009b 
51 Involves; coating particles of 
lamotrigine with a taste-masking 
layer. Followed by mixing the 
coated particles with rapidly 
dispersing granules. Finally, direct 
compression is carried out to form 
the tablets.  
- Taste-masking layer: water 
insoluble polymer (ex. 
ethylcellulose) and gastrosoluble 
pore-former (for e.g. calcium 
carbonate). 
- Rapidly dispersing granules: a 
disintegrant and a sugar alcohol 
and/or a saccharide. 
Lamotrigine Orally disintegrating 
tablets of taste-masked 
microcapsules. 
Venkatesh  et al,. 
2009c 
52 Involves; granulating 
diphenhydramine with fillers and a 
binder. Followed by coating the 
particles with a taste-masking layer 
and mixing the coated particles 
- Taste-masking layer: water 
insoluble polymer (ex. 
ethylcellulose) and gastrosoluble 
pore-former (ex. Sodium chloride). 
- Rapidly dispersing granules: a 
Diphenhydramine Orally disintegrating 
tablets of taste-masked 
microcapsules. 
Venkatesh  et al,. 
2009d 
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with rapidly disintegrating granules 
and the compression blend. 
Compression is then performed to 
form the tablets. 
disintegrant and a saccharide. 
 
 
53 Involves; granulating a mixture of 
the drug, a binder and a diluent. 
Followed by coating the granules 
with a water insoluble polymer and 
a water soluble substance. 
This is followed by granulating a 
mixture of the coated 
microcapsules and mannitol with 
an aqueous solution of maltose. 
Finally, compression is carried out 
to form the tablets. 
- Binder (ex. Hydroxypropyl-
methyl-cellulose). 
- Diluent (ex. crystalline cellulose). 
- Water insoluble polymer: (ex. 
ethylcellulose). 
- Water soluble substance (ex. 
Hydroxypropyl-methyl cellulose). 
Wide variety of active 
ingredients. 
Orally disintegrating 
tablets of taste-masked 
microcapsules. 
Kurimoto et al., 
2005 
54 Involves; coating the active drug 
with a lipid base solution. Followed 
by mixing with silicified excipients. 
Compression is then performed to 
form the tablets. 
 
- Lipid (ex. fatty acid glycerol 
ester). 
- Silicified excipient (ex. silicified 
micro-crystalline cellulose). 
Any compound that 
provides a 
therapeutic effect. 
Silicified excipients and 
lipid coating of active 
agents prevent unpleasant 
taste, and provide better 
chemical and mechanical 
stability of the coated 
active substrate. 
Szamosi et al., 
2007 
55 Involves; coating the active 
material by a hot melt fluid bed 
process. Followed by mixing with 
the other excipients. Finally, 
compression is performed to form 
the tablets. 
- Lipid-based coating material (ex. 
an ethoxylated fatty acid). 
-Bulking agent (ex. mannitol). 
- Binder (ex. starch). 
Any biologically 
active material. 
 Harland, 2003 
56 Involves; spray drying a suspension 
of oxycodone and a binder. 
- Binder (ex. cellulose based 
polymers). 
Oxycodone and 
acetaminophen. 
The solvent used in 
spraying the drug pellets 
Hoarau et al., 
2009 
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Followed by applying a subcoat 
onto the drug pellets and coating 
with a taste-masking layer. This is 
then followed by mixing the coated 
pellets with acetaminophen, a 
disintegrant and a soluble diluent. 
Finally, compression is carried out 
to form the tablets.  
- Subcoat: gastric soluble 
compound (ex. polyvinyl alcohol). 
- Taste-masking layer: (ex. 
Eudragit
®
). 
- Disintegrant (ex. crospovidone). 
- Soluble diluent (ex. a polyol). 
and subcoating is 
hydroalcoholic which is 
claimed to reduce 
oxycodone degradation. 
57 Involves; coating the neutral core 
with an opioid and binder solution. 
Followed by subcoating the coated 
pellets and applying additional 
coating with a taste-masking layer. 
Mixing the coated pellets with a 
compression blend is then 
performed, followed by the 
addition of coated crystals of 
acetaminophen with a compression 
blend. 
Precompression of the 
acetaminophen mixture is carried 
out, followed by the 
addition of the opioid mixture 
above the precompressed tablet 
and finally compression is 
performed again. 
 
- Neutral core (ex. a sugar). 
- Binder (ex. cellulose based 
polymers). 
- Subcoat: gastric soluble 
compound (polyvinyl alcohol). 
- Taste-masking layer: water 
insoluble polymer (ex. Eudragit
®
) 
and pore forming agent (ex. 
polyol). 
- Compression blend: diluents, 
lubricants glidants, binders 
sweeteners, preservatives and 
colorants. 
Oxycodone and 
optionally 
acetaminophen. 
Multilayer orally 
disintegrating tablet. 
Oury et al., 2005 
58 Involves; granulating a mixture of a 
drug and excipients. Followed by 
sub-coating with a film and enteric 
- Basic inorganic salt; a salt of 
magnesium and/or a salt of 
calcium. 
An acid-labile 
physiologic-ally active 
substance. 
Orally disintegrable tablet 
consisting of an enteric 
coated acid-labile 
Shimizu et al., 
2001  
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coating of the core. 
Mixing of the coated pellets with 
rapidly dispersible granules is 
carried out, and finally compression 
is performed to form the tablets. 
- Sugar alcohol (ex. erythritol). 
- Crystalline cellulose and 
sustained-release agent/enteric 
polymer agent (ex. methacrylate 
copolymer). 
physiologically active 
substance. 
59 Involves; coating a neutral core 
with the drug and basic inorganic 
salt. Followed by coating with a 
water- soluble polymer and enteric 
coating. An additional coat with 
mannitol is applied. Blending the 
granules with a comprssion blend is 
performed, and finally compression 
is carried out to form the tablets. 
- Neutral core (ex. crystalline 
cellulose). 
-Basic inorganic salt (ex. 
magnesium carbonate). 
- Water-soluble polymer (ex. HPC). 
- Enteric polymer agent (ex. methyl 
acrylate copolymer). 
- Compression blend: crystalline 
cellulose, sugar alcohol (ex. 
mannitol), binder (ex. HPC) and 
disintegrants. 
Lansoprazole Orally disintegrating 
tablets of enteric coated 
granules of acid-labile 
drug. 
Shimizu et al., 
2008a 
60 Involves; coating of active-loaded 
beads with sustained or enteric 
coating. The manufacture of 
cushioning components is then 
carried out. Followed by the co-
processing of active-loaded beads 
with cushioning components into 
Cushion Beads™. Freeze drying is 
then carried out, and finally 
compression is performed to form 
the tablets. 
- Coating polymers (ex. Eudragit). 
- Highly compactable filler (ex. 
microcrystalline cellulose) to 
synthesize cushioning 
components. 
 
Dietary supplements, 
Pharmac eutically 
active drugs, or 
prodrugs. 
Milling of Cushion Beads™ 
to a particle size of 
between 10-50 mesh 
results in immediate 
dispersion of tablets in the 
mouth without losing the 
ability to protect coated 
particles during 
compression. 
Do et al., 2004 
61 Involves; coating the active 
ingredients. Followed by mixing 
with disintegrating agents, soluble 
- Soluble diluent agents (30-90% 
w/w) (ex. Polyols). 
- Disintegrants (ex. 
Ibuprofen, 
paracetamol and 
aspirin. 
Permeabilizing agents 
enhance the formation of 
hydrophilic networks 
Chauveau et al., 
2006 
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diluents, permeabilizing agents and 
lubricants. Homogenising by a dry 
mixer is then carried out. Finally, 
compression is performed to form 
the tablets. 
Croscarmellose). 
- Lubricants. 
- Permeabilizing agents (ex. 
Syloid
®
). 
which facilitates saliva 
penetration and in turn 
tablet disintegration. 
62 Involves; wet granulating a mixure 
of ion-exchange resin/active drug 
complex with the excipients. 
Sieving and drying is then carried 
out. Finally, compression is 
performed to form the tablets. 
- Ion-exchange resin (ex. Duolite 
AP™ 143). 
- Coating polymers (ex. 
methacrylate). 
- Binder (ex. maltodextrin). 
-Diluent (ex. Lactose). 
Any ionic active 
ingredients (ex. 
Diphenhydramine 
hydrochloride, 
cetirzine hydrochlor-
ide). 
The fast melting properties 
of the tablets is achieved 
by using highly plastic 
granules. 
Jeong et al., 2006 
63 Involves; dispersing the active 
ingredients in a hydrogel. The 
matrix hydrogel is then hardened 
to form microcapsules. Surfactant 
is then added. 
Granulating the microcapsules with 
the excipients is then carried out. 
Finally, compression is performed 
to form the tablets. 
- Hydrogels (ex. gelatin, albumin, 
alginates). 
- Surfactants (ex. lecithin). 
- ODT excipient (ex. sugar alcohol). 
Drugs which cause 
irritation to GIT such 
as antacids, anti-
ulcer, cimetidine, 
ranitidine, nizatidine. 
Surfactant is added to 
prevent aggregation of 
microcapsules. 
Yang et al., 2005 
64 Involves; forming nanoparticles of 
poorly soluble drugs and a surface 
stabilizer. One or more water-
soluble or water dispersible 
excipients are then added. Finally, 
compression is performed to form 
the tablets. 
- Surface stabilizer (ex. lecithin or 
gelatin). 
-Water dispersible excipient (ex. 
sugar or sugar alcohol).  
- Other excipients for e.g. binders, 
fillers, buffers, sweeteners. 
Wide range of drugs; 
preferably poorly 
soluble active agents 
(ex. penicillins), 
ketoprofen, 
nifidipine). 
Nanoparticulate 
compositions are 
characterised by large 
surface area and hence 
rapid disintegration. 
Jain et al., 2001 
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Enteric coating has also been used to deliver acid-labile drugs as compressed ODTs. Shimizu et 
al (2001) and Shimizu et al (2008a) described a multi step method to prepare enteric coated 
pellets of lansoprazole suitable for direct compression into ODTs, in which the pellets comprise 
of coating a neutral core with the drug and basic inorganic salt, undercoating with a water-
soluble polymer (ex. hydroxypropyl methylcellulose), enteric coating and finally applying an 
additional coat of a sugar alcohol (mannitol or erythritol). The tablets disintegrate completely 
in the mouth to allow easy swallowing of enteric coated pellets that can maintain their 
integrity in the acidic environment of the stomach to protect the drug from degradation and 
then dissolve upon contact with the basic environment of the intestine to release the active 
form of the drug. 
Furthermore, some patents have addressed various formulation difficulties associated with the 
inclusion of coated multiparticulates in an ODT. One of the major challenges of compressing 
coated pellets into tablets is the ability of the coating layer to withstand the compression force 
which is applied to produce tablets with acceptable mechanical properties (Bodmeier, 1997). 
In a trial to address this issue in ODT formulations, Do et al (2004) proposed a method to cover 
the coated pellets with cushioning components, consisting of highly compactable filler, highly 
water absorbing material and disintegrants. The cushioning component allows the coated 
pellets to be compressed into tablets, protecting against any possible rupture of the coating 
layer during compression and providing rapid disintegration behavior in the mouth. The 
manufacturing steps are summarized in Table 1.3 (patent no. 60). Szamosi et al (2007) have 
reported the use of silicified excipients such as silicified microcrystalline cellulose as part of the 
ODT compression mixture to aid in retaining the beneficial properties of the coated particles. 
Achieving short and smooth disintegration in the mouth is another challenge of incorporating 
coated pellets in an ODT system. Chauveau et al (2006) reported the use of permeabilizing 
agent such as the precipitated silica (Syloid® FP244) in addition to standard ODT excipients 
(saccharides, superdisintegrants and hydrophilic binders). The permeabilizing agent allows the 
formation of hydrophilic networks which facilitates the penetration of the saliva and 
consequently encourages quick oral disintegration.    
Ion exchange resins have been employed to overcome the uncontrolled burst effect and 
limited drug loading of the coated pellets. Jeong et al (2006) described a method of preparing 
ODTs based on ion exchange resins and active drug complexes with sustained release, enteric 
coating and taste masking properties (patent no. 62 in Table 1.3). 
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Incorporating microcapsules in ODT formulations has been employed to deliver drugs which 
cause irritation to the gastrointestinal tract when introduced directly to the mucosa as a solid 
such as antiacids (cimetidine, ranitidine, nizatidine), non steroidal anti-inflammatory drugs 
(NSAIDs) and calcium channel blockers (Yang et al., 2005). 
Nanoparticles of poorly soluble drugs have been incorporated in a compressed ODT 
formulation to provide fast onset of action through combining the rapid disintegrating ODTs 
and the rapid dissolution profiles of nanoparticles (Jain et al., 2001).  
 
1.2.1.4. Post-compression treatment 
Treatment of compressed ODTs after their removal from the compression dies has been 
disclosed in patents to enhance the mechanical properties and improve the disintegration 
profile of the ODT, Table 1.4. Moistening and subsequent drying treatment of the compressed 
tablets has been applied to improve the mechanical property of ODTs (Fu et al., 2006; 
Kajiyama et al., 2003). The moistening process is carried out by introducing the compressed 
ODTs to a relative humidity value above the critical relative humidity of the compressed 
mixture for a predetermined time sufficient to form liquid bridges between the particles inside 
the tablet (Fu et al., 2006; Kajiyama et al., 2003). Subsequent drying solidifies the liquid bridges 
and hence the tablet strength is increased substantially (Lee et al., 2002). Aging the tablets by 
allowing them to stand at room temperature for several hours to several days is another 
method to enhance mechanical properties of highly porous compressed ODTs that has been 
patented, see Table 1.2 patent no 27 (Shirai et al., 2002). An alternative approach in case of 
humidity sensitive drugs has also been disclosed in patents. Uemura et al (2009) applied 
alcohol solvent on the surface of the compressed tablets to enhance the hardness of ODTs 
without deteriorating the disintegration time. Treatment with alcohol liquefies the binder and 
consequently builds bridges between the granules that are solidified after evaporating the 
alcohol (patent no 45 in Table 1.2). 
To improve the disintegration profile of compressed ODTs, various techniques for post 
compression treatment have been developed. The idea is to create highly porous structure for 
the tablet that promotes fast penetration of the disintegrating medium inside the tablets and 
consequently shorter disintegration time. Lee et al (2002) proposed a method to prepare 
highly porous ODTs by compressing a mixture of spray dried particles containing an active drug  
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Table 1.4 Summary of Patents that employed post compression treatment to manufacture ODTs.   
Patent no. Manufacturing Steps Excipients Drug Comments Reference 
65 Involves; mixing the drug with the 
excipients. This is followed by direct 
compression to form the tablets. Moisture 
treatment is then performed, and finally the 
tablets undergo drying. 
- Mannose as a principal 
component (structure-
former). 
Any pharmaceutically 
effective drug of choice. 
The incorporation of 
mannose imparts both 
structure-forming and fast-
dissolution properties to 
the tablets. 
Fu et al., 
2006 
66 Involves; granulating a mixture of a drug and 
excipients. Compression is then carried out 
to form the tablets. This is followed by 
moistening and drying of the tablets. 
- Saccharide (ex. mannitol). 
- Pharmaceutical 
preparation carrier (ex. 
aqueous ethyl cellulose). 
Any pharmaceutically 
active component with an 
unpleasant taste and 
inferior fluidity. 
Masking bitter tasting drugs 
and improving the fluidity 
of inferior fluidity drugs. 
Kajiyama et 
al., 2003 
67 Involves; a sublimable substance being 
tableted together with a spray-dried 
particulate containing an active ingredient, a 
poly (ethylene glycol) and other excipients. 
The tablet is then dried at 42-48ºC by 
sublimation until the tablet becomes 
porous.  
- Binder (ex. 
Polyvinylpyrrolidone). 
- Inorganic substance (ex. 
silicon dioxide). 
- Sublimable substance (ex. 
menthol). 
-Poly (ethylene glycol). 
-Saccharide (ex. Mannitol). 
Any pharmacologically 
active ingredient. 
A tablet having an 
enhanced strength as well 
as a high disintegration rate 
in the oral cavity. 
Lee et al., 
2002 
68 Involves; granulating a mixture of a drug and 
excipients. This is followed by compression 
to form the tablets. The tablets then 
undergo moisturizing and drying. 
- Water-soluble saccharide 
(ex. Mannitol). 
Any medicinal agent. A tablet that can 
disintegrate in the oral 
cavity typically between 3 
and 5 seconds. 
Tatara et 
al., 2001 
69 Involves; granulating a mixture of a drug and 
excipients. Compression of the wet granules 
then takes place. The compressed tablets 
are then dried. 
- Saccharide (ex. mannitol). 
- Binder (ex. polyvinyl 
alcohol). 
Any medicine. A tablet which does not 
have uncomfortable tastes, 
which is superior in 
stability. 
Morita et 
al., 2003 
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and a sublimable substance suitable for oral administration such as menthol. Introducing the 
compressed tablet to sublimation conditions, vacuum and/or temperature, remove the 
sublimable substance and consequently creates highly porous tablets. Tatara et al (2001) 
added moisturizing and drying steps in the manufacturing step of ODTs after removing from 
the compression dies to reshape the compressed tablet into highly porous matrix. Whereas, 
Morita et al (2003) prepared ODTs with high porosity by compressing wet powder into tablets 
and then drying them in the mould. 
 
1.2.2. Moulding 
Moulding technology is used mainly to prepare ODTs using water-soluble ingredients such as 
saccharrides. The powdered form of these ingredients is moistened with water or ethanol and 
moulded under pressure (usually lower than the conventional tablet compression pressures). 
Moulded forms can be prepared by heat moulding; by dissolving or dispersing the drug into a 
molten matrix, or by no-vacuum lyophilisation, in which the solvent is evaporated from the 
drug suspension or solution at standard pressure (Fu et al., 2004). 
Some moulded ODTs are solid dispersions; as the drug does not dissolve completely in the 
molten carrier or could exist as micro-particles or discrete-particles. Despite the fast 
disintegration time of the moulded ODTs, they do not posses high mechanical strength, and 
therefore break easily upon handling or opening of blister pockets. Recently, non-conventional 
equipments and multistep processes have been used to improve the mechanical properties of 
moulded tablets. 
Table 1.5 summarises recent patents of ODTs manufactured by moulding technology. Some 
patents focused on formulating moulded ODTs with high mechanical properties (hardness of 
4kp) and without prolonging the disintegration time (less than 1 minute). Takaishi et al (2005) 
used low melting point saccharides such as mannitol and erythritol which upon heating result 
in melting of the excipients and formation of bridges between different excipients and the 
drug to improve the mechanical properties. On the other hand, Bunick and Luber (2009) 
utilised hydrated salts with dehydration temperatures between 20-120oC as binders. Heating 
these hydrated salts promotes their fusion with other ingredients to form aggregates with 
better mechanical properties. In 2010, Bunick and Luber (2010) selected binders from groups 
of fats, waxes or water-soluble polymers with melting points less than 160oC. 
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Table 1.5 Summary of patents that produced ODTs by moulding technology. 
Manufacturing Steps Excipients Drug Comments Reference 
Involves; moulding the diluent, drug and 
saccharides at low pressure. This is followed by 
heating until the saccharides melt. Cooling then 
takes place to re-solidify the saccharides. 
- Saccharides (0.5-25% w/w) (ex. xylitol or 
maltose). 
- Diluent (ex. crystalline cellulose). 
- Polymers for bitter-tasting drugs (ex. 
ethylcellulose). 
Wide range of 
active ingredients 
can be used. 
Saccharides should 
have a melting point 
lower than the other 
excipients. 
Takaishi et 
al., 2005 
Involves; materials being dispensed into a 
recess. The recess is then sealed and the 
materials are heated above the dehydration 
temperature of the hydrated salt to form 
aggregates. The preparation is then cooled to 
form solid tablets. 
- One hydrated salt (5-40%) like sodium sulphate 
hydrate. 
- Carbohydrates (40%) such as dextrose. 
- Effervescent couples (ex. calcium carbonate and 
citric acid). 
Wide range of 
active ingredients. 
 
Should be free from 
directly compressible 
water insoluble fillers 
such as cellulose and 
starch. 
 
Bunick and 
Luber, 2009 
Involves; preparing a liquefied mixture of the 
excipients. This is followed by filling a pre-
measured volume of tableting material into a 
tablet package having an open-ended cavity. 
Finally, the tableting material is heated to form 
the desired tablet.  
- Binder (ex. cocoa butter). 
- Carbohydrate or carbohydrate alcohol (ex. 
dextrose or mannitol). 
- Filler (ex.cellulose derivative). 
-Flavouring agent (ex. menthol). 
- Other auxiliary excipients. 
Pharmaceuticals, 
minerals, vitamins 
and other 
nutraceuticals. 
A method and 
apparatus for forming 
an orally disintegrating 
dosage unit directly in 
the package, without 
the use or with the 
minimal use of 
solvents. 
Bunick and 
Luber, 2010 
Involves; blending the dry constituents, and 
subsequent addition of a solution comprising of; 
water and ethyl alcohol to the dry components. 
This is followed by blending to form a wet 
blend. Finally, moulding is performed to form 
the tablets. 
 
- Mannitol 75-95%. 
 - Disintegrating agent 1-10% (ex. sodium starch 
glycolate). 
- Other excipients, such as; diluents binders and 
lubricants. 
Olanzapine  Chungi et 
al., 2006 
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Involves; preparing diphenhydramine particles. 
This is followed by coating with a taste-masking 
layer, and mixing the coated particles with 
rapidly disintegrating granules. Finally, 
compression is carried out to form the tablets. 
 
- Film-forming binder (0.5-10%) (ex. PVP). 
- Polymeric binder (1-10%) (ex. povidone). 
- Taste-masking water insoluble polymers 5-30% 
(ex. cellulose acetate). 
- Rapidly dispersing granules comprising 1-10% 
disintegrant and 90-99% sugar alcohol. 
Diphenhydramine  Venkatesh 
et al., 
2009d 
Involves; core preparation and subsequent 
coating of the core with a water-soluble 
polymer. This is followed by enteric coating and 
blending. Moulding is then performed to form 
the tablets. 
- Enteric coating polymers (ex. cellulose acetate 
phthalate). 
- Basic inorganic salt (sodium carbonate). 
- Water-soluble polymers (for e.g. hydroxypropyl- 
cellulose). 
- Water-soluble sugar alcohol (ex. mannitol). 
- Crystalline cellulose (3-50%). 
Benzimidazoles 
(ex. lansoprazole). 
 Shimizu et 
al., 2008b 
Involves; mixing the uncured shearform matrix 
and active ingredients. This is followed by 
moulding the mixture using compression to 
form the tablets. Finally, curing of the uncured 
shearform matrix takes place to yield crystalline 
stable tablets. 
- Carrier material (ex. sugar combinations or 
maltodextrins). 
- Crystallization modifier (ex. Spans™ and 
Tweens™). 
- Effervescent disintegration agent. 
Wide range of 
active ingredients 
can be used. 
The patent disclosed an 
apparatus for preparing 
ODTs consisting of a 
mixing station, 
moulding station, and 
curing station. 
Myers et 
al., 1999 
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Other patents focused on incorporating drugs into moulded ODTs; Chungi et al (2006) 
prepared Olanzapine ODTs and provided the appropriate relative percentage by weight to 
prepare such formulations. Venkatesh et al (2009d) succeeded in preparing diphenhydramine 
ODTs using moulding technique. 
Shimizu et al (2008b) designed a method to prepare coated benzimidazole ODTs by moulding. 
Firstly, a core of crystalline cellulose, lactose, acid-labile active ingredient and basic inorganic 
salt was prepared followed by coating with a water-soluble polymer. The resultant 
composition was enteric coated (2-3 layers) with polyethylene glycol, triethyl citrate and finally 
mannitol to form granules. The resultant granules were then blended with additives and 
moulded at low pressure (0.5-3ton/cm2), to form tablets. Only one patent, filed by Myers et al 
(1999), had designed an apparatus for formulating moulded ODTs. The apparatus implements 
the mixing, filling, tamping and curing procedures in a continuous process and consists of three 
stations; mixing station, tamping/forming station which applies low pressures to form the 
dosage forms and a curing station where the formed matrix is bound and crystallized by 
subjecting to heat or controlled moisture.  
 
1.2.3. Freeze-drying 
Freeze-drying or lyophilisation is a process of removing solvent (water) at a temperature below 
its freezing point under the influence of high vacuum, by a physical process called sublimation. 
Sublimation occurs when a frozen liquid goes directly to the gaseous state bypassing the liquid 
state. Thus, removing the solvent at the solid state retains the structure of the formulation and 
consequently creates a highly porous structure (Mascarenhasa et al., 1997).  
Freeze-drying has been used extensively in the drying process of thermo-labile active proteins 
and biological drugs, as the drying is carried out at low temperatures. However, the ability to 
form highly porous structures has attracted scientists to apply freeze-drying in fabricating 
tablets that allow faster penetration of disintegrating medium and disrupt the structure 
quickly, causing complete disintegration (Segar, 1998). Compared to other freeze-dried 
products such as lyophilized proteins and small molecules, tablets are exposed to many 
mechanical stresses during packaging, shipping and handling by patients, therefore a binding 
agent should be included in the formulation, which upon drying forms a continuous matrix 
that has definite shape (Chandrasekhar et al., 2009). The binder should be hydrophilic in 
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nature, to allow fast dispersion in the saliva, and, preferably with low glass transition 
temperature (37°C), which helps in the disintegration, and gives a smooth texture after 
disintegration (Segar, 1998). In addition, the formulation includes highly hydrophilic small 
molecules that disperse in the binder solution, cementing the porous structure in the dry state 
and dissolve upon hydration with the saliva and consequently disrupt the structure of the 
tablet. This type of material is usually referred to as matrix supporting/disintegration 
enhancing agents (AlHusban and Mohammed, 2010).  
Other additives incorporated in the formulation include taste masking agents, colorants, in 
addition to stability promoting agents that ensure the integrity of the formulation during and 
after freeze-drying (Segar, 1998). Active drugs with varied physicochemical properties and at 
varied doses can be incorporated within the formulation as a solution, suspension or emulsion 
provided the drug has sufficient stability in an aqueous environment. However, for water-
soluble drugs a limitation in the maximum dose is imposed by the plasticising effect of the 
drug molecules on the matrix system that results in lowering of the glass transition 
temperature or eutectic melting temperature and consequently lowers the collapse 
temperature resulting in longer freeze drying regimes. This limitation can be solved by adding 
crystallising agents within the formulation which gives rigidity and stability to the formulation 
against possible collapse. Another strategy to increase drug loading of water-soluble drugs, is 
to promote complex formation between the drug molecules and ion exchange resins, to 
conceal their plasticising behavior, which also provide an additional benefit of masking the 
taste of bitter drugs (Segar, 1998). Insoluble drugs can be incorporated in freeze-dried tablets 
without complications, by preparing aqueous suspensions or emulsions of the drug, which 
might need the addition of suitable thickening or emulsifying agents that does not deteriorate 
the properties of the tablets (Sastry et al., 2000).   
After preparing the liquid system of the drugs and the required excipients, the formulation is 
filled into blister cavities, frozen at low temperature and then freeze-dried in suitable 
conditions. The resultant tablet requires special packaging to provide extra protection from 
external pressure and moisture, as the tablets can fracture and absorb moisture easily because 
of their spongy and highly porous nature (Dobetti, 2001). 
Recent patents in lyophilised ODTs are principally different only in their disclosed excipients, 
mainly the polymeric binder and matrix supporting/disintegration enhancing agents, as the 
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general procedure for manufacturing lyophilised ODTs (see above) is common in all the 
patents.  
Remon et al (2000) described a lyophilised ODT which is able to deliver a wide range of active 
ingredients utilizing maltodextrin, having a DE (dextrose equivalent) value between 12 and 40, 
isomalt or mixures of both as matrix forming agents, and water-soluble polymers such as 
xanthan gum, methylcellulose and hydroxypropyl methylcellulose as binding agents.  
Johnson et al (2002) disclosed the use of a wide range of polymeric materials from animal, 
plant or synthetic origin as binding agents such as; gelatin, dextrin, acacia, guar, agar, xanthan, 
polysaccharides, alginate, dextran and polyvinylpyrrolidone in addition to sugars, sugar 
alcohols and/or amino acids as matrix supporting/disintegration enhancing agents to 
manufacure ODTs of a dopamine agonist and testosterone.  
Li et al (2007) described a lyophlised ODT composition intended to solve some ethical and 
formulation problems associated with using gelatin as a main excipient. The composition 
which comprises of pullulan as a binder and amino acids as matrix supporting/disintegration 
enhancing agents is claimed to have easier formulation steps and shorter freeze-drying time 
than gelatin based systems.  
 
1.2.4. Tablet loading 
Recently, a patent was granted which refers to disintegrating loadable tablets (Holm and Slot, 
2009). Disintegrating loadable tablets in compressed form, comprise of at least 60% w/w of a 
sorbent material selected from metal oxides (for e.g. magnesium oxide) and metal silicates (for 
e.g. sodium silicate) having a specific surface area of at least 50m2/g or mixtures of such 
sorbent materials, hydrophilic substances and a disintegrant or a mixture of disintegrants (0.5-
15% w/w). A hydrophilic substance (15% w/w) for example glucose functions as a wetting 
agent or a humectant. A suitable superdisintegrant was sodium carboxymethyl cellulose.  
Prior to loading, the tablet in compressed form has; a porosity of 45% v/v or more, a hardness 
of at least 20 Newton, and a loading capacity of at least 30% of a liquid. The loading of the 
tablet with the active substance (in pharmaceutically acceptable liquid formulation), involves 
spraying the liquid onto the tablet or by placing the tablet in an excess of the pharmaceutically 
acceptable liquid formulation to saturate the tablet.The pharmaceutically acceptable liquid 
 
Chapter 1 – Introduction   
61 
 
formulation can comprise; an oil/oily-like material (for example a vegetable oil), or a 
pharmaceutically acceptable solvent, which can be in the form of an emulsion, microemulsion 
or a suspension. Loadable tablets may also contain other pharmaceutically acceptable 
excipients, for example; fillers, diluents, binders etc. 
This method of preparing an ODT is particularly suitable for the loading of tablets with 
substances having low water-solubility, as these substances can be dissolved in oil/oily-like 
materials and especially in such cases where the substance is desired to be delivered in 
microcrystalline and/or amorphous form to increase release and absorption (Holm and Slot, 
2009). 
 
1.2.5. Compression of pulverized components  
In 2007 a patent was published which relates to a novel method of manufacturing ODTs, by 
compressing components which are in a pulverized form. It is claimed that tablets produced 
from this method, have a similar porous structure as usually that results from freeze-drying 
processes (Bauer and Rohrer, 2007).  
The manufacturing process begins with preparing a dry mixture comprising a suitable binding 
agent, such as acacia, active ingredients, fillers (ex. Mannitol) and other components 
(lubricants). Liquefied or compressed gases (ex. fluoroalkanes) or gas mixtures (ex. azeotropic 
mixtures) under high pressure, optionally in the presence of low-boiling solvents (ex. 
methanol), is used to moisten the dry mixture. This is followed by stirring, homogenisation and 
the production of the mouldable plasticized mass in an autoclave, where the high pressures 
can be tolerated. The tablet is produced by filling the wetted mixture into a mould under 
pressure (between normal pressure and up to 100 bar). Decompression process is applied to 
remove the gaseous component and consequently creating highly porous ODTs (Bauer and 
Rohrer, 2007).  
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1.2.6. Factors affecting the selection of technology 
 1.2.6.1. Manufacturing cost  
The general cost of manufacturing ODTs, varies considerably from one technology to another. 
Freeze-drying technology is considered an expensive method of manufacturing ODTs. Long 
freeze-drying cycles, complex and specialist industrial plants, processes and equipment, are 
responsible for the high production costs (Tang and Pikal, 2004). Compression of pulverized 
components technology can also be considered as an expensive method of manufacturing 
ODTs, as specialist equipment is required which can tolerate the high pressures used during 
the manufacturing process. Meanwhile, the use of direct compression and granulation-
compression methods to manufacture ODTs is considered a more cost effective method, 
where production costs are much lower, as standard equipment and materials are used. 
 
1.2.6.2. Active ingredient dose  
The dose of drug which can be incorporated into an ODT relies heavily on the technology used 
to manufacture the tablets. High doses of active ingredients can be incorporated into tablets 
prepared by moulding and standard tableting methods, up to 1000mg per tablet. However in 
freeze-drying, incorporation of high doses of water-soluble active ingredients can be 
challenging, typically up to 60mg of water-soluble drugs a tablet (Lee et al., 2002).  
 
1.2.6.3. Physicochemical properties of active ingredients and excipients  
The physicochemical properties of active ingredients and excipients can be factors which 
determine the technology to manufacture ODTs. Technologies such as direct compression and 
moulding appear flexible and versatile when it comes to the physicochemical properties of 
active ingredients and excipients. They generally include a mixture of excipients which exhibit 
high aqueous solubility and good mouldabilility, which ensure the formation of robust tablets 
with rapid disintegration profiles. 
Meanwhile, technologies such as freeze-drying and tablet loading appear more selective when 
it comes to the physicochemical properties of the active ingredients and excipients. The active 
drug should exhibit sufficient stability in solution to allow efficient incorporation in to the final 
dosage form. Also, excipients for freeze dried ODTs should accomplish stringent characteristics 
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such as reasonable drying time, stability during freeze-drying process, as well as formation of 
elegant tablets with short disintegration time and adequate mechanical properties 
(Chandrasekhar et al., 2009). Nevertheless, freeze drying is principally more suitable than 
other technologies in cases of heat sensitive active drugs as the manufacturing is carried out at 
low temperatures. 
 
1.2.6.4. Required performance and properties of the ODTs  
The performance and properties of ODTs varies considerably, based on the technology used to 
prepare the tablets. For example the use of freeze-drying technology produces highly porous 
tablets which disintegrate and dissolve smoothly in the oral cavity in a matter of seconds, but 
these tablets show poor physical properties in terms of tablet hardness and fracturability (Fu 
et al., 2004). Whilst the use of direct compression and standard tableting technologies produce 
tablets which exhibit better physical properties than the freeze dried tablet, but generally 
most of them need a minute to disintegrate/dissolve completely in the oral cavity (Lee et al,. 
2002). 
 
1.2.7. Current and future developments  
The review of ODT patents from 1999 to 2010 has shown that current technologies namely; 
compression-based methods, moulding and freeze-drying, have been extensively researched, 
developed and modified. In particular, compression-based methods (direct compression and 
granulation-compression) are the technologies which have seen the most extensive 
development and modification, as these methods are more easily adapted and developed. 
Areas of these technologies which have been developed and modified include; method 
modification, selection of specific excipients and post compression treatment of the tablets. 
Other areas of these technologies which have been developed include; development of ODTs 
for a specific active ingredient or group of active ingredients, various taste-masking 
approaches, in case of bitter-tasting active ingredients, and coating technologies. 
The last ten years has seen the emergence of novel technologies and methods of 
manufacturing ODTs, such as tablet loading, compression of components which are in 
pulverized form and sublimation. Based on the review of patents of the last ten years, the 
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future development of ODTs appears to lie with the emergence of new technologies to 
produce ODTs which exhibit both rapid oral disintegration and improved physical properties 
(hardness and fracturability).  
In terms of freeze-drying technology, developments in method modification and/or material 
selection is required in order to enhance the physical strength of the tablet and minimise the 
primary drying time of the freeze-drying cycle, as this will result in a shorter and more efficient 
manufacturing process. In terms of compression-based technologies, developments need to 
take place which will lead to an increase in tablet porosity, as this is the limiting factor in the 
fast disintegration of tablets manufactured from compression-based methods, and to simplify 
the manufacturing steps especially when incorporating multiparticulates into compressed 
ODTs. 
Development of taste-masking technologies to ensure that bitter-tasting active ingredients can 
be administered conveniently to patients is also required. Finally, the development of ODTs 
which exhibit sustained, modified or controlled release/delivery of active ingredients will 
ultimately improve the therapeutic efficiency and treatment of a variety of medical conditions, 
through reducing frequency of dosage administrations. 
 
1.3. Rationale and aim of the research project 
Among the existing approaches to prepare ODTs, lyophilisation (freeze drying) has been 
considered the most successful in terms of sales value, sales volume and number of products 
available on the market (Muir, 2007). As mentioned previously, the disintegration time for the 
lyophilised tablets is very short (the shortest among other technologies) due to their highly 
porous and hydrophilic matrix. However, the formulation still suffers from some disadvantages 
that need to be addressed. The tablets usually have very poor mechanical properties (Kuno et 
al., 2005; Narazaki et al., 2004; Fukami et al., 2006) and require protection in the form of 
specialized packaging like the ZYDIS blister peel back packing. Furthermore, the formulation of 
lyophilised ODTs is usually restricted by the dose and characteristics of the drug that can be 
incorporated. For instance, the maximum dose of water insoluble drug is less than 400mg and 
for water soluble is 60 mg. Also, the drug should be chemically stable with acceptable taste 
and particle size smaller than 50 µm (Segar, 1998).  
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Although there are many patents describing the preparation of ODTs by lyophilisation very 
scanty literature is available detailing factors that control mechanical properties and 
disintegration time of these formulations (Ahmed and Aboul-Einien, 2007; Corveleyn and 
Remon, 1998). Accordingly, the current research aims to investigate the role of formulation 
excipients and processes in the development of lyophilised orally disintegrating tablets (ODTs) 
and use this knowledge to achieve further advances in the field. The research strategy is 
rationalised as follows:  
 Chapter two: to investigate the role of the most common excipients used in 
commercial products (gelatin and saccharides) for their influence on the 
manufacturing process and performance of the lyophilised ODTs.   
 Chapter three: to develop saccharide free ODTs by investigating the feasibility of using 
naturally occurring amino acids, individually, as a matrix supporting/ disintegrating 
enhancing agent.  
 Chapter four: to investigate the feasibility of novel combinations of two amino acids to 
combine the benefits of the incorporated amino acids and minimize their drawbacks, 
and to determine the influence of the freezing protocol on tablets characteristics and 
primary drying time. 
 Chapter five: to optimise ODT formulations suitable for the delivery  multiparticulate 
systems of challenging drugs using a novel formulation that exploite the electrostatic 
associative interaction between gelatin and carrageenan 
 Chapter six: to explore advantageous natural polymers for their use as a binder in the 
formulation of lyophilised ODTs to replace gelatin with ethically and morally accepted 
components. 
 Chapter seven: to study and optimised the application of gum arabic as a binder in the 
formulation of lyophilised ODTs to deliver highly water soluble, slightly soluble or 
insoluble active drugs using factorial design studies.  
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Chapter Two: Preparation, Optimisation 
and Characterisation of Lyophilised ODTs 
Based on Gelatin and Saccharide 
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Preparation, Optimisation and Characterisation of 
Lyophilised ODTs Based on Gelatin and Saccharide 
 
2.1. Introduction and Aims 
Despite recent success, many orally disintegrating tablets (ODTs) still face problems of low 
mechanical strength and therefore require protection in the form of specialized packaging 
(Abdelbary et al., 2004; Kearney, 2002).  
This chapter aims to find a practical balance between the mechanical properties and 
disintegration time of lyophilised ODTs based on gelatin and saccharides through careful 
optimisation of gelatin bloom strength and concentration in addition to type and 
concentration of the saccharide. Tablets containing gelatin with different bloom strength 
value, low (60 bloom) and high (225 bloom), at concentrations of 2, 5, 7.5, and 10 %w/w were 
formulated and characterised to determine the ideal gelatin concentration and bloom strength 
to be used for further studies. Moreover, the effect of gelatin stock solution concentration on 
the sublimation rate and product temperature during the primary drying process was 
investigated. Five saccharides, xylitol, glucose, trehalose, maltotriose and mannitol, at 
concentrations ranging from 10 to 80 % w/w (of total solid material) were incorporated in the 
optimised  gelatin solutions and the resultant formulations were characterised in terms of 
thermal properties, physical appearance, mechanical strength and disintegration time. 
Clonidine HCl (C9H9Cl2N3. HCl, MW: 266.55 g/mol) was incorporated in the optimised 
formulation as it is one of the off patent drugs included in the priority list published in 2007 by 
European Medicines Agency for development of paediatric formulation. It is a centrally acting 
alpha2-adrenoceptors agonist, used in management of mild to moderate hypertension, and it 
is available as tablets for oral administration in three dosage strengths: 0.1 mg, 0.2 mg and 0.3 
mg (Katzung, 2005).  
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2.2. Selection of excipients 
All the excipients used in this study are well known as safe materials for human use and have 
been used or investigated in many pharmaceutical applications. Gelatin is a pure protein that 
is obtained by thermal denaturation of collagen. It is widely used in solid oral dosage forms, 
i.e. hard and soft gelatin capsules, as it forms thermo-reversible gels upon hydration with 
melting points around 35-37 °C (just below body temperature). It occurs in different bloom 
strength according to its gel rigidity, with the higher bloom strength value forming more rigid 
gel (Segtnan and Isaksson, 2004). In the formulation of lyophilised ODTs, gelatin has been used 
extensively as a binder in ZYDIS® products to give shape and resilience to the table after freeze 
drying (Seager, 1998). The saccharides with varied physicochemical properties and structural 
features were studied to determine their effect on the formulation of ODT.  
Xylitol, C5H12O5, is a naturally occurring non-reducing sugar alcohol with a molecular weight of 
152.15 g/mole. Due to the sweet taste, cooling sensation in the mouth and non-cariogenic 
profile xylitol has been used extensively in orally administered products such as chewing gums 
(Moss, 1999). However, its highly hygroscopic nature may affect the stability of the product 
(Ciper and Bodmeier, 2005).  
Glucose is a reducing monosaccharide that is globally used as intravenous diluent. The 
empirical formula of glucose is C6H12O6 and the molecular weight is 182 g/mole. Glucose has 
been recently investigated as a lyoprotectant in many pharmaceutical formulations 
(Shahgaldian et al., 2003; Zhang et al., 2008).  
Trehalose is a non-reducing disaccharide consisting of two glucose unit linked by an α,α-1,1- 
glycosidic linkage. The empirical formula is C12H22O11 and the molecular weight is 342.31 
g/mole. Trehalose occurs as white crystals with low hygroscopic profile (Richards et al., 2002; 
Elbein et al., 2003). It has been included in many pharmaceutical formulations as a 
lyoprotectant, such as cellular, protein (Elbein et al., 2003) and liposomal (Christensen et al., 
2007; Mohammed et al., 2007) formulations, and as a diluent in tablets (Rowe et al., 2006). 
Maltotriose is a trisaccharide formed by two 1, 4 glycosidic linkage between three D-glucose 
molecules. It has a molecular formula of C18H32O16 and weight of 504.44 g/mole.  
Mannitol is a naturally occurring non-reducing sugar alcohol. The molecular formula and 
weight are C6H14O6 and 182.17 g/mole, respectively. Mannitol is used extensively in tablet 
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formulation, due to its low hygroscopic profile, sweet taste and cooling sensation in the mouth 
(Rowe et al., 2006). It is, also, used as bulking agent in lyophilised preparations, as it readily 
crystallise and consequently improve the appearance and stability of the product (Pyne et al., 
2003). Furthermore, mannitol is incorporated into ZYDIS® products to give crystallinity, 
hardness and elegance appearance (Seager, 1998). 
 
2.3. Materials 
Type B gelatin with 60 bloom strength (from calf skin) and 225 bloom strength (from bovine 
skin), xylitol, D-glucose, maltotriose, D-mannitol, and clonidine hydrochloride were purchased 
form Sigma-Aldrich Chemicals (Pool, UK). Trehalose (anhydrous) was supplied by Acros (New 
Jersey, USA). Triethylamine was supplied by Fisher Scientific (Loughborough, UK). All the 
chemicals used were of analytical grade. 
 
2.4. Methods 
2.4.1. Preparation of lyophilized tablets 
2.4.1.1. Influence of gelatin bloom strength and concentration 
Gelatin of different bloom strength (60 and 225) was dissolved in double distilled water at 
about 40 ºC to obtain a concentration of 2, 5, 7.5 and 10% w/w. 1.5 g of the solution was 
poured into a bijou tube, frozen at -80 °C for about 60 minutes and freeze-dried (ADVANTAGE 
Freeze-dryer, VIRTIS) according to an optimized regime (primary drying for 48 hours at shelf 
temperature of -40 °C and secondary drying for 10 hours at shelf temperature of 20 °C and 
vacuum of 50 m Torr. All the formulations were prepared in triplicate from three independent 
batches. 
 
2.4.1.2. Influence of varying the concentration of different Saccharides 
Xylitol, mannitol, glucose, trehalose and Maltotriose were added individually to 2 or 5 % (w/w) 
low bloom strength gelatin (60) stock solutions at concentration of 10, 20, 30, 40, 50, 60, 70, 
and 80 % of total solid material. 1.5 g of the solution was poured into a bijou tube, frozen at -
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80 °C for about 60 minutes and freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to 
the optimized regime (primary drying for 48 hours at shelf temperature of -40 °C and 
secondary drying for 10 hours at shelf temperature of 20 °C and vacuum of 50 m Torr. All the 
formulations were prepared in triplicate from three independent batches. 
 
2.4.1.3. Orally disintegration tablets containing clonidine HCl 
17.120 mg clonidine HCl was solubilised in 256.745 g of a solution consisting of 237.500 g 
double distilled water, 12.500 g low bloom strength gelatin (60), 5.355 g mannitol and 1.390 g 
trehalose. This formulation resulted in a clonidine HCl dose of 100 µg per 1.500 g solution. 
1.500 g of the solution was poured into a bijou tube, frozen at -80 °C for about 60 minutes and 
freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to the optimized regime (primary 
drying for 48 hours at shelf temperature of -40 °C and secondary drying for 10 hours at shelf 
temperature of 20°C and vacuum of 50 m Torr. The formulation was prepared in triplicate 
from three independent batches. 
 
2.4.2. Sublimation rate and product temperature 
Gelatin (60 bloom strength) was dissolved in double distilled water at about 40 °C to obtain a 
concentration of 2, 3.5, 5, 7.5 and 10% w/w. 1.5 g of the solution was poured into a PEG mould 
(13.80 mm diameter, 8.50 mm height), frozen at -80 °C for 60 minutes and freeze-dried at shelf 
temperature of -40 °C, condenser temperature of -80 °C and 55 mTorr vacuum. Samples were 
withdrawn from the freeze dryer at predetermined time intervals (2, 4, 10, 16, and 24 hours) 
and the amount of water sublimed was evaluated using weight difference method. The 
product temperature was automatically recorded using thermo couple that was inserted in the 
central bottom of the tablet.  
 
2.4.3. Total porosity 
The relative porosity was calculated from the apparent and true density of the tablet. 
Apparent density was found by dividing the mass of the tablet by the measured volume. The 
strut density was determined using helium pycnometry (Accupyc 1330, Micromeritics, UK) 
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with 3 cm³ sample cup at 22 °C. Prior to analysis the helium pycnometry was calibrated against 
a standard steel ball. Each determination included 10 purges at 19.5 psi and 10 analytical runs 
at 19.5 psi with an equilibration rate of 0.0050 psi/min.  
 
2.4.4. Differential scanning calorimetry studies 
Differential scanning calorimetry (Pyris Diamond DSC and Intracooler 2P: Perkin Elmer, 
Wellessey, USA) was employed to determine glass transition temperatures (Tg) and 
crystallisation event of the formulation in their liquid state (before freeze drying). 10-15mg of 
the liquid samples were loaded into aluminium pans, cooled to -65 °C and then heated to 20 °C 
at 5 °C/min with a nitrogen purge of 20ml/min. An empty aluminium pan was used as 
reference for all measurements. The resulting graphs were analysed by Pyris manager 
software. Tg value was determined from the intersection of relative tangents to the baseline. 
All the measurements were done in triplicate of independently prepared samples.  
The DSC was calibrated for temperature and heat flow using standard samples of indium 
(melting point: 156.6 °C, ∆Hm: 28.42 J/g) and Zinc (melting point: 419.5 °C, ∆Hm: 108.26 J/g). 
 
2.4.5. Mechanical properties of the tablets 
The mechanical properties of the tablets (hardness and fracturability) were investigated with a 
texture analyzer (QTS 25: Brookfield, Essex, UK) equipped with a 25 kg load cell. The 
instrument was calibrated by standard weight of 500 g and 5 kg. The tablet was placed in a 
holder with a cylindrical hole. The hardness was taken as the peak force after 1mm 
penetration of 5mm diameter probe at a speed of 6 mm/min. Fracturability was the peak force 
after 3mm penetration of 1mm diameter probe at a speed of 6 mm/min. The results were 
average of three measurements from independently prepared batches. 
 
2.4.6. Disintegration time of the tablets 
The disintegration time of the tablets was measured using a USP disintegration tester (Erweka 
ZT3, Erweka Apparatebau, Germany). Distilled water (800 ml) kept at 37 °C was used as a 
medium and the basket was raised and lowered at a fixed frequency of 30 cycles/min. At each 
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time, one tablet was placed in the basket rack assembly and covered by transparent plastic 
disk. The disintegration time was taken as the time required for ODTs to disintegrate 
completely without leaving any solid residue. All the formulations were evaluated in triplicate 
and standard deviation was calculated. 
 
2.4.7. Morphological examination 
The inner structural morphology and pore size of the freeze-dried tablets were examined by 
scanning electron microscopy (SEM, STEREOSCAN 90, Cambridge Instrument). A thin horizontal 
cross-section sample was prepared by cutting the tablet with a razor blade. The samples were 
placed onto double-sided adhesive strip on an aluminium stub. The specimen stub was coated 
with a thin layer of gold using a sputter coater (Polaron SC500, Polaron Equipment, Watford, 
UK) at 20 mA for three 3 minutes and then examined by the SEM. The acceleration voltage (kV) 
and the magnification can be seen on each micrograph. 
 
2.4.8. HPLC analysis of clonidine HCl 
HPLC analysis of clonidine HCl in the tablets was carried out using Reverse phase HPLC (Dionex 
AS 50 autosampler with GP50 gradient pump HPLC System: Dionex, UK) at room temperature 
using a 4.6 x 150 mm column (Phenomenex La Luna: Phenomenex, Torrance, USA) and 20 µL 
injection volume, with UV detection at 245 nm. The mobile phase consisted of methanol-water 
(60/40) and 0.5% Triethylamine (Sarisuta et al., 1999). The mobile phase flow rate was 1 
ml/min. Under these HPLC conditions the retention time for clonidine HCl was about 3.35 
minutes. Concentration of clonidine HCl in the tablets was determined by reference to a 
calibration curve prepared from dilutions of stock solution of clonidine HCl (5-100 µg/ml), 
using water as solvent. The calibration curve was performed in triplicate and resulted in a 
linear correlation in the concentration range studied (r²=0.99). 
 
2.4.9. Viscosity and pH measurements 
The lyophilised tablet was dissolved in 2 ml water in order to measure the pH and viscosity. All 
the measurements were done in triplicate from independently prepared samples. 
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 The pH was measured using a pH meter (MP230, Mettler Toledo) at room temperature. The 
pH meter was calibrated using standard solutions at pH 4 and 7. 
The viscosity was measured using the automated micro-viscometer (Anton Parr, AMVn, Graz, 
Austria). Each sample (400 µL) was loaded into a glass capillary (diameter: 1.8 mm) using a 1ml 
syringe, and care was taken to ensure that no air bubbles were present in the loaded sample 
within the capillary. The glass capillary was loaded into the capillary block, where the 
temperature of the sample was equilibrated at 25 ˚C. Viscosity measurements were conducted 
by measuring the rolling ball time (ball diameter: 1.5 mm) four times through the capillary at 
an angle of 50˚. 
 
2.4.10. Statistical analysis 
The hardness, fracturability and disintegration of the lyophilised tablets produced from varied 
concentrations of low or high bloom strength gelatin were compared using one-way analysis of 
variance with Tukey-Kramer multiple comparison test. The hardness, Fracturability and 
disintegration of the lyophilised tablets after inclusion of saccharides were statistically 
compared to those of the control (composed of gelatin only) using one-way analysis of 
variance with Dunnett multiple comparison test. The significance level was 0.05. 
 
2.5. Result and discussion 
2.5.1. Studying the Influence of gelatin bloom strength and 
concentration on the hardness and disintegration time 
2.5.1.1. Mechanical properties of the tablets 
Generally, tablet dosage forms are exposed to various mechanical stresses during the 
manufacturing steps (e.g. packaging process), shipping and handling by patients. Therefore a 
successful tablet formulation must have an adequate mechanical strength.  
In this study, the mechanical properties of the tablets were evaluated by applying 
combinations of compression and shear force. The hardness was measured using a 5 mm 
diameter probe, which provides more compression force. While the fracturability was 
measured using a 1 mm diameter probe, which provides more shear force. The results of the 
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hardness and fracturability are presented in Figures 2.1 and 2.2, respectively. The hardness of 
the tablets (Figure 2.1) increased significantly by increasing gelatin stock solution 
concentration (one way ANOVA/Tukey-Kramer: ρ<0.05). Surprisingly, the results showed that 
there was no impact of gelatin bloom strength on the hardness of the lyophilized tablets. Ciper 
and Bodmeier (2005) noticed that high bloom strength gelatin enhanced the mechanical 
properties of fast disintegration capsule. Figure 2.2 illustrates the effect of gelatin bloom 
strength and stock solution concentration on the fracturability of the tablets. The test was not 
carried out for tablets that were fabricated from 2% gelatin stock solution. This was because 
the test's probe (1mm diameter) was unable to penetrate these tablets, due to the spongy 
nature of these tablets that tend to deform in response to the force applied by the probe. The 
results showed that increasing gelatin concentration in the stock solution significantly 
enhanced the fracturability of the tablets (one way ANOVA/Tukey-Kramer: ρ<0.05) with no 
significant difference between tablets based on low or high gelatin bloom strength at similar 
concentration (one way ANOVA/Tukey-Kramer: ρ>0.05). The results suggested that the 
fracturability of the tablet was influenced by the concentration of gelatin in the stock solution 
rather than the bloom strength. 
 
 
Figure 2.1 The effect of gelatin bloom strength and concentration in the stock solution on the 
hardness of the lyophilised tablets. (Mean ± SD, n=3). 
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Figure2.2 The effect of gelatin bloom strength and concentration in the stock solution on the 
fracturability of the tablets. (Mean ± SD, n=3). 
 
2.5.1.2. Disintegration time of the tablets 
The assessment of the disintegration time is considered the fundamental issue in optimising 
and developing fast orally disintegrating tablets. According to the U.S. FDA specification, the 
disintegration time of such tablets should not exceed 30 seconds (US FDA, 2007). The effect of 
gelatin bloom strength and concentration in the stock solution on the disintegration time of 
the lyophilised tablets is presented in Figure2.3. The results showed that the disintegration 
time of the tablets decreased with decreasing gelatin bloom strength and stock solution 
concentration. The tablets produced from low bloom strength gelatin at 2, 5, 7.5 and 10 % 
(w/w) stock solution disintegrated in 3, 29, 189 and 360 seconds respectively, whilst high 
bloom strength gelatin (225) at similar concentrations disintegrated in 6, 38, 348 and 608 
seconds, respectively. Also, the results indicated that the differences in the disintegration time 
between the tablets produced from high and low bloom strength gelatin increased with 
increasing gelatin stock solution concentration (3, 9, 159 and 448 seconds at 2, 5, 7.5 and 10% 
w/w stock solution, respectively).  
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Despite the fact that the USP disintegration test was able to detect the difference in the 
disintegration time between the formulations in the current study, concerns about the 
reliability, accuracy and suitability of the test to evaluate fast disintegrating tablets were 
experienced. The qualitative nature of the test that depends on the visual evaluation in 
addition to the fact that few seconds' inaccuracy in evaluating the disintegration time can 
cause huge error (as the disintegration time is very short) are the main problems associated 
with this test. Accordingly, new method for measuring the disintegration time is required for 
better evaluation and development of fast orally disintegrating tablets. 
 
 
 
 
Figure 2.3 The effect of gelatin bloom strength and concentration in the stock solution on the 
USP disintegration time of thelyophilised tablets. (Mean ± SD, n=3). 
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2.5.1.3. Morphological examination 
The inner structure of the lyophilised tablets was viewed by scanning electron microscopy. 
SEM micrograph offers a great opportunity for direct assessment of the size, shape and 
direction of the pores inside the tablets, thus aiding in understanding and explaining the 
differences in properties of the tablets. Figure 2.4 shows SEM micrographs of lyophilised 
tablets produced from 2, 5, 7.5 and 10% gelatin stock solutions. The gelatin molecules in the 
tablets produced from freeze drying of a 2% low bloom strength (60 bloom) gelatin solution 
(Figure 2.4 a) seemed to be arranged in two dimensional ordered channel structure with an 
average channel height of about 35 µm. The walls of these channels were very thin (like a 
ribbon) and connected to each other along a length of 50 - 100 µm by very thin bridges (Figure 
2.4 a). Partially, the same features were noticed in the case of 5% low bloom strength gelatin 
but with more partitioned channel and thicker wall (Figure 2.4 b). Higher concentration (10, 
7.5 and partially 5%) of low bloom strength gelatin solution resulted in tablets composed of 
polygonal to spherical shaped pores arranged in three dimensional orders (Figures 2.4 d, c, 
and b, respectively). The pores were about 80, 40, and 70 µm in diameter, for the 5, 7.5, and 
10% stock solution, respectively. Surprisingly, the 10% formulation had larger pores size 
compared to the 7.5% formulation, possibly due to fusion of the pores during the secondary 
drying phase. On the other hand, high bloom strength gelatin at the entire concentration 
range (2-10%) displayed three dimensional ordered pores which were polygons to spherical in 
shape (Figures 2.4 e, f, g and h). The pores were about 70, 40, 30, and 70 µm in diameter, for 
the 2, 5, 7.5, and 10% stock solution, respectively. However, all the high bloom strength 
formulation seemed to be more compacted than similar concentration of the low bloom 
strength. The formation of polygonal or spherical pores in gelatinous lyophilised tablets can be 
explained as a result of the film forming properties of gelatin molecules around water 
molecules in the gel state of the stock solution (Kaushik and Roos, 2006), as the freeze drying 
process is believed to retain the structure of the formulation (Abdelbary et al., 2004). The 
difference in the structural features between low and high bloom gelatin based tablets at low 
stock solution concentration (≤ 5%) can be explained in terms of their differences in gelling 
property. It is generally accepted that low bloom strength gelatin has weaker gelling capability 
(Segtnan et al., 2003); therefore it is incapable of forming film around the water at such low 
concentration and after freeze-drying channel like structure was formed instead of the 
spherical pores. This channel like structure seems to promote the entry of water and offers 
larger surface area for the water to interact and disrupt the intermolecular bond between  
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Figure 2.4 Scanning electron micrograph of the lyophilised tablets based on : a) 2% 60 bloom 
strength gelatin, b) 5% low bloom strength gelatin, c) 7.5% low bloom strength gelatin, d) 10% 
low bloom strength gelatin, e) 2% high bloom strength gelatin, f) 5% high bloom strength 
gelatin, g) 7.5% high bloom strength gelatin, and h) 10% high bloom strength gelatin. 
 
gelatin molecules; thereby resulting in faster disintegration, as confirmed from the results 
(Figure 2.3). 
 
2.5.1.4. Primary drying rate and product temperature during freeze 
drying  
The effect of gelatin stock solution concentration on the primary drying rate is presented in 
Figure 2.5. The decrease in the sublimation rate with time is a result of increasing the thickness 
of the dried layer (Tang et al., 2006). The results clearly showed that increasing gelatin 
concentration in the formulation decreases the sublimation rate significantly, which means 
longer primary drying time is required to formulate ODT from high concentration of gelatin. 
The product temperatures during the primary drying (Figure 2.6) confirmed this observation as 
the fast sublimation rate of the formulation with low gelatin concentration maintained low 
product temperatures by increasing heat removal from the latent heat of sublimation 
(Patapoff and Overcashier, 2002).  
a b c d 
e f g h 
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Figure 2.5 Effect of gelatin stock solution concentration on the sublimation rate of the ODT at 
shelf temperature of -40 °C vacuum of 50 m Torr. Results are mean ± SD, n=3. 
 
 
Figure 2.6 Effect of gelatin stock solution concentration on product temperature during 
primary drying at shelf temperature of -40 °C vacuum of 50 m Torr. 
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The results can be explained depending on the total porosity results of the lyophilized ODT 
(Table 2.1), where increasing gelatin concentration in the formulation decreases the total 
porosity and consequently increases the resistance of the dried layer to mass transfer of water 
vapor (MTR) (Patapoff and Overcashier, 2002). 
 
Table 2.1 Total porosity of ODTs prepared from varied concentration of gelatin stock solution. 
Gelatin concentration (%w/w) Total porosity (%) 
2.0 98.6 ± 0.1 
3.5 97.6 ± 0.2 
5.0 96.1 ± 0.2 
7.5 90.3 ± 0.5 
10.0 87.0 ± 0.4 
 
 
2.5.2. Inclusion of varied concentration of saccharides 
To the best of our knowledge, the effects of inclusion of saccharides on the properties of 
gelatin based lyophilised fast disintegrating tablets have not been documented. To investigate 
this, five saccharides, glucose, trehalose, maltotriose, xylitol and mannitol, were added to 2 
and 5 % gelatin (60 bloom strength) stock solution with concentrations ranging from 10 to 80 
% (w/w of solid material) and investigated for their disintegration time, mechanical and 
thermal properties. 
 
2.5.2.1. Impact of saccharides on the physical appearance of the tablets 
Although all the formulations were freeze-dried according to the same cycle (primary drying 
for 48 hours, at a shelf temperature of -40 °C, secondary drying for 10 hours, at a shelf 
temperature of 20 °C and a constant vacuum of 50 m Torr) inclusion of saccharides showed 
different behavior in forming intact tablets depending on the type and concentration of 
saccharide used and on the concentration of gelatin stock solution. Addition of glucose or 
xylitol, up to 40 % (w/w of solid material), to both 2 and 5% gelatin stock solution resulted in 
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formation of intact tablets (Figures 2.7a and b respectively). However, higher concentration 
(50-80%) produced tablets with signs of deformation (Figures 2.7f and g respectively) as in the 
case of 5% gelatin stock solution, or with very weak mechanical properties as in the case of 2% 
gelatin stock solution. Trehalose and maltotriose provided intact tablets up to 50% (Figures 
2.7c and d). On the other hand, addition of mannitol produced intact tablets throughout the 
entire concentration range (10-80%) (Figures 2.7e and k). 
 
2.5.2.2. Differential scanning calorimetry investigation 
Differential scanning calorimetry profiles of the liquid formulations were used to study the 
effect of saccharides at different concentration on the thermal properties (glass transition 
temperature and crystallisation event) of 2 and 5% gelatin stock solution. The glass transition 
temperatures of the frozen solution are summarised in Table 2.2. These values were based on 
5%w/w gelatin solutions and have been confirmed for formulations based on 2%w/w gelatin 
(data not shown), where similar values were obtained. As expected, increasing the saccharides 
concentration in the formulation resulted in lowering their Tg, due to the plasticising effect of 
 
 
 
Figures 2.7 Physical appearance of lyophilised tablets based on 5% gelatin stock solution after 
inclusion of: a) 30% xylitol w/w of total solid material, b) 30% glucose, c) 30% trehalose, d) 30% 
maltotriose, e) 30% mannitol, f) 60% xylitol, g) 60% glucose, h) 60% trehalose, i) 60% 
maltotriose, k) 60% mannitol. 
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Table 2.2 The glass transition temperature of 5% gelatin solution in water with 10, 30, 50, 70 % 
(of total solid material) of Xylitol, Glucose, Trehalose, Maltotriose and Mannitol. 
 
 
the saccharides. This was true for all the saccharides except in the case of 70% mannitol, 
where the Tg was higher than the Tg value for the 50% concentration. This was due to partial 
crystallisation of mannitol during the freezing step. Crystallisation of mannitol during the 
cooling step has been well studied in literature (Hawe and Friess, 2006a; Hawe and Friess, 
2006b). Also, the results showed that xylitol had the highest plasticising effect on the gelatin 
solution when compared to the similar concentration of other saccharides, followed by 
mannitol and glucose (close Tg values) then trehalose, while maltotriose exhibiting the lowest 
effect (Table 2.2). It is interesting to note, that this order is directly related with the increase in 
the molecular weight of the saccharides, as xylitol has the lowest molecular weight (152.15), 
followed by mannitol, glucose, trehalose (182.17, 180.16 and 242.30respectively) and 
maltotriose  (504.44). This is in agreement with literature, where low molecular weight 
compounds have lower Tg values when compared to the high molecular weight compounds 
(Roos, 1997). Glass transition temperature is an important parameter in understanding and 
developing the lyophilisation process, as it determines the mobility of the molecules inside the 
system at any temperature. Usually, lyophilisation of stock solutions at temperature 1 to 3 ˚C 
higher than their Tg results in the collapse of their structure. This temperature is known as the 
collapse temperature (Tc) (Pikal and Shah, 1990).  
Given that the shelf temperature in the primary drying was -40 ˚C and the secondary drying 
was carried out at 20 ˚C, the anticipated Tc results (which are 1 to 3 ˚C higher than the Tg) 
suggested that the damage noticed in the lyophilised tablet at high concentration of 
saccharide might possibly occur during the primary drying step, as the Tc became closer to the 
Saccharide Tg (˚C) 
10  % 30% 50% 70% 
Xylitol -17.12 ± 0.09 -31.21 ± 1.45 -40.56 ±  0.51 -44.40 ± 0.16 
Glucose -15.09± 0.11 -25.59 ± 0.51 -33.20 ± 0.18 -36.70 ± 0.23 
Maltotriose -12.89 ± 0.32 -15.63 ± 0.77 -18.10 ± 0.64 -20.25 ± 0.41 
Mannitol -17.05 ± 0.22 -27.45 ± 0.03 -33.32 ± 0.03 -29.31 ± 0.03 
Trehalose -14.91 ± 0.08 -18.31 ± 0.14 -21.49 ± 0.02 -24.97 ± 0.09 
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shelf temperature (-40 ˚C). Mannitol formulations did not show any damage or collapse during 
the lyophilisation; although it had close Tc values to glucose formulations. This might be due to 
the crystallisation behaviour of mannitol during the lyophilisation process. 
On the other hand, DSC scans of the formulations showed that all the saccharides at the full 
concentration range studied (10-70 %) maintained an amorphous state during the heating step 
(from -65 to 20 ˚C), except in the case of 50 and 70% mannitol, where crystallisation 
exothermic peaks have been detected at about -24 ºC (onset) (Figures 2.8). This finding along 
with the increase in Tg at 70% mannitol mentioned above suggests that mannitol has higher 
tendency to crystallise than the other saccharides and increasing the concentration of 
mannitol in the gelatin stock solution promotes mannitol crystallisation. Although low 
concentration of mannitol in the stock solution (10-30 %) did not crystallise during the heating 
scan, crystallisation during the freeze drying step is highly expected (Pyne et al., 2003).  
 
 
Figure2.8 Overlaid DSC heating curves of frozen gelatin stock solution (5%) with 70% (total 
solid materials) of the saccharides. The figure shows glass transition (Tg), crystallization (Cr) 
and ice melting (M) events as a function of temperature. (A) xylitol; (B) glucose; (C) mannitol; 
(D) trehalose; (E) maltotriose. 
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The DSC study along with the morphological evaluation of the lyophilised tablets (Figures 2.7) 
indicated that mannitol is the most suitable bulking agent among the other saccharides (xylitol, 
glucose, trehalose and maltotriose), as it readily crystallised during the lyophilisation process 
and produced elegant tablets. The other saccharides are more suitable as lyoprotectant 
agents, as they showed high tendencies to exist in the amorphous status (Crowe and Crowe, 
2000). This is in agreement with literature, where mannitol was used for its crystalline bulking 
property combined with other materials such as trehalose and human serum albumin that 
maintain their amorphous nature throughout and after the lyophilisation process (Hawe and 
Friess, 2006a; Lu and Pikal, 2004; Izutsu and Kojima, 2002). 
 
2.5.2.3 The influence of saccharide concentration on the mechanical 
properties 
Enhancing the mechanical property of fast disintegration tablets and capsules by inclusion of 
saccharides has been applied in several studies (Seager, 1998; Ciper and Bodmeier, 2005). The 
effect of inclusion of varied concentration of the saccharides on the fracturability of the 
lyophilised tablets is presented in Figure 2.9. The test was done only for tablets that were 
fabricated based on 5%w/w gelatin stock solution. This was because the test's probe (1mm 
diameter) was unable to penetrate the tablets formulated based on 2%w/w gelatin solution 
due to the spongy nature of these tablets that tend to deform in response to the force applied 
by the probe. The results (Figure 2.9) showed that the fracturability of the tablets was 
improved by increasing the concentration of the saccharides in the stock solution. Statistically, 
maltotriose started to provide significantly higher fracturability at concentration of 30%, with 
fracturability of about 3.4 N, when compared to the reference tablets (made from 5 % gelatin 
solution alone), (one-way ANOVA/ Dunnett: ρ < 0.05), while the rest of the saccharides 
showed significant improvements at 40% (w/w), with fracturability of about 3.2, 2.8, 3.7 and 
3.6 N for xylitol, glucose, mannitol and trehalose, respectively (one-way ANOVA/ Dunnett: ρ < 
0.05). It is interesting to note that different saccharides at similar concentration provided 
tablets with no significant difference in the fracturability (one way ANOVA/Tukey-Kramer: 
ρ>0.05) suggesting that the fracturability of the lyophilised tablets is influenced by the 
concentration of the saccharides regardless of the type of the saccharide. 
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Figure 2.9 The effect of varying the concentration of xylitol, glucose, maltotriose, mannitol and 
trehalose on the fracturability of lyophilised tablets based on 5% Gelatin solution. Results are 
mean ± SD, n=3. 
 
Figure 2.10 and 2.11 demonstrate the hardness of the tablets based on 2 and 5%w/w gelatin 
stock solution, respectively, after inclusion of varied concentration (10-80%) of the 
saccharides. The results showed that all the saccharides, at concentration of 10% w/w (solid 
material), significantly improved the hardness of the tablets when compared to tablets based 
2% gelatin solution alone (one-way ANOVA/ Dunnett: ρ < 0.05). However, only trehalose, 
maltotriose and mannitol continued the trend at higher concentrations (Figure 2.10). 
In the case of tablets formulated from 5% gelatin stock solution (Figure 2.11), xylitol and 
glucose did not show any significant improvement in the hardness for the entire concentration 
range (10-40 % w/w). Whilst trehalose, maltotriose and mannitol showed no significant 
differences at concentrations below 30%, higher concentrations resulted in significant increase 
in hardness (Figure 2.11). Although, at similar concentration, the improvement in the hardness 
was not significantly different between these three saccharides the hardness after inclusion of 
maltotriose was the highest, at any given concentration, followed by trehalose then mannitol,  
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Figure 2.10 The effect of varying the concentration of xylitol, glucose, maltotriose, mannitol 
and trehalose on the hardness of lyophilised tablets based on 2% Gelatin solution. Results are 
mean ± SD, n=3. 
 
 
Figure 2.11 The effect of varying the concentration of xylitol, glucose, maltotriose, mannitol 
and trehalose on the hardness of lyophilised tablets based on 5% Gelatin solution. Results are 
mean ± SD, n=3. 
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which may suggest that increasing the molecular weight of the saccharide improves the 
hardness of the tablets. In conclusion, this study suggests that improving the mechanical 
properties of lyophilised tablets can be effectively achieved by inclusion of high concentration 
(equal or higher than 40% w/w) of trehalose, maltotriose or mannitol. 
 
2.5.2.4. Investigation of disintegration time 
The disintegration time of 2 and 5 % (w/w) tablets after incorporation of varied concentration 
of the saccharides are illustrated in Figures 2.12 and 2.13, respectively. The results indicated 
that the effect of the saccharides on the disintegration time was highly influenced by the 
concentration of gelatin in the stock solution, in addition to the type and concentration of 
saccharide used. The disintegration time of the tablets based on 2% gelatin stock solution 
seemed to be retarded (increased) by the saccharides in the entire concentration range. 
Statistical analysis of the data showed that all the formulations had significantly higher 
disintegration times when compared to the control, 2% gelatin alone (P<0.05), with the 
exception of low glucose concentration (10 and 20%) and moderate mannitol concentration 
(30 and 40), (which had disintegration times of 6 seconds or less (Figures 2.12). On the other 
hand, the effects of the saccharides on the disintegration time of tablets based on 5% gelatin 
stock solution when compared to the control, 5% gelatin alone, could be categorized 
statistically into three groups: i) significant increase in the disintegration time, which was 
noticed with trehalose at concentration range from 10 to 40% (w/w). ii) No significant effect, 
which was the case in high concentration of trehalose (50%), low mannitol concentration 
(10%), high mannitol concentration (40-80 %) and xylitol, glucose and maltotriose in the entire 
concentration range. iii) significant decrease, which was only achieved with moderate 
concentration of mannitol (20-40 %). 
Interestingly, nearly all the disintegration time profiles (Figures 2.12 and 2.13) tended to form 
parabolic relationships with saccharide concentration with different dip values (shortest 
disintegration time) that were obtained at distinctive concentrations for each saccharide. For 
example, mannitol achieved the shortest disintegration time of 4 and 5 seconds at 
concentration of 30% (in 2 and 5% gelatin formulations, respectively), whilst the shortest 
disintegration time for glucose formulations was 5 and 20 seconds, for 2 and 5% gelatin based 
tablets, respectively, and occurred at concentration of 20% in both cases. This parabolic  
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Figures 2.12 The disintegration time of tablets based on 2% gelatin stock solution after 
inclusion of varied concentration of xylitol, glucose, maltotriose, mannitol and trehalose. 
Results are mean ± SD, n=3. 
 
 
Figures 2.13 The disintegration time of tablets based on 5% gelatin stock solution after 
inclusion of varied concentration of xylitol, glucose, maltotriose, mannitol and trehalose. 
Results are mean ± SD, n=3. 
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relationship could be explained by the disintegration mechanism of the lyophilised tablets. The 
porous structure of the tablets allows fast diffusion of water (disintegrating medium) through 
hydrophilic matrixes that disintegrate/dissolve rapidly with water. Accordingly, the tablet’s 
porosity and hydrophilicity play a major role in determining the disintegration time (Sunada 
and Bi, 2002). Addition of saccharide to the formulation increases the hydrophilicity of the 
matrix but, at the same time, decreases the porosity, as a result of decreasing the water 
concentration in the stock solution (because water is the porogen element in the formulation). 
Therefore, each saccharide has an optimal concentration where an optimal balance between 
the porosity and hydrophilicity is created and consequently gives the shortest disintegration 
time. 
 
2.5.2.5. The lyophilised tablet index 
Successful development of fast disintegrating tablets by lyophilisation technique requires 
careful optimization of formulation parameters in order to obtain an optimal balance between 
the tablet properties, namely: mechanical properties and disintegration time. Different 
saccharides at varied concentration range were included in the formulation to enhance the 
mechanical properties and disintegration time in parallel. However, the results (see above) 
showed that the disintegration time and mechanical properties of the tablets were improved 
in different ways and to different extent (see above discussion). Therefore, a value that 
assesses the improvement in both parameters together was identified as following: 
LTI = (H/DT) ÷ (H˚/DT˚), Where: 
LTI: lyophilized tablets index 
H: hardness of the tested tablet 
DT: disintegration time of the tested tablet 
H˚: hardness of the control tablets 
DT˚: disintegration time of the control tablet 
The index was formulated by using the hardness and disintegration time only, as the 
fracturability was simply being influenced by the concentration of material in the stock 
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solution. The concept of LTI ensures higher value for the better improvement in both 
parameters. The lyophilized tablet index values of the 2 and 5% gelatin based formulation are 
presented in Tables 2.3 and 2.4, respectively. Although different values have been obtained 
from 2 and 5% gelatin formulation for the same saccharide the two sets of values are in 
agreement about the best formulation (highest LTI value). For example, mannitol at 
concentration of 30 and 40 % has the highest values in both Tables (2.3 and 2.4). 
 
 Table 2.3 The lyophilised tablet index values of tablets based on 2% gelatin stock solution and 
varied concentration of xylitol, glucose, maltotriose, mannitol and trehalose. 
- No intact lyophilised tablets were formed 
 
 
Table 2.4 The lyophilised tablet index of tablets based on 5% gelatin stock solution and varied 
concentration of xylitol, glucose, maltotriose, mannitol and trehalose. 
Saccharide LTI 
10% 20% 30% 40% 50% 60% 70% 80% 
Xylitol 0.57 1.25 1.15 0.94 - - - - 
Glucose 1.08 1.22 1.05 1.18 - - - - 
Trehalose 0.72 0.52 0.78 0.74 1.27 - - - 
Maltotriose 0.90 0.95 1.13 1.34 1.84  - - 
Mannitol 0.79 1.96 8.10 7.33 1.27 1.28 2.65 1.90 
- No intact lyophilised tablets were formed 
 
 
 
Saccharide LTI 
10% 20% 30% 40% 50% 60% 70% 80% 
Xylitol 0.54 0.56 0.34 0.27 - - - - 
Glucose 1.00 0.49 0.28 0.18 - - - - 
Trehalose 0.44 0.42 0.45 0.48 0.46 - - - 
Maltotriose 0.65 0.45 0.75 0.70 0.81 - - - 
Mannitol 0.62 1.10 1.42 2.10 0.90 0.90 0.87 0.65 
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2.5.3. Fast disintegration tablets of clonidine HCl 
Clonidine HCl (as model drug) was formulated as a lyophilized fast disintegrating tablet based 
on the formulation that had achieved the highest LTI value, 30% mannitol (w/w of total solid 
material) in 5% gelatin stock solution (Tables 2.4). Trehalose was added to the formulation in 
low concentration to act as lyoprotectant, as it well known for its efficient lyoprotectant 
activity in protein formulation (Richards et al., 2002; Elbein et al., 2003). The low dose of 
clonidine HCl (100 µg/tablet) was not expected to affect the formulation properties. The 
composition resulted in successfully freeze dried and elegant tablets that were strong enough 
to be easily handled. The tablets disintegrated in 6.3 ± 0.6 seconds and had a hardness of 17.3 
± 0.7 N and fracturability of 3.6 ± 0.3 N. The results suggested that the tablet properties 
(mechanical properties and disintegration time) were not significantly different when 
compared to formulations containing only 30% mannitol. The mean drug content in one tablet 
analysed by HPLC was 92.5 µg with standard deviation of 2.0. Reconstitution of one tablet in 2 
ml water resulted in solution with viscosity of 3.1 ± 0.1 m.pas/s and pH value of 5.2 ± 0.1. The 
results suggest the ability of such system, to deliver a clonidine HCl dose in efficient and 
convenient way. 
 
2.6. Conclusion 
The disintegration time of the tablets dramatically decreased by decreasing the concentration 
and bloom strength of gelatin in the stock solution, whereas the mechanical properties of the 
tablets were influenced by the concentration of gelatin rather than the bloom strength. 
Enhancing the mechanical properties of the freeze-dried tablets by increasing gelatin 
concentration inversely influences their disintegration time. Low bloom strength gelatin with 
stock solution concentration between 2-5% (w/w) is most suitable for developing rapid 
disintegrating lyophilised tablets. Mannitol crystallises during the freeze drying process and 
consequently produces elegant tablets. Xylitol, glucose, trehalose and maltotriose are more 
resistant to crystallisation, which proposes their lyoprotection role in the formulation. The 
disintegration time profiles of the gelatin/saccharide systems are parabolic with different dip 
values (shortest disintegration time) at distinctive concentrations for each saccharide. High 
concentration of trehalose, maltotriose and mannitol (equal or higher than 40% w/w) 
significantly enhances the mechanical properties of the tablets. Mannitol at concentrations 
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between 30 to 40 % w/w (of total solid material) achieved the greatest balance between the 
disintegration time and hardness as demonstrated by the LTI value. The optimised rapid 
disintegrating tablet in this study is able to efficiently deliver clonidine HCl. 
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Formulation and Characterisation of Lyophilised ODTs 
Using Amino Acids as Matrix Forming Agents 
 
3.1. Introduction and Aims 
The fabrication of lyophilised ODTs is based on creating a porous matrix by subliming the water 
from pre-frozen aqueous formulation of the drug containing matrix forming agents and other 
excipients such as lyoprotectants, preservatives and flavours (Seager, 1998). The matrix of the 
lyophilised ODT consists of two components that work together to ensure the development of 
a successful formulation. The first component is water soluble polymers such as gelatin, 
dextran, alginate (Seager, 1998), maltodextrin (Corveleyn and Remon, 1998). This component 
maintains the shape and provides mechanical strength to the tablets (binder). The second 
constituent is matrix supporting/ disintegration enhancing agents such as sucrose and 
mannitol, which acts by cementing the porous framework provided by the water soluble 
polymer and accelerates the disintegration of the ODT (Chandrasekhar et al., 2009). Although 
there is wide availability of literature describing the preparation of ODTs by lyophilisation, the 
number of matrix supporting/ disintegration enhancing agents used has been limited to 
saccharides and polyols with majority of the work dedicated to the inclusion of mannitol 
(Seager, 1998; Chandrasekhar et al., 2009). This is primarily because the incorporation of these 
matrix forming agents requires fulfilment of stringent characteristics such as reasonable drying 
time, stability during freeze-drying process, as well as formation of elegant tablets with short 
disintegration time and adequate mechanical properties (see chapter two). However, high 
concentration of saccharides and polyols is required to achieve these quality features (Seager, 
1998; Chandrasekhar et al., 2009), thus restrains their application in delivering drugs for the 
treatment of long term chronic conditions especially for children, diabetic and obese patients, 
due to  limited intake requirement. Therefore this chapter aims to explore alternative novel 
excipients by investigating the feasibility of using amino acids as matrix supporting agents 
(second component) in the fabrication of rapid disintegrating tablets prepared by freeze drying 
in order to produce tablets with enhanced properties and wider application to pediatric and 
geriatric patient population. 
Amino acids are the basic structural units (monomer) of proteins. An alpha amino acid consists 
of an amino group, a carboxyl group, a hydrogen atom, and a distinctive side chain bonded to a 
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carbon atom (alpha carbon). The side chains of amino acids are responsible for the variation in 
their physicochemical properties. Naturally occurring amino acids can exist in both the L 
(laevo) and the D (dextro) forms, which are mirror images of each other.  However 
incorporation of the D form of the amino acid has been limited for pharmaceutical applications 
due to their potential pharmacological activity, microbiological concerns and toxicity (Tsai et 
al., 1998; Williams et al., 2005; Friedman, 1999).  On the other hand, the L form of the amino 
acids has been used extensively in pharmaceutical and cosmetic formulations such as pH 
sensitive drug carrier (Oh et al., 2008), cicatrisation topical dermatological preparations 
(Marrubini et al., 2008), salt conjugate of poorly soluble drug (Anacardio et al., 2003), oral 
tablets, as lubricant (Rotthauser et al 1997) and disintegration enhancer (Fukami et al., 2006), 
inhalable delivery systems (Alhusban and Seville, 2009) and freeze dried product, as 
cryoprotectants (Mohammed et al., 2007) and bulking agent (Akers et al., 1995). 
In this study, L-amino acids with adequate aqueous solubility, which allow their inclusion at 
varied concentration, were chosen (alanine, arginine, threonine, glycine, cysteine, serine, 
histidine, lysine, valine, asparagine, glutamine and proline) and their potential as matrix 
supporting/ disintegration enhancing agents were investigated individually at concentration of 
10, 30, 50 and 70 % w/w (total solid) using 5% aqueous solution of low bloom strength gelatin 
(60 bloom strength) as a binder. The formulations were examined for their thermal properties 
in their frozen state in order to explain their behaviour during the freeze drying process. The 
freeze dried tablets were evaluated for their disintegration time and mechanical properties. In 
addition, the porosity of the ODTs and the wettability profile of the amino acids were 
investigated to explain the disintegration time and mechanism. 
 
3.2. Materials 
Gelatin of bloom strength 60 (from calf skin), L-alanine, L-arginine, L-threonine, glycine, L-
cysteine, L-serine, L-histidine, L-lysine, L--valine, L-asparagine, L-glutamine and L-proline were 
purchased form Sigma-Aldrich Chemicals (Pool, UK). All the chemicals were of analytical grade. 
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3.3. Methods 
3.3.1. Preparation of lyophilized tablets 
The amino acids were added individually to 5 % (w/w) gelatin (60 bloom strength) stock 
solutions at concentrations of 10, 30, 50 and 70% of total solid material. 1.5 g of the solution 
was poured into the tablet mould (13.80 mm diameter, 8.50 mm height), frozen at -80 °C for 
about 60 minutes and freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to an 
optimized regime (primary drying for 48 hours at shelf temperature of -40 °C and secondary 
drying for 10 hours at shelf temperature of 20 °C and vacuum of 50 m Torr). All formulations 
were prepared in triplicate from three independent batches. 
 
3.3.2. Differential scanning calorimetry studies 
Differential scanning calorimetry (Pyris Diamond DSC and Intracooler 2P: Perkin Elmer, 
Wellessey, USA) was used to determine the glass transition temperature (Tg) and 
crystallisation event of the formulation in its frozen state (before freeze drying). 10-15mg of 
the liquid formulation were loaded into aluminium pans, cooled to -65 ˚C and then heated to 
20 ºC at 5 ºC/min with a nitrogen purge of 20ml/min. To determine the glass transition 
temperature of the maximally freeze concentrate sample (Tg’), after initial cooling to -65 ºC, 
annealing for 10 min at -15  ºC was added before carrying out the above method. An empty 
aluminium pan was used as reference for all measurements.  
The resulting plots were analysed by Pyris manager software. Tg and Tg’ values were 
determined from the intersection of relative tangents to the baseline. All the measurements 
were done in triplicate from independently prepared samples. 
The DSC was calibrated for temperature and heat flow using standard samples of indium 
(melting point: 156.6 ºC, ∆Hm: 28.42 J/g) and Zinc (melting point: 419.5 ºC, ∆Hm: 108.26 J/g). 
 
3.3.3. Mechanical properties of the tablets 
The mechanical properties of the tablets (hardness) were investigated with a texture analyzer 
(QTS 25: Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated 
with standard weight of 500 g and 5 kg. The tablet was placed in a holder with a cylindrical 
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hole. The hardness was taken as the peak force after 1mm penetration of 5mm diameter 
probe at a speed of 6 mm/min. The results were average of three measurements from 
independently prepared batches. 
 
3.3.4. Disintegration time of the tablets 
The disintegration time of the tablets was measured using a USP disintegration tester (Erweka, 
ZT3). Distilled water (800 ml) kept at 37 ºC was used as a medium and the basket was raised 
and lowered at a fixed frequency of 30 cycles/min. One tablet was tested at a time. All the 
formulations were evaluated in triplicate and standard deviation was calculated. 
 
3.3.5. Porosity 
The relative porosity was calculated from the apparent and strut density of the tablet. 
Apparent density was found by dividing the mass of the tablet by the measured volume. The 
strut density was determined using helium pycnometry (Accupyc 1330, Micromeritics, UK) 
with 3 cm³ sample cup at 22 ºC. Prior to analysis the helium pycnometry was calibrated against 
a standard steel ball. Each determination included 10 purges at 19.5 psi and 10 analytical runs 
at 19.5 psi with an equilibration rate of 0.0050 psi/min.  
 
3.3.6. Wetting profile 
The wetting profile of the amino acids was analysed by measuring their contact angle using 
Wilhelmy method. The amino acids were analysed in their powder form after brief milling 
using mortar and pestle. Cover slides (24*24 mm) were covered by double sided tape (Scotich 
12*1 mm) and dipped into a container of the milled amino acid to create a uniform coating. 
Excess powder was removed by tapping the cover slide. After measuring the perimeter (width 
and thickness), using a micrometer, the coated cover slide was attached to the balance loop of 
microbalance in the tensiometer (QCT-100 Interfacial Tensiometer, Camtel Ltd, UK). The 
beaker under the sample was filled with 75 ml double distilled water at temperature of 25 ºC 
(liquid medium).  
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The computer was programmed to lower the sample to a distance of 10 mm after contact with 
the liquid medium at a constant speed of 0.20 mm/s. The contact angle was calculated 
automatically (using Wilhelmy equation) at regular interval and recorded as a function of time.                   
 
3.3.7. Morphological examination 
 The inner structural morphology and pore size of the freeze-dried tablets were examined by 
scanning electron microscopy (SEM, STEREOSCAN 90, Cambridge Instrument). Thin horizontal 
cross-section sample was prepared by cutting the tablet with a razor blade. The samples were 
placed onto double-sided adhesive strip on an aluminium stub. The specimen stub was coated 
with a thin layer of gold using a sputter coater (Polaron SC500, Polaron Equipment, Watford, 
UK) at 20 mA for three 3 minutes and then examined by SEM. The acceleration voltage (KV) 
and the magnification can be seen on each micrograph. 
 
3.3.8. Statistical analysis 
The effect of inclusion amino acids on the glass transition temperature of the formulation in 
the frozen state was compared to those of the control (composed of gelatin only) and against 
each other using one-way analysis of variance with Dunnett multiple comparison test and one-
way analysis of variance with Tukey-Kramer multiple comparison test, respectively. The 
hardness, fracturability and disintegration of the lyophilised tablets after inclusion of the 
amino acids were statistically compared to those of the control (composed of gelatin only) 
using one-way analysis of variance with Dunnett multiple comparison test. The total porosity 
of the tablets and the wetting parameters of the amino acids were compared against each 
other using one-way analysis of variance with Tukey-Kramer multiple comparison test. The 
significant level was 0.05. 
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3.4. Result and discussion 
3.4.1. Thermal analysis 
Thermal analysis of the frozen formulations is crucial in the development of lyophilised tablets 
to ensure the formation of intact tablets with minimal morphological defects and also to 
determine the molecular state of the excipients (amorphous or crystalline). Measurement of 
glass transition temperature of maximally freeze concentrated (Tg’) solution reflects the 
molecular mobility of the excipients as a function of temperature within the frozen matrix 
which in turn dictates the stability of the formulation during the lyophilisation process.  
Freeze-drying of formulations at temperatures 1-3 ˚C above their Tg’ (collapse temperature, 
Tc) usually induces physical collapse due to the increase in the mobility of the frozen solution 
(Pikal and Shah, 1990). Accordingly, to protect the formulation matrix from possible collapse, 
the temperature of the freeze dried product should not exceed the collapse temperature and a 
safety margin is required between the two temperatures (2-5 ˚C) to ensure the reproducibility 
of the process (Tang and Pikal, 2004). This has a direct impact on the freeze drying regime, as 
lower shelf temperature is required to successfully freeze dry formulations comprising of low 
Tg’, which in turn prolongs the primary drying time significantly (Pikal, 1990). In addition, 
crystallisation during the freeze drying stages (freezing, annealing or primary drying) is 
believed to give more stability to the formulation, protect against possible collapse and 
produce elegant lyophilised product (Seager, 1998; Chandrasekhar et al., 2009). Therefore, 
excipients that crystallise during the freeze drying process are more suitable as bulking agents 
(Lu and Pikal, 2004). However amorphous materials are also required in the lyophilized 
formulation to replace the sublimed water molecules and consequently protect against any 
structural changes or aggregation in the final product (lyoprotectant) (Crowe and Crowe, 
2000). 
The thermal properties of frozen aqueous solutions containing 5% gelatin and various 
concentrations of amino acids are summarized in Table 3.1. Limitations in the aqueous 
solubility of some amino acids prevented them from undergoing thermal analysis at higher 
concentration. At concentration of 10% w/w (total solid) of amino acids, the tested 
formulations showed thermal step in the baseline, glass transition of maximally freeze 
concentrated sample (Tg’), of the heating scan, indicating that the formulations remained in 
amorphous state during the freezing, annealing and heating processes. Given that the Tg’ of 
the control (5% gelatin without amino acid) was -11.72 ± 0.72 ˚C (n=3), addition of 10% w/w of 
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the different amino acids significantly lowered the Tg’ of the formulation (one-way ANOVA/ 
Dunnett: ρ < 0.05). The lowest Tg’ was recorded for alanine and proline. The decrease in the 
glass transition of the formulations was possibly due to the plasticizing effect of the amino 
acids. This is in line with previously reported research, which has shown that freeze dried 
systems upon inclusion of solutes within the formulation results in lowering of the glass 
transition temperature and is dependent on the interactions between the added excipient and 
unfrozen water (Nesarikar and Nassar, 2007).  Addition of plasticizing agents potentially 
reduces the intermolecular forces between binder molecules and increases polymer chain 
mobility thereby providing a cushioning effect.   However, the degree of plasticizing varied 
between the amino acids, which can be attributed to the differences in their physicochemical 
properties (Kagimoto et al., 2006) and total number of moles added.  
In order to further understand the differences, a plot between the molecular weight and 
plasticising effect of amino acids on gelatin solution was plotted (Figure 3.1). The low 
correlation coefficient (R²= 0.695) was probably due to the role of other physicochemical 
properties such as solubility and viscosity (Kagimoto et al., 2006).  However a general trend 
which showed that low molecular weight amino acids had a higher plasticising effect was 
observed (Figure 3.1). This could be a consequence of the higher number of amino acid moles 
provided by the low molecular weight amino acid in the formulation, as all the amino acids 
were added to the formulation mixture as a weight per weight percent. The presence of larger 
number of particles within the formulation may eventually have a higher cushioning effect 
resulting in greater decrease of intermolecular forces between the gelatin as well as gelatin- 
water molecules.  
Upon increasing of concentration to 30 % w/w, all the tested amino acids showed significant 
reduction in their Tg’ values when compared to their 10% formulation (one-way ANOVA/ 
Dunnett: ρ < 0.05) except glycine and valine, where partial crystallization was observed (Table 
3.1). At this concentration, the amino acids that showed lower Tg’ values appeared to retain 
their amorphous state throughout the heating range (-65 to 20 ˚C) except glycine, cysteine and 
valine, where partial crystallization was observed. However at a concentration of 50% w/w 
alanine, serine, glycine, cysteine and valine exhibited crystallisation, whereas the rest of the 
amino acids retained their amorphous state in the formulation during the cooling, annealing 
and heating processes as demonstrated by their Tg’ values (Table 3.1). At the highest studied 
concentration (70% w/w), arginine, threonine, lysine and proline retained their amorphous 
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Table 3.1 The glass transition temperature of maximally freeze concentrated (Tg’) and crystallisation event of 5% gelatin solution in water with 10, 30, 
50 and 70 % (of total solid material) of amino acids (mean ± SD, n=3).  
(Tg’) Glass transition temperature of the maximally freeze concentrate sample 
(Cr) Crystallisation 
(*) No event detected 
 (-) Not soluble 
 
 
Amino Acid 10   % 30% 50% 70% 
Tg’ (˚C) Cr (˚C) Tg’ (˚C) Cr (˚C) Tg’ (˚C) Cr (˚C) Tg’ (˚C) Cr (˚C) 
Alanine -21.55 ± 0.50 * -36.68 ± 0.15 * -12.85 ± 0.22 -32.77 ± 0.43 * -40.11 ± 0.80 
Arginine -14.46 ± 0.27 * -21.36 ± 0.13 * -27.32 ± 0.21 * -32.60 ± 0.09 * 
Threonine -18.51 ± 0.11 * -30.21 ± 0.45 * -35.41 ± 0.37 * -38.61 ± 0.49 * 
Glycine -20.46 ± 0.17 * -12.51 ± 0.82 -28.81 ± 0.85 * -45.53 ± 0.52 * -32.32 ± 1.00 
Cysteine -17.22 ± 0.69 * -25.01 ± 0.39 -10.33 ± 0.40 -13.14 ± 0.29 -23.01 ± 0.40 * * 
Serine -18.75 ± 0.22 * -25.70 ±0.58 * -12.56 ±0.18 -16.98 ± 0.33 * -24.00 ± 0.53 
Histidine -16.25 ± 0.41 * -21.34 ± 0.13 * -24.59 ± 0.30 * - - 
Lysine -20.34 ± 0.20 * -34.63 ± 0.63 * -39.08 ± 0.21 * -46.84 ± 0.22 * 
Valine -19.09 ± 0.17 * -12.02 ± 0.26 -24.25 ±0.44 * * - - 
Asparagine -16.82 ± 0.28 * -21.90± 0.16 * - - - - 
Glutamine -17.57 ± 0.60 * -24.84 ± 0.14 * - - - - 
Proline -21.47 ± 0.51 * -37.05 ± 0.86 * -50.43 ± 0.30 * > -65 * 
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Figure 3.1 The effect of molecular weight of amino acids on the glass transition temperature of 
frozen solutions containing 5% aqueous gelatin solution at concentration of 10% w/w (total 
solids) of the tested amino acids. Tg’: glass transition temperature of maximally freeze 
concentrated sample of 5% gelatin with 10% amino acid, T˚g’: glass transition of maximally 
freeze concentrated sample of 5% gelatin solution. 
 
state. The ability of arginine to preserve the amorphous behavior in the freeze concentrated 
solution has previously been documented by Izutsu et al. (2005), studying the effect of 
counterions on the physical properties of arginine in frozen solutions and freeze-dried solids.  
Although there was no event detected in 70 % proline formulations it can be anticipated that 
the glass transition was below the heating range employed (-65 to 20 ˚C), based on the data 
recorded for lower concentrations where lowering of the glass transition was noted upon 
increase of proline concentration. On the other hand, the crystallisation behavior of alanine, 
glycine, serine and cysteine prohibited the formulations from undergoing any glass transition 
event at this high concentration (Table 3.1). 
Freeze drying of the formulations in this study using the applied regime (primary drying for 48 
hours at shelf temperature of -40 °C and secondary drying for 10 hours at shelf temperature of 
20 °C and vacuum of 50 mTorr) revealed that the formation of intact tablets (with no signs of 
morphological defect) was crucially influenced by the above thermal properties of the 
formulation. All the formulations that showed tendency to crystallise formed elegant tablets 
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with no signs of morphological defect regardless of their Tg’ temperatures, which confirms the 
role of readily crystalline excipient in the formulation of lyophilised ODTs as discussed above. 
For amorphous formulations, the formation of intact tablet was dependant on Tg’. 
Formulations with Tg’ lower than -40 °C showed major structural collapse after freeze drying, 
while intact tablets were formed from higher Tg’. In the case of 30% proline formulation, 
partial collapse was noticed possibly due to the narrow safety margin between the shelf 
temperature and Tg’, therefore these tablets were excluded from further characterisation.  
 
3.4.2. Porosity 
The porosity of the ODTs at amino acid concentrations of 10, 30, 50 and 70% (w/w) is 
summarised in Table 3.2. The results suggested that each increment in the concentration of 
the amino acid in the ODTs was associated with a significant decrease in the total porosity (ρ 
<0.05), possibly due to a decrease in the water concentration in the stock solution (because 
water is the porogen element in the formulation). The results also showed that inclusion of 
different amino acids at concentration of 10% (w/w) produced tablets with insignificant 
differences in their total porosity (ρ >0.05). However, at higher concentrations (30, 50 and 70% 
w/w) of amino acids some variations in the total porosity were noticed. As all tablets in this 
study were produced using the same procedure and the same binder stock solution, any 
differences in their porosity were attributed to the inclusion of amino acids and their 
concentration. Tablets based on the same concentration of alanine, arginine, threonine, 
serine, cysteine, histidine and asparagine had very close total porosity values (less than 2% 
variation), whereas tablets fabricated from glycine and lysine at similar concentration 
produced tablets with slightly lower total porosity (ρ <0.05) and even much lower porosity was 
displayed by valine and glutamine formulations (ρ <0.001) when compared to the rest of the 
amino acids.  Further discussion about the impact of porosity on ODT characteristics is 
described in the sections of mechanical properties and mechanism of disintegration (below).  
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Table 3.2 The total porosity of ODTs based on 10, 30, 50 and 70% (w/w) amino acids.  
Amino acid Porosity (%) 
10% 30% 50% 70% 
Alanine 96.01 ± 0.32 94.12 ± 0.13 91.37 ± 0.15 86.12 ± 0.41 
Arginine 95.84 ± 0.41 94.09 ± 0.27 90.70 ± 0.22 85.31 ± 0.52 
Threonine 95.92 ± 0.22 94.36 ± 0.24 92.76 ± 0.23 86.61 ± 0.54 
Glycine 95.43 ± 0.35 92.42 ± 0.23 88.14 ± 0.21 82.03 ± 0.40 
Cysteine 96.12 ± 0.45 94.67 ± 0.27 92.71 ± 0.31 86.31 ± 0.35 
Serine 96.47 ± 0.30 95.00 ± 0.24 93.14 ± 0.32 87.83 ± 0.29 
Histidine 95.79 ± 0.43 94.14 ± 0.20 92.64 ± 0.30 - 
Lysine 95.21 ± 0.27 92.45 ± 0.31 88.21 ± 0.15 * 
Valine 95.12 ± 0.25 88.49 ± 0.27 74.94 ± 0.34 - 
Asparagine 96.35 ± 0.12 94.94 ± 0.35 - - 
Glutamine 95.17 ± 0.50 87.21 ± 0.62 - - 
Proline 96.10 ± 0.18 * * * 
(*) No intact lyophilised tablets were formed 
 (-) Not soluble 
 
 
3.4.3. Mechanical properties 
One of the inherent issues associated with the formulation of lyophilized orally disintegrating 
tablets is their weak mechanical properties (Fukami et al., 2006; Kuno et al., 2005; Narazaki et 
al., 2004) with the consequence that additional protection in the form of specialized packaging 
is required for the tablet to withstand mechanical stresses during shipping, storage and 
handling by patients. The poor mechanical properties are as a result of the porous anatomical 
architecture of the lyophilized ODT consisting of a three dimensional network of binder 
molecules (see Figure 3.2).  Our previous research (chapter 2) has shown that the two 
common methods to enhance the mechanical strength of the lyophilized ODTs is the inclusion 
of higher concentration of the binder or addition of excipients such as matrix supporting 
agents (saccharides and polyols).  However increase of binder concentration has a detrimental 
effect on the disintegration time of the tablets due to increase in intermolecular attraction 
between the binder molecules resulting in retardation in disintegration time profile leaving the 
incorporation of matrix supporting agents as a more pragmatic method. 
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Figure 3.2 Scanning electron micrographs of ODTs based on:  (a) 50% arginine, (b) 50% valine, 
(c) 50% lysine, (d) 50% alanine, (e) 50% threonine, (f) 50% serine, (g) 30% glutamine, (h) 50% 
histidine, (i) 50 % cysteine, (k) 30% asparagine, (m) 50% glycine.  
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In this study the use of 5% (w/w) gelatin stock solution as a binder proved to give the ODTs 
high resistant to friability, less the 0.15% (data not shown). However, due to the highly porous 
structure, the ODTs have a spongy nature, which is easy to deform in response to external 
forces. Therefore, the effect of inclusion of varied concentration of amino acids on the 
mechanical properties of the tablets was evaluated by applying a compression force through a 
5 mm diameter probe, and the peak force after 1mm compression was taken as the hardness.  
The hardness of the ODTs after inclusion of varied concentration of amino acids is presented in 
Figure 3.3. The results showed that inclusion of amino acids at low concentration of 10 and 30 
% w/w (total solid) did not improve the hardness of the tablets significantly when compared to 
gelatin only formulation (one way ANOVA/Tukey-Kramer: ρ >0.05). However upon increase of 
concentration to 50%, alanine (ρ<0.01), arginine (ρ<0.05), threonine (ρ<0.05), glycine (ρ <0.05) 
and serine (ρ <0.01) significantly (one way ANOVA/Tukey-Kramer) improved the hardness of 
the tablets from 13.5 ± 0.7N for gelatin only tablet (control) to 18.3 ± 1.0N, 17.5 ± 1.8N, 20.3 ± 
1.2N, 18.1 ± 0.9N, 19.7 ± 1.5N and 22.2 ± 1.7N, respectively.  At the highest studied 
concentration (70% w/w) only tablets based on arginine, glycine and serine achieved 
progressive enhancement in hardness over their 50% formulation, with the highest hardness 
recoded by the serine formulation (37.0 ± 4.5N).  
Generally, the mechanical properties of tablets are mainly influenced by the intermolecular 
bonding force and contact points between the excipients (Bi et al., 1996). The extent of 
contact between the matrix forming agents within the lyophilised ODTs is influenced by the 
total porosity of the tablets, decreasing the porosity increases the contact points between the 
matrix forming agents within the ODT. Accordingly, the improvement in the mechanical 
properties of the ODTs upon increasing the concentration of amino acids in the formulation 
was a result of decreasing the porosity (see porosity results). However, the degree of 
improvement was varied between the amino acids as a consequence of their variation in the 
molecular interaction with the binder (gelatin). For instance, although valine and glutamine 
formulation had the lowest porosity values (higher contact points) no improvement in the 
hardness was achieved and even significant deteriorations were noticed in the 10% glutamine 
and 50% valine formulations when compared to the control, which suggests weak bonding  
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Figure 3.3 The effect of varied concentration of amino acids on the hardness of lyophilised 
tablets based on 5% Gelatin solution. Results are mean ± SD, n=3. Statistical difference (one 
way ANOVA/Tukey-Kramer) from control: † ρ <0.05, ‡ ρ <0.01,   • ρ <0.001.       
 
interaction of these amino acids with gelatin fibers. These data appear to be supported by 
scanning electron microscopy (SEM) images (Figure 3.2) of the inner structure of the ODTs, 
which show that valine (Figure 3.2b) and glutamine (Figure 3.2g) molecules deposited at the 
surface of gelatin fibres instead of integrating within the fibre suggesting incompatibility of 
these amino acids with gelatin. On the other hand, SEM images of tablets based on amino 
acids that improved the hardness show homogenous network of fibres without any 
segregation/deposition of particles on the surface suggesting that these amino acids 
integrated completely with gelatin fibre and consequently added extra support to the tablet 
structure (Figure 3.2). 
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3.4.4. Disintegration time 
The results from the disintegration study are summarised in Figure 3.4.  As expected, the 
disintegration profile of the ODTs was distinctive for each amino acid (Figure 3.4), possibly due 
to differences in their physicochemical characteristics. At concentration of 10% (w/w), all of 
the tested amino acids showed no improvements on the disintegration time when compared 
to 5% gelatin formulation except alanine and glycine, which decreased the disintegration 
significantly (one way ANOVA/Tukey-Kramer: ρ <0.05), from 29 ± 2s for the 5% gelatin 
formulation to 17 ± 3s and 16 ± 4s, respectively. By increasing the concentration to 30% (w/w), 
alanine progressively promoted the disintegration profile to  6 ± 1s, which was the shortest 
disintegration time in the current study, whereas glycine showed a significant deterioration 
when compared to its 10% formulation (ρ <0.05). Interestingly, tablets based on 30% histidine  
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Figure 3.4 The disintegration time of tablets based on 5% gelatin stock solution after inclusion 
of   varied concentration of amino acids. Results are mean ± SD, n=3. Statistical difference (one 
way ANOVA/Tukey-Kramer) from control (shorter): † ρ <0.05, ‡ ρ <0.01,   • ρ <0.001. 
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and glutamine achieved significantly shorter disintegration times compared with their 10% 
counterparts and  control (5% gelatin) and recorded disintegration times of 18 ± 2s (ρ <0.05) 
and 9 ± 4s (ρ <0.01), respectively. The rest of the tested amino acids continued their trends by 
not offering any improvement over the disintegration time of the control (Figure 3.4). 
Inclusion of higher concentration of amino acids: (50 and 70% (w/w)) seemed to have negative 
effect on the disintegration profile of the tablets, except in case of arginine, where the 
disintegration profile seemed to be independent of concentration (one way ANOVA/Tukey-
Kramer: ρ >0.05).  
 
3.4.5. Wettability and wetting time 
The wettability of compressed ODT formulations has been investigated and correlated to the 
disintegration profile in previous research (Bi et al., 1996; He et al., 2008). However, in the 
case of lyophilised ODT, measurement of the wetting properties of the whole tablet is 
extremely difficult due to the very short disintegration time of the tablets.        
In the current study, all the ODTs were formulated by adding amino acids individually at varied 
concentration to a fixed concentration of gelatin stock solution (5% w/w). Therefore, the 
disintegration time of the ODTs is believed to be influenced by both the concentration and 
wetting properties of the amino acid. Accordingly, the wetting profiles of the tested amino 
acids in the powder form were investigated and correlated to the disintegration time of the 
ODTs.  
Measuring the wettability (expressed as contact angle) of pharmaceutical powder requires 
precision in sample preparation and is associated with extreme experimental care (Kwok and 
Wilhelm Neumann, 2003). Among the different techniques available, the Wilhelmy method 
which uses powder coated glass slides as a measurement plate has been shown to 
demonstrate superior reproducibility and accurate measurement of contact angle (Dove et al., 
1996). 
The contact angle (θ) profiles of the tested amino acids are presented in Figures 3.5 and 3.6. 
Valine displayed the highest contact angle which increased steadily with time until it was 
stabilized on an average of 147 ± 5 (n=5), indicating that valine is not wettable in water (θ 
>90˚). Serine, lysine, glutamine and histidine showed partial wetting profile (90˚< θ <0˚) with  
 
Chapter 3 – Amino acids as matrix forming agents   
110 
 
 
Figure 3.5 Representative profiles of contact angles of water on poorly and partially wettable 
amino acids as a function of time. 
 
 
Figure 3.6 Representative profiles of contact angles of water on highly wettable amino acids as 
a function of time. Phase transition time: is the time required for phase transition from partial 
(90˚< θ <0˚) to complete wetting (θ=0˚). Wetting time: is the time taken for the complete 
wetting phase to finish. 
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average contact angle values of 50 ± 3˚, 39 ± 2˚, 27 ± 4˚ and 23 ± 3˚ (n=5), respectively (Figure 
3.5). The rest of the tested amino acids (alanine, arginine, threonine, glycine, cysteine, 
asparagine and proline) displayed complete wetting profile (zero contact angle) (Figure 3.6). 
To differentiate between the wettability profiles of these amino acids, two parameter were 
identified, the phase transition time, which is the time required for phase transition from 
partial (90˚< θ <0˚) to complete wetting (θ=0˚), and wetting time, the time taken for the 
complete wetting phase to finish, which appears in the wettability profile as sudden increase 
in the contact angle (Figure 3.6). This increase in the contact angle is caused by the exposure 
of the adhesive layer to the water (wetting medium) as the tested powder starts to depart the 
plate into the liquid medium (Dove et al., 1996). The summary of the two parameters is 
presented in Table 3.3. The results revealed that proline, threonine, glycine, cysteine and 
asparagine showed complete wetting without delay (phase transition time = 0s), whilst alanine 
and arginine required 1.0 ± 0.7s and 4.9 ± 2.1s, respectively, to display complete wetting. On 
other hand, proline displayed the shortest wetting time of 1.3 ± 0.6 s, followed by alanine, 
glycine, cysteine, arginine, threonine and asparagine (Table 3.3). Interestingly, alanine, which 
is classified as hydrophobic amino acid, had shorter wetting time than arginine, threonine and 
asparagine, which are known to be more hydrophilic. The shorter wetting time of alanine 
compared to higher hydrophilic amino acids has been previously reported (Fukami et al., 
2005).  
 
 
Table 3.3 The wetting properties of the amino acids that showed complete wetting. Results 
are mean ± SD, n=5.  
Amino acid Phase transition time (s) Wetting time (s) 
Proline 0 1.3 ± 0.6 
Alanine 1.0 ±  0.7 15.8 ± 3.7 
Glycine 0 20.0 ± 3.2 
Arginine 4.9 ± 2.1 27.5 ± 1.2 
Threonine 0 34.3 ± 1.5 
Cysteine 0 25.5 ± 2.2 
Asparagine 0 42.9 ± 0.3 
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3.4.6. Mechanism of disintegration 
In this study, the disintegration time profiles of the ODTs as a function of amino acid 
concentration (Figure 3.4) was analysed depending on the wetting profile of the incorporated 
amino acids in order to determine the factors that influence the disintegration of the ODTs and 
consequently understand the mechanism of disintegration. In the case of poorly wettable 
amino acid (valine), the inclusion of higher concentration of valine in the formulation 
deteriorated the disintegration time possibly due to the decrease in the total porosity and 
creation of matrix that interacts less favorably with water (low wettability). For highly wettable 
amino acids (alanine, arginine, threonine, glycine, cysteine and asparagine), parabolic 
relationships between the disintegration time and the concentration of amino acid were seen, 
but with different dip values (shortest disintegration time) that were obtained at distinct 
concentrations for each amino acids (Figure 3.4). This parabolic relationship may be due to the 
inclusion of highly wettable amino acid within the formulation of ODTs which enhances the 
interaction of tablet’s matrix with water (disintegrating medium) but, at the same time, 
decreases the porosity which inhibits water penetration into the tablet. Therefore, each amino 
acid exhibited a decrease in disintegration time at an optimal concentration where a balance 
between porosity and high wettability was created and consequently achieved the shortest 
disintegration time. Figure3.7 represents a correlation between the wetting time of these 
highly wettable amino acids and average disintegration time of ODTs. The linearity of the 
correlation observed suggested that the measured wetting time of the amino acid plays an 
important role in determining the disintegration time of ODTs. However, this role is seemed to 
be highly affected by the porosity of the ODTs. For instance, the correlation between the 
wetting time and disintegration time for ODTs based on 50% amino acids was poor, due to 
different porosity of the ODTs at this concentration (Table 3.2). Accordingly, the total porosity 
of the tablet and wetting time of the amino acid play a major role in determining the 
disintegration time. This mechanism of disintegration, usually referred as wicking, is due to 
weakening of the intermolecular bonds upon penetration of the disintegration medium 
between the tablet’s excipients and consequently resulting in complete disintegration of the 
tablets. 
On the other hand, partially wettable amino acids (serine, lysine, glutamine and histidine) 
showed a mix of the two previous profiles. The amino acid with lower contact angle (higher 
wettability) such as glutamine and histidine, mimicked the highly wettable amino acid profiles  
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Figure 3.7 Relationship between wetting time of the amino acids and disintegration time of the 
ODTs at amino acids concentration of 30%. 
 
and a parabolic relationship with the concentration was noticed, whereas amino acids with 
higher contact angle such as serine and lysine, followed the trend of poorly wettable amino 
acids as increasing their concentration in the ODT profoundly increased the disintegration 
time.  
 
3.4.7. The lyophilised tablet index 
In order to evaluate the effect of inclusion of amino acids on the hardness and disintegration 
at the same time and compare it to the gelatin only formulation (control), lyophilised tablets 
index (LTI) values were calculated according to the following equation:  
LTI = (H/DT) ÷ (H˚/DT˚) 
 Where H: hardness of the tested tablet, DT: disintegration time of the tested tablet, H˚: 
hardness of the control tablets, DT˚: disintegration time of the control tablet. 
The LTI value provided a ratio indicative of whether the prepared amino acid formulation was 
better than the gelatin only formulation (chapter 2). Values greater than 1 indicate 
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improvements over the gelatin formulation, whereas lower values suggest retardation in the 
overall tablet properties (disintegration time and hardness). In addition, LTI values can be used 
to rank the improvements in tablet properties among various formulations.   The results (Table 
3.4) revealed that alanine, glutamine, glycine, arginine, histidine, serine and threonine were 
able to improve the overall tablets properties to different extent at different concentration. 
Alanine achieved the highest value at concentration of 30% (w/w) with LTI value of 4.99, 
followed by the 30% glutamine formulation (LTI= 3.39) and then the 10% glycine (LTI= 3.39). 
Our data in chapter 2 showed that the inclusion of saccharides and polyols in formulation of 
lyophilised ODTs based on 5% gelatin stock solution (similar conditions to the current study) 
enhanced the overall tablet properties by recording LTI values ranged between 0.52 - 8.10, 
which are comparable to the LTI values from this current study demonstrating the suitability of 
the amino acids in the formulation of ODTs. 
 
 
Table3.4 The lyophilised tablet index of tablets based on 5% gelatin stock solution and varied 
concentration of amino acids. 
(*) No intact lyophilised tablets were formed 
 (-) Not soluble 
      
Amino Acid LTI 
10   % 30% 50% 70% 
Alanine 1.26 4.99 1.58 0.39 
Arginine 0.82 0.85 1.47 1.84 
Threonine 0.66 0.95 1.96 0.63 
Glycine 2.54 1.01 0.59 0.48 
Cysteine 0.82 1.35 0.44 0.53 
Serine 0.72 1.26 0.67 0.30 
Histidine 0.87 1.63 1.10 1.73 
Lysine 0.84 0.73 0.23 - 
Valine 0.65 0.54 * * 
Asparagine 0.79 0.77 * * 
Glutamine 0.55 3.39 * * 
Proline 0.78 - - - 
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3.5. Conclusion 
The current study suggests that successful formulation of saccharides free lyophilised ODTs 
requires amino acids that crystallise in the frozen state or display relatively high Tg' in the 
formulation, interact and integrate completely with the binder and, also, display short wetting 
time with the disintegrating medium. The tested amino acids have showed varied capability to 
fulfil all the required characteristics for the formulation of lyophilised ODTs. However, 
inclusion of an optimised concentration of alanine achieved the best balance and therefore 
produced ODTs with superior characteristics. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
116 
 
 
 
 
 
Chapter Four: Investigation of Formulation 
and Process of Lyophilised ODTs Using 
Novel Amino Acid Combinations 
 
 
 
 
 
 
Papers relating to this chapter 
Alhusban FA, Perrie Y, Mohammed A - Investigation of formulation factors on the 
sublimation rate of orally disintegrating tablets. 37th Annual Meeting of the Controlled 
Release Society, July 2010, Portland, USA. 
AlHusban, F., ElShaer, A., Kansara, J., Smith, A., Grover, L., Perrie, Y., Mohammed, A. 
(2010) Investigation of formulation and process of lyophilised orally disintegrating 
tablet (ODT) using novel amino acid combination. Pharmaceutics, 2 (1), 1-17. 
 
Chapter 4 – Novel combinations of amino acids as matrix forming agents   
117 
 
Investigation of Formulation and Process of Lyophilised ODTs 
Using Novel Amino Acid Combinations 
 
4.1. Introduction and Aims 
Investigating the feasibility of using individual amino acids as matrix supporting/ disintegration 
enhancer agents in the formulation of lyophilised orally disintegrating tablets (chapter 3) 
showed varied capability of the amino acids to fulfil all the required characteristics for the 
formulation of lyophilised ODTs. For instance, proline showed complete wettability in water 
(disintegrating medium) with short wetting time, which is expected to improve the 
disintegration of ODTs; however, its inclusion in freeze dried formulations was limited due to 
the extremely low glass transition temperatures and consequently resulting in the collapse of 
the prepared formulations. On the other hand, serine based formulations displayed higher 
collapse temperature and produced elegant tablets even at high concentration, due to its 
tendency to crystallise in the frozen state, but was characterised by long disintegration time, 
which was explained by serine's partial wetting property, as the measured contact angle (θ) 
with water was 0˚ < θ < 90˚.  
The main aim of the this chapter was to combine the benefits of proline and serine in the 
formulation of ODT with the aim to achieve a tablet with shorter disintegrating time (mainly 
due to the presence of highly wettable proline) and enhanced stability during freeze drying 
(due to the high glass transition and crystallisation capacity of serine). The study investigated 
the influence of inclusion of various ratios of proline and serine at different total 
concentrations on the thermal properties of the frozen formulations, formation of intact 
tablets after freeze drying and ODT characteristics in terms of disintegration time and 
mechanical properties. Furthermore, the optimised formulation was then used to investigate 
the effect of freezing drying conditions on the sublimation rate, disintegration time and 
mechanical properties of ODTs. 
Typical freeze drying cycle consists of three main stages; freezing, primary drying and 
secondary drying. Primary drying is the longest stage in the freeze drying cycle and takes 
several hours to few days to complete. The rate of primary drying is governed by factors 
related to the process conditions, including: shelf temperature, vacuum pressure and heat 
transfer process from the shelf fluid to the frozen formulation, and factors related to the 
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product, which determine the mass transfer resistance (MTR) to sublimation (Kuu et al., 2006). 
Non optimum freeze drying conditions and/or formulation factors may result in longer cycle 
and consequently higher cost than is necessary. 
In the freeze-drying process, the freezing step is one of the most important steps as it 
determines the size and morphology of the ice crystals within the frozen material and, 
consequently, the final inner-structural feature of the freeze-dried material (Hottot et al., 
2004). Accordingly, the freezing protocol can influence the primary drying process by affecting 
the mass transfer resistance (MTR) to sublimation,  as the sublimed water vapour should flow 
through the formed pores to the condenser (Hottot et al., 2007).  Moreover, in lyophilised 
tablets, the freezing protocol is expected to influence the ODT characteristics after freeze-
drying (the disintegration time and mechanical properties), due to its effects on the total 
porosity and pore size.  
In this chapter, three freezing protocols; freezing at -80 °C using pre-cooled shelves with or 
without annealing at -20 °C for 12 hours and flash freezing using liquid nitrogen, were 
investigated for their effects on the sublimation rate, inner-structural features of the freeze 
dried tablets and tablets characteristics. 
 
4.2. Materials 
Gelatin from bovine skin, type B (Bloom strength ~ 75), L-Proline (C5H9NO2, Reagent plusTM ≥ 
99%), L-Serine (C3H7NO3, Reagent plusTM ≥ 99%), were all purchased from SIGMA®, USA. All 
the materials were used as received. 
 
4.3. Methods 
4.3.1. Formulation of ODTs to investigate the effect of L-proline and L-
serine combination on the tablets characteristics 
Various ratios (100:0, 85:15, 70:30, 45:55, 30:70, 15:85, 0:100) of L-proline and L-serine at total 
concentrations of 10%, 30%, 50%, and 70% w/w (total solid) were added to 5% (w/w) gelatine 
stock solution. 1.5 g of the prepared solution was transferred to a PEG mould, frozen at -80 °C 
for 2 hours and then freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to an 
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optimized regime (primary drying for 48 hours at a shelf temperature of -40 °C and secondary 
drying for 10 hours at a shelf temperature of 20 °C and vacuum of 50 mTorr. All the 
formulations (28 different formulations) were prepared in triplicate from three independent 
batches. From each batch 3 tablets were freeze dried and characterised for disintegration 
time, hardness and fracturability. In total 252 tablets were prepared (28 X 3 X 3). 
 
4.3.2. The influence of freezing protocol on the primary drying rate and 
ODTs characteristics 
The formulation with the best performance in terms of disintegration time and mechanical 
properties from the previous study (2.2.1) was used to investigate effects of freezing protocols 
on the sublimation rate and tablets characteristics. The following three freezing protocols were 
applied: 
Protocol 1: the formulation was frozen in -80 °C freezer. 
Protocol 2 (flash freezing): The formulation was immersed in liquid nitrogen for 40 seconds 
then kept at -80 °C freezer. 
Protocol 3 (annealing): the formulation was frozen at -80 °C pre-cooled freezer for 2 hours, 
annealed at -20 °C pre-cooled freezer for 12 hours and then transferred back to -80 °C freezer. 
The sublimation rate was studied by freeze drying samples (from each protocol) at shelf 
temperature of -40 °C, condenser temperature of -80 °C and 55 mTorr vacuum. Samples were 
withdrawn from the freeze dryer at predetermined time intervals (2, 6, 12, 24, 36 and 48 
hours) and the amount of water sublimed was evaluated using weight difference method. All 
the measurements were done in triplicate of independently prepared samples.  
In order to study the effect of freezing protocol on tablet characteristics, nine samples from 
each protocol entered a complete freeze drying cycle using similar regime used in section 
(2.2.1). 
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4.3.3. Differential scanning calorimetry 
Differential scanning calorimeter (Pyris Diamond DSC) was used to investigate the glass 
transition temperatures (Tg) and the crystallization events of the frozen formulations. 10–15 
mg of the liquid formulation was transferred into an aluminium pan (50 μL capacity) and then 
sealed with an aluminium top. The sample was cooled to -65 ºC and then heated to 20 ºC at 5 
ºC/min. To determine the glass transition temperature of the maximally freeze concentrate 
sample (Tg’), after initial cooling to -65 ºC, annealing for 10 min at temperature of 2 ºC higher 
than the relevant glass transition temperature (Tg) was added before carrying out the above 
method. Nitrogen was used as a purge gas at a flow rate of 20 mL/min. Indium and zinc were 
used to calibrate the heat flow and melting point onset (melting point: 156.6 °C, ΔHm: 28.42 
J/g for Indium and melting point: 419.47 °C ΔHm: 108.26 J/g for Zinc). The obtained 
thermograms were analysed using Pyris Manager Software (version 5.00.02) where Tg and Tg' 
values were determined from the intersection of relative tangents to the baseline. The 
experiment was performed in triplicate and an empty aluminium pan was used as a reference 
cell for all the measurements. 
 
4.3.4. Texture analysis 
In order to investigate the fracturability and hardness of the prepared tablets, QTS 25 texture 
analyser (CNS Farnell, Hertfordshire, UK) was used. Fracturability was studied by using 1 mm 
diameter penetration probe which penetrates 4 mm of the tablet at a speed of 6 mm/min and 
the peak force was measured in Newton (N) after 3 mm of penetration. The tablet hardness 
was measured using a 5 mm diameter compression probe which compresses the tablets to 2 
mm depth at a speed of 6 mm/min and the peak force is measured in Newtons after 1 mm 
compression. The obtained data was analysed by TexturePro software. All fracturability and 
hardness measurements were performed in triplicate for each formulation and the data is 
presented as mean ± standard deviation. 
 
4.3.5. In vitro disintegration study of the tablets 
Disintegration time is the time required for ODTs to disintegrate completely without leaving 
any solid residue. In vitro disintegration time for lyophilised ODTs was evaluated using US 
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pharmacopoeia monograph (<701> disintegration). Erweka (ZT3, Appartebau, GMBH) was 
used in this study as a disintegration apparatus and distilled water (800 mL) as disintegration 
medium; the disintegration medium temperature was maintained at 37 °C by thermostat. At 
each time, one tablet was placed in the basket rack assembly and covered by transparent 
plastic disk. The disintegration time was taken as the time required for ODTs to disintegrate 
completely without leaving any solid residue. All the measurements are carried out six times 
and presented as (mean ± standard deviation). 
 
4.3.6. Mercury porosimetry 
Mercury porosimetry was used to evaluate the influence of the freezing protocol on the pore 
size distribution of the resulting tablets. Measurements were made using an Autopore IV 9500 
mercury porosimeter (Micromeritics, UK). Samples were stored overnight in a vacuum to 
remove moisture and were then weighed and loaded into a 5 cc bulb 1.190 ml stem, 
penetrometer (Micromeritics, UK). Measurements of pore size distribution were made in the 
low and high pressure chambers of the porosimeter to provide the pore size distribution in the 
range 6 nm to 360 μm. The resulting measurements of intrusion volume (ml/g/nm) were used 
to calculate pore size distribution. 
 
4.3.7. Statistical analysis 
Graph Pad Instat® software was used for the statistical analysis study. Data groups were 
compared using one way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey-Kramer multiple comparison test). Standard deviation (SD) was used to report 
the error in the figures and texts. Probability values of 95% (P < 0.05) were used to determine 
the significant difference. 
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4.4. Result and discussion 
4.4.1. Thermal analysis and formation of intact tablets 
The successful production of intact lyophilised tablets is totally dependent on the thermal 
profile of the frozen formulation and freeze drying conditions. The maximum tolerable product 
temperature during primary drying which ensures the formation of intact tablets, known as 
collapse temperature, can be estimated from the DSC profile of the frozen formulation. For 
amorphous formulations, the collapse temperature is usually 1 to 3 ˚C higher than the glass 
transition (Pikal and Shah, 1990).  
At total amino acids concentration of 10% and 30% w/w (serine:proline combinations), all the 
studied combinations of serine and proline showed glass transition step (Tg’) in their heating 
scans at different temperatures depending on the total concentration and ratio of both amino 
acids (Table 4.1). The inclusion of these two amino acids in the formulation had a plasticising 
effect in the formulation as increasing the total concentration of the amino acids significantly 
lowered the Tg’ temperature. However, proline had a higher plasticising effect on the system 
than serine since a gradual increase in proline ratio within the formulations was associated 
with a steady decrease in Tg’ values. For example, at a total concentration of 30% (w/w), 
increasing proline ratio from 0 to 45 to 100 decreased the Tg’ from -25.66 ± 0.01 to -32.26 ± 
0.1 to -37.65 ± 0.24 ˚C, respectively (Table 4.1). Estimation of the collapse temperatures for 
10% w/w amorphous formulations suggested the presence of a high safety margin between 
the shelf and collapse temperature which resulted in the formation of intact and smooth 
tablets. On the other hand, formulations at 30% w/w total concentration of the combined 
amino acids did not reveal any morphological deterioration despite the small difference 
between the glass transition and shelf temperature. The possibility of any micro collapse for 
these formulations cannot be ruled out. 
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Table 4.1 Glass transition temperatures (˚C) of maximally freeze concentrate solutions of 5% 
gelatin after inclusion combinations of proline and serine at total concentration of 10% and 
30% w/w. Values are represented as mean ± standard deviation (n = 3). 
Combination 
(proline:serine) 
Total concentration (w/w) 
10% 30% 
0:100 -18.63 ± 0.05 -25.66 ± 0.01 
15:85 -19.12 ± 0.11 -27.97 ± 0.12 
30:70 -19.71 ± 0.09 -29.52 ± 0.42 
45:55 -20.35 ± 0.21 -32.26 ± 0.10 
70:30 -20.87 ± 0.16 -34.24 ± 0.10 
85:15 -21.31 ± 0.08 -35.57 ± 0.07 
100:0 -21.47 ± 0.12 -37.65 ± 0.24 
 
 
DSC analysis of formulations with total concentration of 50% and 70% w/w (total solid) of 
combinations of proline and serine are presented in Figure 4.1 and Table 4.2, respectively. At 
these high concentrations, formulations containing serine only displayed crystallisation event 
during their heating scans. Inclusion of small amount of proline, 15:85 (proline:serine), seemed 
to drift the crystallisation temperature of serine to a higher temperature when compared to 
serine alone formulation (Figure 4.1A). Further increase in proline ratio within the formulation 
inhibited serine crystallisation completely and the trend continued as observed in 10% and 
30% w/w formulations, which was evident by lowering of the glass transition temperature 
(Figure 4.1B and Table 4.2). Freeze drying of these formulations was less efficient when 
compared to 10% and 30% w/w formulations which can be explained by higher concentration 
of proline that decreases the glass transition and inhibits serine crystallisation. As a result, all 
the formulations with Tg’ less than -40 ˚C collapsed and therefore no tablet was formed. 
Freeze drying of such formulations is possible by decreasing the shelf temperature of the cycle, 
but it is associated with significant increase in the primary drying time. It has been shown 
previously that lowering the shelf temperature by 5 ˚C may result in increase in the primary 
drying time of about 15 hours (Rambhatla et al., 2006). 
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Figure 4.1 Overlaid DSC heating curves of frozen formulations: (A) that exhibited serine 
crystallisation at total concentration of 50% amino acid. (a) Serine to proline ratio of 100:0. (b) 
Serine to proline ratio of 85:15. (B). that did not show tendency to crystallize at total 
concentration of 50% amino acids. (a) 70:30 (serine: proline); (b) 55:45 (serine: proline); (c) 
70:30 (serine: proline); (d) 85:15 (serine: proline); (e) 0:100 (serine: proline). 
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Table 4.2 Glass transition temperatures of maximally freeze concentrate solutions (Tg’) and 
crystallisation temperatures of frozen solutions of 5% gelatin after inclusion of combinations of 
proline and serine at total concentration of 70%. Values are represented as mean ± standard 
deviation (n = 3). 
Proline/Serine ratio Tg’ (˚C) Crystallization temperature (˚C) 
0:100 * -23.99 ± 0.53 
15:85 -33.13 ± 0.43 -16.62 ± 0.95 
30:70 -39.54 ± 0.32 -14.02 ±1.08 
45:55 -44.91 ± 0.64 * 
70:30 -51.44 ± 2.27 * 
85:15 -57.63 ± 0.97 * 
100:0 >65 * 
(*) No events were detected 
 
4.4.2. Characterisation of ODTs 
4.4.2.1. Mechanical properties 
All the successfully freeze dried formulations were characterised in terms of mechanical 
properties by measuring their resistance to compression by a 5 mm diameter probe (hardness) 
and penetration by a 1 mm diameter probe (fracturability). The influence of the total amino 
acids concentration and proline to serine ratio within the formulation on the hardness and 
fracturability of ODTs are presented in Figures 4.2 and 4.3, respectively. The results showed 
that the hardness of the ODTs was significantly improved by inclusion of a higher total 
concentration of both amino acids (one way ANOVA/Tukey- Kramer: ρ < 0.05). For instance, 
each increment in the total concentration of 15:85 of proline:serine formulation was 
associated with a significant increase in the hardness, from 14.46 ± 1.33 N at concentration of 
10% to 17.24 ± 0.92 N at 30% w/w, to 21.29 ± 2.26 N at 50% and then to 37.96 ± 0.68 N at 
concentration of 70% (one way ANOVA/Tukey-Kramer: ρ < 0.05). However, at the same total 
concentration, combinations with higher serine ratio provided stronger tablets compared to 
tablets with high proline ratio suggesting better capability of serine to enhance the hardness of 
lyophilised ODTs (Figure 4.2). For example, at total concentration of 10%, increasing serine 
ratio from zero to 55% resulted in significant improvement in the ODTs hardness from 9.85 ± 
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0.41 N to 12.47 ± 0.5 N (one way ANOVA/Tukey-Kramer: ρ < 0.05) and then to 14.47 ± 1.3 
N(one way ANOVA/Tukey-Kramer: ρ < 0.01) by further increase serine ratio to 85% w/w of the 
total amino acids. 
The ODTs fracturability results are presented in Figure 4.3. Statistical analysis of the data 
showed that increasing the total amino acids concentration from 10% to 30% did not improve 
the fracturability. However, significant improvements were achieved by increasing the total 
concentration to 50% (one way ANOVA/Tukey-Kramer: ρ < 0.01) or 70% (one way 
ANOVA/Tukey-Kramer: ρ < 0.001). Also, the results showed no particular influence of changing 
the ratio of proline and serine within the formulation. Accordingly, the results suggested that 
the fracturability was mainly influenced by the total concentration of the amino acids rather 
than the ratio of proline to serine within the formulation. 
 
 
 
Figure 4.2 The hardness (Newton) of the ODTs after inclusion combinations of proline and 
serine at total concentrations of 10%, 30%, 50%, and 70% w/w. Values are represented as 
mean ± standard deviation (n = 3). 
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Figure 4.3 The fracturability (Newton) of the ODTs after inclusion combinations of proline and 
serine at total concentrations of 10%, 30%, 50%, and 70% w/w. Values are represented as 
mean ± standard deviation (n = 3). 
 
4.4.2.2. Disintegration time of the ODTs 
The disintegration time profile of the tablets is presented in Figure 4.4. At a total 
concentration of 10%, tablets containing proline only achieved the shortest disintegration time 
of 21.0 ± 2.1 s (n =3). Upon gradual increment in serine ratio, the disintegration times 
increased steadily to 29.0 ± 2.2 s for the 45:55 of proline:serine formulation and then to 33.0 ± 
1.0 s for tablets with serine only. At a total amino acids concentration of 30% w/w, the 
shortest disintegration time was 17.3 ± 0.6 s for the 45:55 of proline:serine combination. It was 
anticipated that formulations with higher proline ratio (higher than 45%) would achieve the 
shortest disintegration time but because of their narrow freeze drying safety margin, invisible 
partial micro collapse ( as discussed in the section on thermal properties) might have 
deteriorated their disintegration profile. Formulations with high freeze drying safety margin, 
which contained proline ratio less than 45%, confirmed this theory by following the expected 
trend where longer disintegration time was associated with any increase in serine ratio (Figure 
4.4). 
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Figure 4.4 The disintegration time (seconds) of the ODTs after inclusion combinations of 
proline and serine at total concentrations of 10%, 30%, 50%, and 70% w/w. Values are 
represented as mean ± standard deviation (n = 3). 
 
The successfully freeze dried tablets based on total concentrations of amino acids of 50 and 
70% followed the expected trend and the shortest disintegrations at both concentrations were 
recorded by formulations with the highest ratio of proline (Figure 4.4). These results can be 
explained depending on the mechanism of disintegration of ODTs. Generally, the fast 
disintegration profile of lyophilised ODTs is attributed to the highly porous structure that 
allows fast diffusion of water (disintegrating medium) through highly wettable matrixes, which 
disintegrate/dissolve rapidly upon contact with water (Sunada and Bi, 2002). In the current 
formulations, inclusion of higher concentration of proline is expected to increase the 
wettability of the matrix while increasing total concentration of the amino acids reduces the 
total porosity of the tablets. Accordingly, a balance between the wettability and porosity is 
required to achieve short disintegration time. The current results (Figure 4.4) suggest that 
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45:55 combination of proline:serine at a total concentration of 30% achieved best balance 
between wettability (containing 13.50% proline) and porosity with total amino acid 
concentration of 30% w/w (intermediate concentration) which consequently achieved the 
shortest disintegration time in the study (17.3 ± 0.6 s). It is interesting to note that that even 
small intervention in this balance can lead to significant deterioration in the disintegration 
time. For example, formulations with higher porosity (lower total concentration of amino 
acids) but slightly lower wettability (lower concentration of proline), as in tablets based on 
proline only at total concentration of 10% (of total tablet weight), displayed significantly longer 
disintegration time. Similarly, formulations with higher wettability but smaller porosity, as in 
tablets based on 45:55 of proline:serine at total concentration of 50%, did not achieve shorter 
disintegration time (Figure 4.4). Similar trend was observed from previous chapters that 
investigated the influence of saccharides (chapter 2) and amino acids (chapter 3) on 
disintegration time, where parabolic relationships were noticed within optimal concentration 
(30–40% w/w) of matrix supporting/disintegration enhancing agents. 
 
4.4.2.3. Lyophilised tablet index 
The tablet characterisation results (hardness and disintegration time) have shown that serine 
to proline ratio and their total concentration in the formulation have contrasting influence on 
the mechanical properties and disintegration time of the lyophilised ODTs. Therefore, the 
overall tablets properties were evaluated depending on a single parameter that integrates the 
hardness and disintegration time of ODTs, called lyophilised tablet index (LTI) (chapter 2 and 
3). LTI is calculated by dividing the measured hardness by the disintegration time of certain 
ODT formulation which means the higher value the better the overall properties (high 
hardness and low disintegration time). The results (Table 4.3) proved that combining proline 
and serine as matrix supporting /disintegration enhancing agents in the formulation creates 
ODTs with superior overall properties (disintegration time and harness) than using proline or 
serine individually. The highest LTI value was 0.88 for the formulation with 45:55 of 
proline:serine at total concentration of 30% (LTI= 0.88), followed by the same combination of 
proline and serine but at concentration of 50% with LTI value of 0.82, suggesting that the 
deterioration in the disintegration, caused by increasing the total concentration from 30% to 
50%, was more profound than the improvement in the hardness. 
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Table 4.3 The lyophilised tablet index values of ODTs ODTs that are produced from varied 
concentration of proline and serine combinations. 
Combination 
(prolin:serine) 
Total concentration (w/w) 
10% 30% 50% 30% 
100:0 0.47 0.51 - - 
85:15 0.46 0.78 - - 
70:30 0.41 0.48 - - 
45:55 0.43 0.88 0.84 - 
30:70 0.41 0.82 0.61 - 
15:85 0.54 0.71 0.58 0.39 
0:100 0.44 0.54 0.59 0.12 
 
 
4.4.3. The influence of freezing protocol on the primary drying rate and 
ODTs characteristics 
In the freeze-drying process, the freezing step is one of the most important steps as it 
determines the size and morphology of the ice crystals within the frozen material and, 
consequently, the final inner-structural feature of the freeze-dried material (Hottot et al., 
2004). Thus, in lyophilised tablets, the freezing protocol is expected to influence not only the 
freeze drying process (sublimation rate and primary drying time) (Hottot et al., 2007) but also 
tablet characteristics after freeze-drying (the disintegration time and mechanical properties). 
In this study, three freezing protocols; freezing at -80 °C using pre-cooled shelves with or 
without annealing at -20 °C for 12 hours and flash freezing using liquid nitrogen, were 
investigated for their effects on the sublimation rate, inner-structural features of the freeze 
dried tablets and tablets characteristics of the formulation with the highest LTI value (45:55 of 
proline: serine at total concentration of 30% w/w). 
Mercury porosimetry was used to investigate the structure of the freeze dried tablets, because 
it preserves the internal morphology of the sample during the measurement, does not require 
cutting the tablets which may alter the cake structure and also gives consistent estimation of 
the pore size and pore size distribution for the whole tablets. 
 
Chapter 4 – Novel combinations of amino acids as matrix forming agents   
131 
 
4.4.3.1. Influence on primary drying rate 
Figure 4.5 shows primary drying rates of tablets based on 45:55 of proline: serine at total 
concentration of 30% w/w after applying different freezing methods. At all time points the 
average drying rates of the annealed tablets were significantly higher than tablet frozen using -
80 °C precooled shelves or liquid nitrogen (flash freezing), both without annealing (one way 
ANOVA/Tukey-Kramer: ρ < 0.01). Moreover, the decrease in drying rate with time due to 
increasing the thickness of the dried layer seemed to be steady and consistent for the 
annealed tablets compared to the tablets without annealing. Given that all the tablets were of 
a similar formulation and freeze dried under the same conditions, all the differences in the 
primary drying profiles are attributed to the inner morphology of the tablets imposed by the 
freezing regime. 
The mercury porosimetry data (pore size distribution) are presented in Figure 4.6. The results 
showed that flash freezing produced tablets with the smallest modal pore diameter (6 μm), 
but with a broad pore size distribution between 284 nm to 30 μm. When the formulation froze 
at -80 °C, the pores exhibited a larger modal diameter (30 μm) with pores in the range 1 to 60 
μm. On the other hand, annealed tablets exhibited the largest pores with a modal diameter of 
60 μm distributed from 13 to 370 μm. In case of flash freezing and pre-cooled shelves at -80 
°C, freezing at lower temperature and faster rate resulted in a larger number of dispersed 
minute ice crystals, and consequently smaller pores after freeze drying. These small pores 
create narrow and complex channels for water vapor removal during the sublimation and 
therefore higher mass transfer resistance (MTR), which in turn decreases the sublimation rate 
(Searles et al., 2001). Moreover, the lack of direct control over ice nucleation temperature 
using these freezing methods resulted in wide pore size distributions (Figure 4.6) and hence 
heterogeneous MTR values (Patapoff and Overcashier, 2002), which is translated as 
inconsistent decrease in the average primary drying rate over time (Figure 4.5). 
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Figure 4.5 Sublimation rate (mg/h) as a function of time for the ODT formulation with 45:55 of 
proline: serine at total concentration of 30% w/w frozen by various methods. Values are 
represented as mean ± standard deviation. 
 
 
Figure 4.6 Pore size distributions of ODTs prepared using different drying protocols, including: 
freeze drying, flash freezing and annealing. 
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Annealing, on the other hand, is a known technique to enhance the growth of ice crystals and 
eliminate the initial variation in crystal size distribution by a phenomena known as Ostwald 
ripening, where smaller ice crystals melt quickly and then merge with larger crystals (not 
completely melted) as a result of raising the temperature above Tg’, whereas re cooling the 
sample fixes the structure of the large crystals (Dawson and Hockley, 1992; Kang et al., 1999; 
Searles et al., 2001a). Thus, the annealed tablets in this study exhibited larger mean pore 
diameter with narrower size distribution compared to the tablets without annealing (Figure 
4.6). These structural features facilitated and homogenised water-vapor transmission (low and 
constant MTR) and therefore high and consistent primary drying rates were achieved. The 
current results are consistent with previous studies (Hottot et al., 2004; Hottot et al., 2007; 
Searles et al., 2001b; Abdelwahed et al., 2006), where adding annealing to the freezing regime 
has enhanced ice crystals growth and, consequently, increasing the sublimation. Other 
researchers have employed different physical approaches to enhance and control ice crystals 
growth, with the aim of reducing primary drying times, including ultrasounds (Morris et al., 
2004), vacuum induced surface freezing (Kramer et al., 2002) and high electrical field (Petersen 
et al., 2006). 
 
4.4.3.2. Influence on ODT characteristics 
We have demonstrated above that the structure of the freeze dried cake had changed 
significantly when applying different freezing protocols. These morphological changes can 
directly influence the basic properties of the lyophilised formulation. For ODTs, the 
disintegration time and mechanical properties are the key aspects to investigate. 
The effect of different freezing protocols on the ODTs disintegration time is presented in 
Figure 4.7. The results revealed that the annealed tablets had significantly shorter average 
disintegration time of 8.6 ± 0.6 s when compared to 17.5 ± 0.5 s and 17.3 ± 0.6 s for tablets 
frozen using liquid nitrogen and at -80 °C Pre-cooled shelve, respectively, (one way 
ANOVA/Tukey-Kramer: ρ < 0.001). The fast disintegration of the annealed tablets can be 
attributed to their large pores (Figure 4.6) that facilitate rapid diffusion of water (the 
disintegrating medium). 
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Figure 4.7 Disintegration time of ODTs based on 45:55 of proline: serine at total concentration 
of 30% w/w after applying different freezing protocols. Values are represented as mean ± 
standard deviation (n = 3). 
 
The hardness and fracturability of the ODTs are presented in Figure 4.8. The effect of 
annealing on the mechanical properties of the ODTs was not significant when compared to 
ODTs frozen at -80 °C pre-cooled shelve without annealing, statistically, there was no 
difference in terms of their hardness nor fracturability (ρ > 0.05). However, the results showed 
that flash freezing of the formulation using liquid nitrogen significantly modified the 
mechanical properties of the tablets, as lower hardness of 12.7 ± 0.3 N was recorded 
compared to 16.0 ± 1.3 N for the annealed ODTs (ρ < 0.05) but with significantly higher 
fracturability (4.4 ± 0.1 N compared to 2.8 ± 0.1 N for the annealed, P < 0.05). Thus, the 
organised larger pores structure of the annealed tablets seems to have stronger resistance for 
the compression by the hardness probe (5 mm diameter) but weaker resistance toward 
penetration of the thin probe (1 mm diameter) that measures the fracturability, compared to 
tortuous and smaller pores structure of the flash frozen ODTs (Figure 4.9). 
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Figure 4.8 Hardness and fracturability of ODTs based on 45:55 of proline:serine at total 
concentration of 30% w/w after applying different freezing protocols. Values are represented 
as mean ± standard deviation (n = 3). 
 
 
Figure 4.9 Schematic representations of the effect of freezing protocol on hardness and 
fracturability of ODTs. The organised larger porous structure of the annealed tablets (A) seems 
to have stronger resistance for the compression by the hardness probe (5 mm diameter) but 
weaker resistance toward penetration of the thin probe (1 mm diameter) that measures the 
fracturability, compared to tortuous and smaller pores structure of the flash frozen ODTs (B). 
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4.5. Conclusion 
This study has demonstrated that inclusion of optimised combinations of serine and proline in 
the formulation of lyophilised orally disintegrating tablets can combine the benefits of high 
wettability and stability resulting in the formation of tablets with superior properties over that 
of individual amino acids. The inclusion of serine in the formulation at high concentration 
enhances the mechanical properties of the ODTs without compromising the formation of 
intact tablets. On the other hand, proline promotes the disintegration by enhancing the 
wettability of the ODTs. Annealing induces morphological changes in the ODTs that not only 
allow faster sublimation rate but also shorter disintegration time. 
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Formulation of Multiparticulate Systems as Lyophilised 
ODTs  
 
5.1. Introduction and Aims 
Orally disintegrating (dissolving) tablets (ODTs) are solid dosage forms that are placed in the 
mouth, rapidly disintegrate/dissolve when in contact with the saliva and then easily swallowed 
without the need for water (European pharmacopoeia, 2002). The fast disintegrating 
behaviour of the ODT in the mouth limits the active ingredients that can be incorporated to 
drugs that exhibit good taste, stability in gastric conditions and long half life. Bitter tasting 
drugs can cause discomfort to patients and consequently reduce their compliance, whereas 
incorporating drugs that suffer from instability in gastric fluids reduce the efficiency of the 
dosage form (bioavailability). On the other hand, delivering active drugs that have short half 
life in ODTs compromise the practicality of the dosage form as more frequent administration is 
required. To address these issues, a great deal of interest has been directed towards 
incorporating multiparticulate drug delivery system in ODT formulations (chapter 1).  
The multiparticulate drug delivery system comprises of drug particles encapsulated or coated 
by one or more layers of polymers that control the release of the drug. The polymer can be 
selected to provide extended, delayed or pulsed drug delivery, allowing the rate of release of 
the drug to be tailored as required. Therefore, multiparticulate drug delivery systems can mask 
the unpleasant taste of active drugs, protect acid-labile drugs from possible degradation in the 
stomach, and extend the drug release over several hours. Moreover, they provide many 
advantages over single-unit dosage forms because of their multiplicity nature and small sizes 
such as reduced risk of systemic toxicity, enhanced bioavailability, reduced risk of local 
irritation and reduced patient to patient variability as a result of their more predictable gastric 
emptying (Dey et al., 2008). Accordingly the formulation of multiparticulate into ODTs can 
extend their application to more challenging drugs (eg. acid sensitive) by overcoming some 
restrictions imposed by the nature of these drugs and combine the benefits of ODTs  and 
multiparticulate drug delivery system (chapter 1). 
The compression of multiparticulate into ODT formulations has attracted substantial attention 
in both academia and industry and resulted in many scientific publications (Beckert et al., 
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1996) and patent applications (chapter 1). However, to produce a tablet with good structural 
integrity, relatively high compression pressures are required.  These high pressures can cause 
damage to the polymer layers of the multiparticulate system, and, as a result, compromise 
their release controlling properties (Bodmeier, 1997). 
Freeze drying is an alternative technique to produce ODTs without applying any compaction 
force, which could be useful in the formulation of multiparticulate into ODTs. However, three 
major requirements need to be addressed in order to ensure successful formulations. Firstly, 
the need for high viscous liquid formulation that is able to suspend the multiparticulate long 
enough to complete formulation and freezing without compromising the disintegration 
performance. Secondly, minimum interaction between the liquid formulation and the 
multiparticulate that may lead to unwanted changes in the original properties of the 
multiparticulate such as early drug leakage. For example, for multiparticulate coated with 
hydrophobic polymers, the use of thick hydrophilic environment in the formulation reduces 
the chance of premature drug release, whereas for enteric coated multiparticulate, the use of 
acidic formulation ensures multiparticulate integrity. Thirdly, physical protection against 
possible damage during freezing and annealing step as a result of ice crystal growth.           
The current study aimed to optimise ODT formulations suitable for multiparticulate delivery 
based on gelatin, carrageenan and alanine. The selection of these excipients can potentially 
benefit the formulation in many ways. From one side, the selection can exploit the 
electrostatic associative interaction between the anionic sulphate groups of carrageenan 
polymer and the positive net charge of gelatin (below its pI) to produce highly viscous solution 
at relatively low concentration of both polymer (Michon et al., 2000), which ensures fast 
disintegration property and shorter freeze drying cycle (chapter 2). Also, carrageenan has 
cryoprotectant activity which might be useful to protect the multiparticulate integrity during 
freezing and annealing steps (Choi et al., 2007). Additionally, gelatin and alanine showed 
superior properties as matrix supporting agents in ODT formulations (chapter 3). 
Successful development of new pharmaceutical formulations requires extensive and 
comprehensive research to determine the significant factors that influence formulation, 
understand their effects (individually and collectively), and optimise them to obtain high 
quality products. For lyophilised ODTs, traditional experimentation approach can be time and 
material consuming and consequently is associated with high cost, due to the existence of 
multiple factors that influence the formulation performance and manufacturing process. 
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Recently, design of experiment (DoE) supported by statistical software has been reported as an 
efficient and powerful tool in the development and optimization of pharmaceutical dosage 
forms (Nagarwal et al., 2009). The design evaluates the influence of various formulation 
parameters and their interaction with the lowest number of experiments, hence reducing the 
cost and time of the work (Bhavsar et al., 2006). Moreover, design of experiment is considered 
an essential part of quality by design paradigm (QbD) which is recommended by the FDA as a 
new regulatory requirement for approval of generic drugs (Yu, 2008).     
Response surface modelling (RSM) was applied in this study to evaluate the influence of 
varying the concentration of the selected excipients (independent variables), gelatin, 
carrageenan and alanine, on four crucial responses, disintegration time, hardness, viscosity 
and pH. Quantitative estimation of the significant model terms (linear, polynomial and 
interactive) was used to build statistical model for each response that can describe the 
relationship between the dependant and independent variables. These models were used to 
optimise the concentration of the excipients that maximize the quality of the formulation. 
Further, ODTs containing therapeutic dose of enteric coated pellets of omeprazole were 
prepared based on the optimised formulations and fully characterised to evaluate their 
feasibility as drug delivery system.    
 
5.2. Materials 
Gelatin from bovine skin, type B (Bloom strength ~ 75), lambda carrageenan and L-alanine 
(C3H7NO2, Reagent plusTM ≥ 99%) were all purchased from Sigma-Aldrich Chemicals (Pool, 
UK). Enteric coated pellets of omeprazole (8.5% omeprazole, batch number: OME-020907) 
were supplied by MKPPL (Pune, India). All the materials were used as received. 
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5.3. Methods 
5.3.1. Design of experiment  
The statistical experimental design in this study was performed using MODDE software version 
8 (Umetrics Inc., NJ, USA). The top RSM (response surface modeling) design choice suggested 
by the software was a central composite face centered (CCF) that composed of 34 experiments 
in total, 15 fractional factorial runs in duplicate (15x 2) and four replicated center points. The 
concentration of gelatine (X1), carrageenan (X2) and alanine (X3) were selected as independent 
variables at three levels. The three factorial levels for each independent factors, low, medium 
and high, were coded as -1, 0 and 1, respectively. The disintegration time (Y1), hardness (Y2), 
viscosity (Y3) and pH (Y4) were investigated as dependant variables (responses). 
 
5.3.2. Preparation of ODTs for RSM experiments 
A required amount of gelatine was solubilised in 100 ml double distilled water at about 40 °C 
to obtain a concentration of 3, 4 and 5% (w/v). Carrageenan was added to the solution at 
concentration of 0.2, 0.5 and 0.8% (w/v) and after the formation of clear solution, alanine was 
added at concentration of 2, 3.5 and 5% (w/v). A constant mass of 1.50 g of the formulation 
was poured in a tablet mould with internal diameter of 13.50 mm, frozen at -80 °C for about 
60 minutes, annealed in -20 °C a pre-cooled freezer for 12 hours and then transferred back to 
the -80 °C freezer. The frozen formulation was freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) 
according to an optimized regime (primary drying for 48 hours at a shelf temperature of -40 °C 
and secondary drying for 10 hours at a shelf temperature of 20 °C and vacuum of 50 mTorr). 
The optimised formulation was prepared by the same method and the observed 
(experimental) and the predicted (from the model) values for the responses were compared to 
evaluate the validity of the model. 
 
5.3.3. Viscosity and pH measurements 
The viscosity of the formulation was measured using a rotational viscometer (Brookfield LVT , 
Stoughton, MA, USA) with its spindle number 3 rotating at speed of 20 rpm at room 
temperature in a 100-mL beaker with the spindle guard. 
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The pH was measured using pH meter (MP230, Mettler Toledo). The pH meter was calibrated 
using standard solutions at pH 4 and 7.  
 
5.3.4. Disintegration time 
Disintegration time is the time required for ODTs to disintegrate completely without leaving 
any solid residue. In vitro disintegration time for lyophilised ODTs was evaluated using US 
pharmacopoeia monograph (<701> disintegration). A dissolution tester (Erweka ZT3) was used 
in this study as a disintegration apparatus and distilled water (800 mL) as disintegration 
medium; the disintegration medium temperature was maintained at 37 °C by a thermostat. At 
each time, one tablet was placed in the basket rack assembly and covered by transparent 
plastic disk. The disintegration time was taken as the time required for ODTs to disintegrate 
completely without leaving any solid residue. The results were mean of three measurements. 
 
5.3.5. Mechanical properties 
The mechanical properties of the freeze dried tablet (hardness) were investigated using a 
texture analyzer (QTS 25: Brookfield, Essex, UK) equipped with a 25 kg load cell. The 
instrument was calibrated by standard weight of 500 g and 5 kg. The tablet was placed in a 
holder with a cylindrical hole. The hardness was taken as the peak force after 1mm 
penetration of 5mm diameter probe at a speed of 6 mm/min. The results were average of 
three measurements. 
 
5.3.6. Density and diameter of the enteric coated pellets 
The density of the pellets was determined on 2g of the pellets using Multipycnometry (MVP-
D160-6, Quantachrome, UK) with 4.25 cm³ sample cup at 22 ˚C. Prior to analysis the helium 
pycnometry was calibrated against a standard steel ball. Each determination included 10 
purges at 19.5 psi and 10 analytical runs at 19.5 psi with an equilibration rate of 0.0050 
psi/min. The results were average of three measurements. 
The diameter of 50 randomly chosen pellets were measured using a digital calibre 
(Whiteworth, CA, USA). 
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5.3.7. Drug content and HPLC analysis 
50 mg of omeprazole pellets was dissolved in 50ml of a mixture of acetonitrile:PBS  mobile 
phase (28:72) and transferred immediately to an amber container. After good shaking, the 
solution was filtered through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) in 
autosampler vials for HPLC assay. 
The HPLC analysis was carried out using Reverse phase HPLC (Dionex AS 50 autosampler with 
GP50 gradient pump HPLC System: Dionex, UK) at room temperature using a Gemini 5 µm, 4.6 
x 150 mm, column (Phenomenex La Luna: Phenomenex, Torrance, USA). The mobile phase was 
a mixture of USP phosphate buffer: acetonitrile (72:28). The mobile phase flow rate was 1 
ml/min, the injection volume was 20 µl and the UV absorbance was at 280 nm (Türkoğlu et al 
2004). Under these conditions, the retention time was 3.31 min. The concentration of 
omeprazole was determined by reference to a calibration curve constructed from dilutions of a 
stock solution (1mg/mL), using the mobile phases, in a concentration range between 5 to 200 
µg/mL. The calibration curve was performed in triplicate and resulted in a linear correlation in 
the studied concentration range (r²=0.99). 
 
5.3.8. Dissolution studies 
The dissolution profiles of approximately 120.5 mg unprocessed pellets (containing 10 mg 
omeprazole) and prepared ODTs that contained therapeutic doses of omeprazole pellets(10 
mg omeprazole) were evaluated using the USP type 2 dissolution apparatus (Erweka DT 600, 
Heusenstamm, Germany) with baskets at a rotational speed of 50 rpm, in 900 mL dissolution 
medium at 37 ˚C. Acidic dissolution medium (0.1 N HCl was used during the first 2 hours, 
followed by 1 hour in phosphate buffer saline (pH 6.8). At fixed time intervals, 5 ml samples 
were withdrawn and immediately 1 mL of 0.25 N NaOH was added. The samples were replaced 
with fresh medium (37 ˚C). The samples were filtered through a 0.45 µm nylon filter 
(CHROMACOL LTD, Herts, UK) in autosampler vials for HPLC assay. 
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5.4. Results and discussion 
5.4.1. Design of experiment 
The aim of this work was to optimise formulation parameters for incorporation of enteric 
coated multiparticulate (pellets) of omeprazole in lyophilised ODTs. In theory, a successful 
formulation should keep the pellets stable and suspended throughout and after the 
formulation process, exhibit adequate mechanical strength in the dry state and disintegrate 
quickly upon hydration. Suspending the pellets in the binder solution for enough time can be 
controlled by the viscosity of the solution, whereas the stability of the pellets is linked with the 
pH of the surrounding environment, due to the presence of enteric coating around the pellets. 
Therefore, the crucial responses that were selected as dependant variables were 
disintegration time (Y1), hardness (Y2), viscosity (Y3) and pH (Y4). 
Gelatin, carrageenan and alanine were selected as main excipients. Gelatin was used as matrix 
forming agent which gives shape and provides mechanical strength to the tablets (chapter 2). 
Moreover, it forms thermo-reversible gels upon hydration with melting points around 35-37 °C 
(just below body temperature), which provides smooth feeling in the mouth after 
disintegration. Our previous study (chapter 2) suggested that gelatin at stock solution 
concentration between 2-5% (w/v) is most suitable for developing lyophilised orally 
disintegrating tablets. Carrageenan was added as viscosity modifying agent that drastically 
increases the viscosity of gelatin stock solution, due to the formation of complex coacervates 
(associative interaction) between the two polymers (Michon et al., 1996). Preliminary studies 
(see appendix) showed that concentrations from 0.2 to 0.8% (w/v) of carrageenan were 
capable of increasing the viscosity of gelatin stock solutions (2-5% w/v) efficiently. Alanine was 
used as a matrix supporting/disintegration enhancing agent. Chapter 3 suggested that 
inclusion of 2- 5 % (w/v) of alanine in ODT formulations based on gelatin as a binder were able 
to cement the porous structure of the lyophilised tablets and accelerate the disintegration at 
the same time. Moreover, alanine showed tendency to crystallise in the frozen formulation 
and consequently stabilise the formulation against possible collapse (chapter 3).  
Accordingly, the influence of varying these three formulation (independent) variables, at three 
concentration levels within their pre-optimised ranges (see above), on the selected responses 
was studied using  response surface modelling (RSM). The top RSM design choice suggested by 
the software was a central composite face centered (CCF) which was composed of 34 
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experiments in total, 15 fractional factorial runs in duplicate (15x 2) and four replicated center 
points. The full worksheet is presented Table 5.1. 
 
Table 5.1 The CCF design worksheet 
Exp 
Name 
Run 
Order 
Gelatin 
%(w/v) 
Carrageenan 
%(w/v) 
Alanine 
%(w/v) 
Disintegration 
time (s) 
Hardness 
(N) 
Viscosity 
(mPa.s) 
pH 
N1 32 3 0.2 2 15 6.36 98.8 5.6 
N2 5 5 0.2 2 12 15.45 159.4 5.5 
N3 14 3 0.8 2 23 5.42 153.3 5.8 
N4 17 5 0.8 2 286 16.23 391.9 5.7 
N5 10 3 0.2 5 27 8.44 113.9 5.6 
N6 18 5 0.2 5 24 21.38 156.4 5.5 
N7 20 3 0.8 5 63 10.5 134.1 5.8 
N8 21 5 0.8 5 339 19.53 448.5 5.7 
N9 22 3 0.5 3.5 22 8.84 92.3 5.7 
N10 1 5 0.5 3.5 44 16.91 400.3 5.6 
N11 19 4 0.2 3.5 32 12.06 211.9 5.6 
N12 6 4 0.8 3.5 229 15.26 239.1 5.7 
N13 34 4 0.5 2 28 11.27 210.3 5.6 
N14 26 4 0.5 5 91 15.36 213.4 5.6 
N15 23 4 0.5 3.5 93 17.36 216.9 5.6 
N16 11 4 0.5 3.5 100 17.84 270 5.6 
N17 16 4 0.5 3.5 97 17.74 237.3 5.6 
N18 9 3 0.2 2 14 6.63 105.8 5.6 
N19 31 5 0.2 2 8 15.94 170.5 5.5 
N20 24 3 0.8 2 23 5.56 142.3 5.8 
N21 30 5 0.8 2 81 16.71 381 5.7 
N22 27 3 0.2 5 28 8.79 97.5 5.6 
N23 15 5 0.2 5 36 19.14 181 5.6 
N24 12 3 0.8 5 66 11.16 144.8 5.8 
N25 28 5 0.8 5 341 20.5 453.1 5.7 
N26 25 3 0.5 3.5 26 7.85 108.1 5.7 
N27 3 5 0.5 3.5 43 16.63 420.1 5.6 
N28 2 4 0.2 3.5 31 9.67 142 5.5 
N29 4 4 0.8 3.5 232 16.25 236.7 5.7 
N30 33 4 0.5 2 28 10.56 190.3 5.6 
N31 7 4 0.5 5 93 15.09 203.4 5.6 
N32 29 4 0.5 3.5 93 16.56 237.1 5.6 
N33 13 4 0.5 3.5 100 16.64 224.2 5.6 
N34 8 4 0.5 3.5 102 18.02 206.9 5.6 
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The results (Table 5.1) showed that the disintegration time of the tablets varied from 8 to 341 
s, the hardness from 5.42 to 21.38 N, viscosity from 92.3 to 453.1 % and pH from 5.5 to 5.8. 
The wide variation in the disintegration time, hardness and viscosity values for different 
formulations and the high degree of repeatability (Figure 5.1) suggested that these responses 
are strongly dependent on the selected independent factors. In case of pH, although small 
variations were noticed between different formulations, the results seemed to be systematic 
and repeatable, which may suggest dependency on the studied factors.    
 
 
 
Figure 5.1 Reproducibility of the results for all four responses. Reproducibility: is the variation 
of the response under the same conditions (pure error) compared to the total variation of the 
response. Reproducibility = 1 - (MS(Pure error)/MS(total SS corrected)). A reproducibility value 
of 1 represents perfect reproducibility. 
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5.4.2. Analysis of variance (ANOVA) 
A quadratic statistical model incorporating interactive and polynomial terms was used to 
evaluate the influence of the studied factors (independent factors) on the responses 
(dependent variables). 
Yi = b0 + b1 X1 + b2 X2 + b3 X3 + b12 X1X2 + b13 X1X3 + b23 X2X3 + b11 X1² + b22 X2²+ b33 X3² + b123 X1X2 X3 
Where Yi is the response (dependent variable), b0 is the arithmetic mean response of the 34 
trials, bi is the estimated coefficient for the relevant model terms, X1 is gelatin concentration, 
X2 is carrageenan concentration, and X3 is alanine concentration. The main effects (X1, X2 and 
X3) represent the average result of changing one factor at a time from its low to high value 
while keeping the other factors at their canter point. The interaction terms (X1X2, X1X3, X2X3 
and X1X2 X3) show the change in the response when factors are varied simultaneously. The 
polynomial terms (X1², X2² and X3²) express non linear correlations with the response. 
Analysis of variance (ANOVA) was performed to evaluate the significance of the quadratic 
models (linear, interactive and polynomial) on the responses and to estimate their quantitative 
effects. Table 5.2 summarises the effects of the model terms and associated p values for all 
four responses. At a 95% confidence level, a model was considered significant if the p value 
<0.05. The sign and value of the quantitative effect indicate trend and magnitude of the term’s 
influence on the response, respectively. Positive signs indicate an increase in the response 
value, while negative signs demonstrate a decrease in the response value. The results indicate 
that the disintegration time of the tablets was significantly influenced by the linear models of 
gelatin (X1), carrageenan (X2) and alanine (X3), in addition to the interactive model of gelatin-
carrageenan (X1X2) and carrageenan-alanine (X2X3).  
Quantitative estimation of the significant models indicated that carrageenan and gelatin had 
the prime influence on the disintegration time linearly and interactively, suggesting that 
increasing carrageenan and/or gelatin concentration in the formulation increases the 
disintegration time drastically. The deteriorating effect of X1 and X2 on the disintegration could 
be explained by the associative interaction between gelatin and carrageenan upon hydration 
which forms a strong complex and consequently more resistant to disintegration in aqueous 
medium. Similar behaviour was reported by Bonferoni et al (2004) where muchoadhesive 
systems based on carrageenan and gelatine showed high resistance to erosion in an aqueous 
environment (lachrymal fluid) as a result of their associative interaction.  
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Table 5.2 The quantitative factor effects and associated p value for the responses.  
 Disintegration time Hardness Viscosity pH 
Term Effect P value Effect P value Effect P value Effect P value 
X1 33.9755 <0.0001 3.8395 <0.0001 77.3120 <0.0001 -0.0348 <0.0001 
X2 55.9070 <0.0001 0.5089 0.1318 50.9857 <0.0001 0.0707 <0.0001 
X3 26.9802 0.0008 1.5766 <0.0001 3.3790 0.5917 0.0028 0.5007 
X1² -16.8769 0.1220 -0.7425 0.1431 7.2172 0.4477 0.0201 0.0032 
X2² 20.8862 0.0590 -0.4343 0.3844 -11.5445 0.2291 0.0097 0.1273 
X3² -4.2117 0.6923 -0.5014 0.3166 -9.7039 0.3098 0.0021 0.7388 
X1X2 34.5981 <0.0001 -0.0416 0.8845 31.4688 <0.0001 -0.0041 0.2580 
X1X3 9.9296 0.1162 0.0541 0.8504 5.2006 0.3461 0.0036 0.3149 
X2X3 14.5584 0.0252 0.1815 0.5283 2.5914 0.6363 -0.0044 0.2303 
X1X2 X3 6.9345 0.1566 -0.2460 0.2763 3.9755 0.3547 -0.0031 0.2727 
 
 
Moreover, the formation of viscous solution upon hydration as a consequence of this 
interaction might limit the movement of water (Michon et al., 2001) inside the tablet and 
consequently reduce rate of penetration of the disintegration medium and therefore result in 
longer disintegration time. The large positive coefficient (34.5981) of the interactive term 
(X1X2) suggested that detrimental effect of gelatine and carrageenan on the disintegration of 
the tablet is synergised by increasing the concentration of both polymers simultaneously, 
which might be explained by the existence of more polymer chains available for complexation 
and consequently stronger interaction resulting in viscous environment upon hydration. On 
the other hand, increasing alanine concentration showed significant increase in disintegration, 
linearly (X3) and interactively with carrageenan (X2X3) but to a lower degree when compared to 
gelatin and carrageenan.  The inclusion of high concentration of alanine decreases the porosity 
of the tablets (chapter 3) and increases the probability of forming complex with carrageenan 
due to the presence of positive amino group on alanine structure that can form a complex with 
the negative sulphate group of carrageenan. 
For hardness (Y2), ANOVA results (Table 5.2) suggested that gelatin concentration (X1) and 
alanine concentration (X3) were the only significant terms with a p value <0.00001. Increasing 
gelatin concentration was the most effective way to improve the hardness as indicated by its 
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large positive coefficient (3.8395), possibly due to the formation of more extensive 3D 
networks of gelatin fibres (chapter 2). Increasing alanine concentration also enhances the 
hardness significantly, which could be as a result of cementing the porous structure of the 
tablet, increasing the contact points between the excipients, and enhancing the inter 
molecular bonding forces within the tablets (chapter 3). 
The viscosity (Y3) was significantly influenced by gelatin concentration (X1), carrageenan 
concentration (X2) and their interactive term (X1 X2), with a p value of <0.0001 and positive 
large coefficients for all the terms, suggesting that increasing carrageenan and/or gelatin 
concentration in the formulation increases the viscosity drastically. This could be explained by 
the attractive electrostatic interactions between gelatin and carrageenan which depends on 
the concentration and ratio of both polymers (Michon et al., 1995). Accordingly, the results 
suggested that, at the investigated concentration ranges for both the polymers, the interaction 
was enhanced by increasing the total concentration of the polymers individually and more 
effectively by simultaneous increase of concentrations of both the polymers.  
For the fourth response Y4 (pH), significant terms were identified as X1 (gelatin concentration) 
X2 (carrageenan concentration) and X1² (polynomial model of gelatin concentration). The 
results (Table 5.2) suggested that increasing gelatine concentration decreases the pH of the 
formulation. However, this decrease is limited as indicated by the significant influence of the 
positive coefficient of the polynomial model of gelatin concentration (X1²). Similar effect of 
gelatin on the pH was reported in literature (Michon et al., 2000). Carrageenan concentration 
(X2) had a positive coefficient suggesting that increasing its concentration raises the pH of the 
formulation. 
  
5.4.3. Revised models and surface response plots 
The resulting equations for all four responses, Y1 (disintegration time), Y2 (Hardness), Y3 
(viscosity), and Y4 (pH), are presented below: 
Y1 = + 84.4118 + 35.3049 X1 + 56.6747 X2 + 22.9657 X3 + 33.1818 X1X2 + 12.5 X2X3  
Y2 = + 13.7544 + 3.84851 X1 + 1.54766 X3  
Y3 = + 217.429 + 76.7327 X1 + 50.1198 X2 + 32.1477 X1X2  
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Y4 = + 5.60919 - 0.0354952 X1 + 0.070379 X2 + 0.0268962X1²  
 
Statistical analysis for testing the validity of the models is summarised in Table 5.3. P values for 
all the simulated responses were well below the significant level (<0.05) suggesting that all the 
revised models were significant in predicting their response values. The high value of 
correlation coefficients (R²) for all four responses indicated a good fit to the raw data 
(observed) in the revised model. Low correlation coefficient was noticed for disintegration 
time possibly due to the qualitative nature of the test that depends on the visual evaluation in 
addition to the fact that few seconds' inaccuracy in evaluating the disintegration time can 
result in huge error. 
 
Table 5.3 Summary of results for testing validity of the revised models. DF indicates: degrees of 
freedom; SS: sum of squares; MS: mean of square; F: Fischer’s ratio; p: probability; R2: 
regression coefficient. 
Disintegration time 
 DF SS MS (variance) F p R2 
Regression 5 219302 43860.3 20.4012 <0.0001 0.824 
Lack of Fit 9 39007.7 4334.19 3.88643   
 
Viscosity 
 DF SS MS (variance) F p R2 
Regression 3 322215 107405 77.5712 <0.0001 0.886 
Lack of Fit 11 35393.4 3217.59 9.94932   
 
Hardness 
 DF SS               MS (variance) F p R2 
Regression 2 567.807 283.903 63.3272 <0.0001 0.803 
Lack of Fit 12 129.304 10.7754 21.1665   
 
pH 
 DF SS MS (variance) F p R2 
Regression 3 0.221275 0.0737584 134.959 <0.0001 0.931 
Lack of Fit 11 0.0063957 0.000581427 1.10471   
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Based on the revised equations, the software was used to generate response surface plots 
(three dimensional) that simulate the influence of the independent factors on each response 
individually. The graphs for disintegration time, hardness, viscosity and pH are presented in 
Figures 5.2, 5.3, 5.4 and 5.5, respectively. The plots can provide uninterrupted visual 
assessment of the change in the response surface as a function of varying the independent 
factors, individually and simultaneously, which is valuable to further understand the system 
and optimise the formulation. 
 
 
 
Figure 5.2 Surface response plot showing the influence of varying gelatin and carrageenan 
concentrations in the stock solution (%w/v) at constant concentration of alanine (3.5% w/v) on 
the disintegration time of the ODT.  
 
MODDE 8 - 27/08/2010 16:53:26
Alanine = 3.5
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Figure 5.3 Surface response plot showing the influence of varying gelatin and alanine 
concentrations on the hardness of the ODT.  
   
 
Figure 5.4 Surface response plot showing the influence of varying gelatine and carrageenan 
levels on the viscosity of the stock solution. 
MODDE 8 - 27/08/2010 16:58:08
MODDE 8 - 27/08/2010 17:01:39
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Figure 5.5 Surface response plot showing the influence of varying gelatine and carrageenan 
levels on the pH of the stock solution. 
 
5.4.4. Optimum ODTs formulation 
Based on the response surface plots, the software was used to perform hot spot analysis to 
obtain optimum formulation variables (gelatin, carrageenan and alanine concentrations) to 
produce ODTs with desired characteristics. The request was to minimise the disintegration 
time, and maximise the hardness and viscosity of the formulation, whereas the pH was 
excluded from the optimisation due to its limited variation in response to the studied factors. 
The optimal formulation was determined as 4.7% (w/v) gelatin, 0.02% (w/v) carrageenan and 
3% (w/v) alanine. The observed response values of the optimised formulation compared to the 
predicted values are presented in Table 5.4. The closeness between the experimental 
(observed) and calculated (predicted) values of the responses can add further experimental 
verification to the validity of the established statistical models. 
MODDE 8 - 27/08/2010 17:06:21
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Table 5.4 Observed and predicted responses and residual values for the optimised 
formulation. The observed results are means, n=3. 
Response Observed Predicted Residual 
Disintegration time (s) 14 15 -1 
Hardness (N) 17.22 16.17 1.05 
Viscosity (mPa.s) 172.40  181.26 -8.86 
pH 5.5 5.5 0 
 
 
5.4.5. Inclusion of enteric coated pellets of omeprazole 
The characterisation of the enteric coated pellets of omeprazole used in the study is presented 
in Table 5.5. The results showed that the pellets were able to withstand the gastric condition 
(0.1 N HCl) for 2 hour with less than 10% of the total drug amount being released, which 
complied with the USP specification of enteric coated pellets. The dissolution profile after 
transferring the pellets to a pH 6.8 phosphate buffer is shown in Figure 5.6. Based on the 
optimised formulation, lyophilised ODTs containing 120.5 mg of enteric coated pellets of 
omeprazole (10 mg dose of omeprazole) was prepared using 18 mm diameter mould. The 
solution was able to suspend the pellets long enough before transferring the formulation to 
the freezer with no obvious settling or aggregation of the pellets. Moreover, no degradation or 
colour change was noticed throughout mixing, freezing and lyophilisation steps. 
 
Table 5.5 characterisations of omeprazole enteric coated pellets. Results are mean ± SD, n=3. 
Drug content % (w/w) Drug recovery % Density (g/cm³) diameter (µm) 
8.27 ± 0.29 91.24 ± 1.22 1.439 ± 0.006 710 ± 40 
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Figure 5.6 Cumulative percent of omeprazole released in phosphate buffer (pH 6.8) after 2 
hours of gastric resistance study in 0.1 N HCl. 
 
Characterisation of the tablets is summarised in Table 5.6. The tablets disintegrated in less 
than 19 seconds and had an average hardness of 17.24 ± 0.74 N (n=3). The disintegration time 
and hardness of the prepared tablets was not significantly different when compared to the 
optimised formulation without the pellets (Table 5.5) which suggested that the pellets did not 
compromise the tablets properties.  The results showed no significant decrease in drug 
recovery after two hour in gastric condition compared to the original pellets, suggesting that 
the formulation and manufacturing process did not interfere with the integrity of the pellets. 
The dissolution profile after transferring the pellets to a pH 6.8 phosphate buffer is shown in 
Figure 5.6. 
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Table 5.6 Characterisations of orally disintegrating tablets containing Omeprazole pellets. 
Results are mean ± SD, n=3.  
Disintegration time (s) Hardness (N) Viscosity (mPa.s) Drug recovery %* 
16 ± 3 17.2 ± 0.74 172 ± 21.3 93.14 ± 1.22 
 
 
 
5.5. Conclusion 
The central composite face centered (CCF) design applied in this study was used to provide 
details of the influence of independent variables on the responses. The results of analysis of 
variance (ANOVA) showed that all three independent variables had significant effect on the 
selected response. The revised model showed high degree of reliability and therefore 
succeeded to generate ODT formulations with optimised properties. The study showed the 
successful application of the combination of gelatin, carrageenan to incorporate 
multiparticulate drug delivery systems into lyophilised ODT formulation.    
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Investigation of Alternative Binders for the Formulation 
of Lyophilised ODTs 
 
 
6.1. Introduction and Aims 
Gelatin is the most common binder that has been used extensively in the formulation of 
lyophilised ODTs (Seager, 1998). It has been utilized in most of the commercially available 
lyophilised ODTs (ex. Zyprexa Zydis, Maxalt-MLT, Zelapar). Chapter 2 and 3 showed that gelatin 
can provide lyophilised tablets with adequate mechanical strength and short disintegration 
time. It is a water soluble structural protein obtained by thermal denaturation of collagen that 
is present inside the connective tissue (skin, cartilage and bone) of hogs, cattle and fish. In 
recent years, safety concerns about gelatin have been raised due to the emergence of animal 
diseases such as mad cow, chronic wasting and scrapie. Moreover, the use of gelatin in tablets 
may be unacceptable to certain patient population for example to vegetarian and/or to people 
with certain religious beliefs.  Accordingly, the aim of the current study was to investigate the 
feasibility of replacing gelatin in the formulation of lyophilised ODTs with more ethically and 
morally acceptable components. The fundamental requirement of the new lyophilised ODT 
binder is the ability to produce intact tablets after freeze drying that have adequate 
mechanical strength and most importantly instant disintegration upon hydration. 
Furthermore, due to the high cost of the freeze drying process, polymers that allow short 
freeze drying cycle have a significant economical advantage.  
Reviewing and analysing recent patents and literature in ODT formulations (chapter 1) 
revealed that short disintegration time could be achieved by using hydrophilic and/or 
hydrophobic polymers. However, in the formulation of lyophilised ODTs, high aqueous 
solubility is necessary to allow the easy formation of aqueous polymer solution and 
consequently forming continuous matrix after freeze drying. In this study, two naturally 
occurring hydrophilic polymers were carefully selected depending on their properties and 
previous applications that suggest their potential to act as a binder in the formulation of 
lyophilised ODTs. A progressive three-stage refinement approach was used in this study to 
select a new binder, optimise its concentration, determine its potential advantages as a binder 
  
Chapter 6 – Investigation of Alternative Binders for Lyophilised ODTs      
159 
 
in lyophilised ODTs over gelatin, and study the influence of adding matrix 
supporting/disintegrating enhancing agents on the properties of the formulation. In the first 
stage, the candidate polymers were used individually to prepare lyophilised tablets at suitable 
concentration ranges and the formulation with the best characteristics was taken forward to 
stage 2. The second stage compared the freeze drying cycle and performance of the selected 
formulation with an optimised gelatin formulation. Whereas, stage 3 investigated the 
influence of adding matrix supporting/disintegrating enhancing agents on the properties of the 
formulation. 
 
6.2. Selection of candidate polymers 
The first polymer was gum arabic, which is a natural polymer harvested from the exterior of 
Acacia trees (Islam et al., 1997). Structurally, Gum arabic is a branched chain polysaccharide 
with a backbone consisting of 1,3-linked β-D galactopyranosyl units with other carbohydrates 
such as arabinose, glucuronic acid and rhamnose (Benke et al., 2009). Unlike most of natural 
gums, gum arabic is soluble in water and can yield solutions of up to 50% concentration (Cozic 
et al., 2009). Due to the multi functional properties, high safety profile and availability of gum 
arabic, it is widely used in food, cosmetic and pharmaceutical industries as emulsifying (Yadav 
et al., 2007), stabilising, suspending (lu et al., 2003) and encapsulating agent (Ramakrishnan et 
al., 2007; Kaushik and Roos, 2007). In solid oral dosage forms, gum arabic has been 
investigated and used as an osmotic, suspending and expanding agent in a monolithic osmotic 
tablet system (Lu et al., 2003) and water soluble gum in orally disintegrating films (Fuisz et al., 
2008). Moreover, freeze drying of gum arabic was reported to be faster and more efficient 
than gelatin (Kaushik and Roos, 2007). 
The second polymer was carrageenan, which is extracted from species of marine plants known 
as red seaweeds. Carrageenan is an anionic polysaccharides with a linear structure of 
repeating units of disaccharide that are connected in alternating sequences of 1,4-linked-α-D-
galactose and 1,3-linked-β-D-galactose (Arda et al., 2009). Carrageenans are usually classified 
according to the number of sulphated groups per disaccharide: one, two or three for kappa, 
iota and lambda, respectively (Michon et al., 2005). It is a common ingredient in food, 
cosmetic and pharmaceutical products as suspending, stabilising and viscosity modifying 
agents. The use of carrageenans in various applications depends largely on their rheological 
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properties; water-soluble polymers that dissolve in either cold or hot water to form viscous 
solutions and consequently provide the appropriate texture for the product (Imeson, 2000). In 
food industry, especial in jelly candies, carrageenan is used as vegetarian alternative to gelatin 
(McHugh, 2003). In freeze drying of pharmaceutical products, carrageenan was investigated 
for its cryoprotectant activity which might be useful to protect against possible damage during 
the freezing and annealing steps (Choi et al., 2007), and was reported to enhance the 
redispersibility of freeze dried nanoparticulate systems (Kim and Lee, 2010). 
 
6.3. Materials 
Gum Arabic, gelatin from calf skin (type B, Bloom strength ~ 60), lambda carrageenan, alanine 
and mannitol were purchased from Sigma-Aldrich Chemicals (Pool, UK). All the materials were 
used as received. 
 
6.4. Methods 
6.4.1. Formulation of tablets to investigate the suitability of candidate 
polymers as binders in ODTs 
The candidate polymers were dissolved in double distilled water at room temperature to 
obtain predetermined concentrations. Gum arabic was investigated at stock solution 
concentrations of 5%, 10%, 15%, 20% and 25% w/w. Carrageenan was investigated at 
concentration of 0.5%, 1. %, 1.5%, 2%, 2.5% w/w. 1.5 g of the stock solution was poured into a 
PEG mould (13.5mm in diameter ), frozen at -80 ˚C for about 60 min, annealed for 12 hours at -
15 ˚C and freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to an optimised regime 
(primary drying for 48 h at a shelf temperature of -40 ˚C, followed by secondary drying for 10 h 
at a shelf temperature of 20 ˚C, vacuum of 50 m Torr), which resulted in a moisture content of 
less than 3% w/w. All the formulations were prepared in triplicate from three independent 
batches. 
 
 
 
  
Chapter 6 – Investigation of Alternative Binders for Lyophilised ODTs      
161 
 
6.4.2. Product temperature during the primary drying time 
The product temperature profiles (Tb) during primary drying of the optimised formulation 
from the previous study (6.4.1) and the optimised gelatin formulation (5% low bloom 
strength)were recorded and used as an indication to compare the freeze drying conditions for 
the  polymers. The product temperature was automatically recorded using thermo couples 
that were inserted in the centre bottom of the tablet. All the measurements were done in 
triplicate from three independent batches. 
 
6.4.3. Formulation of tablets to the influence of the inclusion of matrix 
supporting/disintegrating enhancing agents   
Alanine and mannitol were added individually to the optimised formulation from the previous 
study (6.4.1) at concentrations of 30% and 50% w/w (total solid). 
 
6.4.4. Differential scanning calorimetry 
Differential scanning calorimeter (Pyris Diamond DSC) was used to investigate the glass 
transition temperatures (Tg) and the crystallization events of the frozen formulations. 10–15 
mg of the liquid formulation was transferred into an aluminium pan (50 μL capacity) and then 
sealed with an aluminium top. The sample was cooled to -65 ˚C and then heated to 20 ˚C at 
5˚C/min. To determine the glass transition temperature of the maximally freeze concentrate 
sample (Tg’), after initial cooling to -65 ˚C, annealing for 10 min at a temperature  higher than 
the relevant glass transition temperature (Tg) was added before carrying out the above 
method. Nitrogen was used as a purge gas at a flow rate of 20 mL/min. Indium and zinc were 
used to calibrate the heat flow and melting point onset (melting point: 156.6 °C, ΔHm: 28.42 
J/g for Indium and melting point: 419.47 °C ΔHm: 108.26, J/g for Zinc). The obtained 
thermograms were analysed using Pyris Manager Software (version 5.00.02) where Tg and Tg' 
values were determined from the intersection of relative tangents to the baseline. The 
experiment was performed in triplicate and an empty aluminium pan was used as a reference 
cell for all the measurements. 
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6.4.5. In vitro disintegration study of the tablets 
Disintegration time is the time required for ODTs to disintegrate completely without leaving 
any solid residue. In vitro disintegration time for lyophilised ODTs was evaluated using US 
pharmacopoeia monograph (<701> disintegration). Erweka (ZT3, Appartebau, GMBH) was 
used in this study as a disintegration apparatus and distilled water (800 mL) as disintegration 
medium; the disintegration medium temperature was maintained at 37 °C by thermostat. At 
each time, one tablet was placed in the basket rack assembly and covered by transparent 
plastic disk. The disintegration time was taken as the time required for ODTs to disintegrate 
completely without leaving any solid residue. All the measurements were carried out six times 
and presented as (mean ± standard deviation). 
 
6.4.6. Mechanical properties of the tablets 
The hardness of the lyophilized tablets was investigated with a texture analyzer (QTS 25: 
Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated with 
standard weight of 500 g and 5 kg. The tablet was placed in a holder with a cylindrical hole and 
the hardness was taken as the peak force after 1mm penetration of 5mm diameter probe at a 
speed of 6 mm/min.  
 
6.4.7. Statistical analysis 
 Graph Pad Instat® software was used for the statistical analysis study. Data groups were 
compared using one way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey-Kramer multiple comparison test). Standard deviation (SD) was used to report 
the error in the figures and texts. Probability values of 95% (P < 0.05) were used to determine 
the significant difference. 
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6.5. Results and discussion 
6.5.1. Stage 1: the influence of polymers concentration on the 
formulation properties 
The studied concentration ranges of arabic gum (5- 25 % w/w) and carrageenan (0.5- 2.5 
%w/w) were determined based on preliminary studies that were conducted to ensure that all 
the formulations can be prepared easily and form intact tablets after freeze drying for full 
characterisation. Formulation of lower concentrations than the studied range was associated 
with very fragile and delicate tablets that were difficult to handle and characterise. On the 
other hand, higher concentrations took longer time to dissolve completely in water, gave very 
viscous solutions that were difficult to transfer into the mould and resulted in lyophilised 
tablets with very long disintegration time. 
The glass transition temperature of maximally freeze concentrate samples (Tg’) of 
formulations based on varied concentrations of gum arabic and carrageenan are summarised 
in Tables 6.1 and 6.2, respectively. The results showed that formulations based on gum arabic 
had Tg’ values of about -14.00 ˚C irrespective of the concentration of the polymer (one way 
ANOVA/Tukey- Kramer: p>0.05). Similarly, all formulation based on varied concentration of 
carrageenan displayed T’g values (around -34.50 ˚C) that were not significantly different (one 
way ANOVA/Tukey- Kramer: p>0.05). The results suggested that each polymer has a distinctive 
Tg’ with no significant influence of the polymer concentration on the Tg’ (Figure 6.1).    
The glass transition temperature of maximally freeze concentrate formulation (Tg’) is crucial 
parameter to determine the freeze drying conditions that ensure the formation of intact 
tablets. Usually, lyophilisation of formulations at temperature 1 to 3 ˚C higher than their Tg’ 
(collapse temperature) results in the collapse of their structure (Pikal and Shah, 1990), and in 
turn formulations with low Tg’ are required to be freeze dried at low shelf temperature and 
consequently take longer time for the freeze drying cycle to finish (Rambhatla et al., 2006). 
Accordingly, formulations based on gum arabic are expected to have more efficient freeze 
drying cycle as they can tolerate higher shelf temperature and consequently shorter primary 
drying time than carrageenan formulation. 
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Table 6.1 The glass transition temperature of maximally freeze concentrate samples (Tg’) of 
formulations based on varied concentrations of gum arabic. 
Concentration of gum arabic (% w/w) Tg’ 
5 -13.88 ± 0.33 
10 -13.70 ± 0.34 
15 -13.79 ± 0.41 
20 -13.75 ± 0.20 
25 -13.69 ± 0.27 
 
 
Table 6.2 The glass transition temperature of maximally freeze concentrate samples (Tg’) of 
formulations based on varied concentrations of carrageenan. 
Concentration of carrageenan (% w/w) Tg’ 
0.5 -34.42 ± 0.54 
1 -34.23 ± 0.46 
1.5 -34.74 ± 0.34 
2 -34.66 ± 0.29 
2.5 -34.69 ± 0.24 
 
 
 
Figure 6.1 DSC heating scans of aqueous solutions of gum arabic and carrageenan show the 
glass transition temperature of maximally freeze concentrate samples.  
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The hardness of ODTs based on gum arabic and carrageenan are presented in Figures 6.2 and 
6.3, respectively. Similar trend was followed by both polymers; increasing the concentration of 
the polymer in the formulation increased the hardness significantly (one way ANOVA/Tukey- 
Kramer: p>0.05). However, wide variations in the improvement were obtained for each 
polymer, which can be attributed mainly to the physicochemical properties of the polymer and 
its concentration range in the study. In case of tablets made from gum arabic, the hardness 
was found to progressively increase from 0.56 ± 0.15 N in the 5% formulation to reach 9.22 ± 
0.22 N in the 25% formulation (Figure 6.2) compared to a lesser improvement in case of 
carrageenan, from 0.37 ± 0.05 N in the 0.5% formulation to a maximum hardness of 2.39 ± 
0.26 N in the 2.5% formulation (Figure 6.3). Carrageenan was found to be suitable to formulate 
lyophilised ODTs only at low concentration due to the formulation limitations that were 
mentioned earlier, therefore fluffy and highly porous tablets were produced after freeze 
drying as very low mass of carrageenan (1-2 mg) was distributed in a relatively large volume of 
the tablet (1.5 ml). In case of gum arabic much higher mass of the polymer could be 
incorporated in the tablets, consequently resulting in closer polymer networks and high 
hardness values. 
 
 
Figure 6.2 Mechanical properties of lyophilised tablets based on varied concentration of gum 
arabic. Results are mean ± SD, n=3. 
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Figure 6.3 Mechanical properties of lyophilised tablets based on varied concentration of 
carrageenan. Results are mean ± SD, n=3. 
 
With regard to the disintegration time of the tablets, the results showed (Figures 6.4 and 6.5) 
that increasing the concentration of the polymers in the formulation resulted in significant 
increase in the disintegration time (p>0.05). The average disintegration time of tablets based 
on gum arabic gradually rose from 2 s in the 5% formulation to reach a maximum time of 51 s 
in the 25% formulation. In case of tablets based on varied concentration of carrageenan, the 
disintegration time increased more substantially with each increment in the polymer 
concentration to reach a maximum time of 190s for the highest concentration (2.5%). The 
results could be explained as increasing the polymer concentration decreases the porosity of 
the tablets and therefore more time is needed for the disintegrating media to penetrate 
through the tablets. The difference in the disintegration time between tablets made from gum 
arabic and carrageenan could be attributed to their differences in the wettability (Fukami et 
al., 2006), molecular weight (Chen et al., 2006) and inner structural characteristics of the tablet 
after freeze drying (chapters 2 and 4). 
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Figure 6.4 The effect of gum arabic concentration on the disintegration time of lyophilised 
ODTs. Results are mean ± SD, n=3. 
 
 
Figure 6.5 The effect of carrageenan concentration on the disintegration time of lyophilised 
ODTs. Results are mean ± SD, n=3. 
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Selection of the polymer and its ideal concentration to be taken forward to Stage II of the 
study depended on finding the best balance between hardness and disintegration time of the 
tablets. A formula termed the Lyophilised Tablet Index (LTI = hardness/disintegration time) 
took both the above mentioned factors into consideration and was used in decision making 
(chapter 2). The LTI values of tablets based on gum arabic and carrageenan are summarised in 
Tables 6.3 and 6.4, respectively. The results suggested that tablets made from 15% gum arabic 
achieved the highest LTI value and consequently was selected to be taken forward to stage II. 
Moreover this formulation is expected to offer efficient freeze drying cycle due to its high Tg’ 
as explained earlier.  
 
Table 6.3 Lyophilised tablet index (LTI) of tablets based on varied concentration of gum arabic. 
Concentration of gum arabic % (w/w) LTI 
5 0.278 
10 0.404 
15 0.557 
20 0.365 
25 0.180 
 
 
Table 6.4 Lyophilised tablet index (LTI) of tablets based on varied concentration of 
carrageenan. 
Concentration of carrageenan % (w/w) LTI 
0.5 0.010 
1 0.010 
1.5 0.009 
2 0.011 
2.5 0.013 
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6.5.2. Stage 2: comparing the freeze drying cycle and performance to 
lyophilised tablets based on gelatin  
The second stage was aimed to explore the benefits of using gum arabic over gelatin, which is 
used extensively as a binder in ODT formulation (chapters 2, 3 and 4). The first advantages was 
observed in the first step of the preparation process, where gum arabic showed complete and 
fast dispersion in water at room temperature, in contrast to gelatin formulations, where 
heating (above 40 ˚C) is necessary. Another drawback of using gelatin as matrix forming agent 
in the formulation of lyophilised ODTs is the long freeze drying cycle (chapter 2). To compare 
the freeze drying cycle of the optimised formulations based on gum arabic (15% w/w) and 
gelatin (5 % of low bloom strength), thermal probes were used to monitor the product 
temperature during the freeze drying process (Figure 6.6). Monitoring the product 
temperature during the freeze drying process is a valuable technique to understand and 
correlate the heat and mass transfer processes (Tang et al., 2005). Moreover, it gives an 
estimation of the end of the primary drying (sublimation), which appears as a sudden increase 
in the product temperature due to the absence of ice crystals that can be sublimed (Schneid et 
al., 2009). The results (Figure 6.6) showed that the product temperatures of the gelatin based 
formulation were always around 10 to 15 ˚C higher than the shelf temperature (-40 ˚C) 
suggesting high resistance to the sublimation process (Tang and Pikal, 2004) and consequently 
slower sublimation rate. Therefore, the end point of the primary drying took long time (an 
average of 2840 ± 104 min) to appear (Figure 6.6). On the other hand, tablets based on gum 
arabic had temperatures close to the shelf temperature during the primary drying, suggesting 
more efficient sublimation process (less resistance to sublimation) than gelatin. As a result, the 
end point of tablets based on gum arabic appeared in drastically shorter time (an average of 
680 ± 74 min). 
These advantages of using gum arabic did not compromise the actual performance of the 
tablets in terms of disintegration time and mechanical properties. The optimised concentration 
of gum arabic (15%) achieved higher LTI value of 0.54 compared to 0.47 for tablets made from 
low bloom strength gelatin at a concentration 5%, which was the highest for tablet made from 
gelatine (chapter 2). 
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Figure 6.6 The temperature profiles of tablets based on gum arabic and gelatin during their 
freeze drying cycles. 
 
Moreover, gum arabic as a natural polymer that extracted from acacia trees can overcome 
some safety and ethical concerns imposed by the origin of gelatin, which comes from the 
hydrolysed product of animal collagen tissues, such as skin, tendon, ligament and bones. 
Compared to tablet based on gelatin, gum arabic has no risk of causing animal origin diseases 
(CJD) and at the same time is more suitable to vegetarian and people with certain religious 
beliefs. 
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6.5.3. Stage 3: The influence of the inclusion of matrix 
supporting/disintegrating enhancing agents 
The third stage of the study involved the addition of matrix supporting/disintegrating 
enhancing agents to the 15% gum arabic formulation brought forward from Stage I (control). 
Alanine and mannitol were chosen on the basis of our previous work and they were included in 
the formulation at two concentrations, 30 and 50% w/w, as they showed the best 
performance in enhancing the hardness and reducing the disintegration time simultaneously 
(chapter 2 and 3). 
The thermal properties of the frozen formulations are summarized in Table 6.5. At 
concentration of 30%, both mannitol and alanine showed lower Tg values than the 15% gum 
arabic with no crystallisation events (Cr) in the heating scan. However, after annealing both 
formulation displayed Tg’ at temperatures higher than their Tg, which is attributed to their 
crystallisation in the annealing step. At concentration of 50% (w/w), both formulation showed 
crystallization (Cr) in the heating steps and consequently showed Tg’ at temperatures 
comparable to the 15% gum arabic alone. 
The disintegration time results (Figure 6.7) showed that addition of mannitol or alanine at 
concentration of 30% (w/w) achieved instant disintegrations of about 4-5 s, which are 
significantly shorter than the formulation of 15% gum arabic alone (p>0.01), which could be 
attributed to the high wetting properties of these two materials (chapter 2 and 3). However, 
inclusion 50% of mannitol and alanine showed slightly longer disintegration time compared to 
the 30%, which can be explained as a result of decreasing the total porosity of the tablets at 
this concentration (chapter 2 and 3). 
 
Table 6.5 Thermal properties of frozen solutions of gum arabic (15% w/w) after the addition of 
matrix supporting/disintegrating enhancing agents. Results are mean ± SD, n=3. 
Excipient  Concentration (% w/w) Tg (˚C) Cr (˚C) Tg' (˚C) 
Alanine  30 -32.8 ± 0.3 - -15.3 ± 0.3 
Alanine  50 -44.9 ± 0.2 -36.2 ± 0.3 -14.7 ± 0.1 
Mannitol  30 -26.3 ± 0.2 - -15.9 ± 0.1 
Mannitol  50 -41.1 ± 0.2 -28.4 ± 0.1 -14.8 ± 0.1 
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Figure 6.7 The disintegration time of ODTs based on gum arabic after the addition of matrix 
supporting/disintegrating enhancing agents. Results are mean ± SD, n=3.  
 
With regards to the mechanical properties (Figure 6.8), addition of 30% alanine and mannitol 
appeared to have no significant improvement on the hardness (p>0.05). However, increasing 
the concentration to 50% enhanced the hardness significantly compared to the control 
formulation (p<0.05). 
In order to evaluate the effect of inclusion of amino acids on the hardness and disintegration 
simultaneously and compare it to the control formulation (15% gum arabic only), Relative 
lyophilised tablets index (RLTI) were calculated according to the following equation:  
RLTI = (H/DT) ÷ (H˚/DT˚) 
 Where H: hardness of the tested tablet, DT: disintegration time of the tested tablet, H˚: 
hardness of the control tablets, DT˚: disintegration time of the control tablet. 
The RLTI value provided a ratio indicative of whether the new formulation was better than the 
control. Values over than 1 indicate improvements over the control whereas lower than 1 
suggest retardation in the overall tablet properties. Also, RLTI values can evaluate the degree 
of improvement for all the formulations, in basis of higher value the better formulation.  
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The RLTI values are presented in Table 6.6. The results suggested that inclusion of alanine and 
mannitol in concentrations range from 30% to 50% (w/w) improved the overall tablets 
properties, which confirmed their role in the formulation as matrix supporting/disintegrating 
enhancing agents.  
 
 
Figure 6.8 The hardness of ODTs based on gum arabic after the addition of matrix 
supporting/disintegrating enhancing agents. Results are mean ± SD, n=3. 
 
 
Table 6.6 The relative lyophilised tablet index of tablets based on 15% gum arabic and 
mannitol or alanine. 
Excipient Concentration % (w/w) RLTI 
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Mannitol 50 1.57 
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6.6. Conclusion 
The current study suggests that gum arabic has an outstanding potential to be used as a binder 
in the formulation of lyophilised ODTs. Arabic gum showed immediate dispersion in either cold 
or hot water to form low viscosity solutions, which allowed the incorporation of high 
concentration of polymer and simplified the formulation process at the same time. The use of 
gum arabic as a binder was found to provide elegant freeze dried tablets with rapid 
disintegration time and sufficient mechanical strength to withstand manual handling. Tablets 
based on 15% w/w gum arabic achieved the best balance between hardness the disintegration 
time. Compared to gelatin formulation, the tablets based on gum arabic showed superior 
performance in term of disintegration time and hardness. Moreover, tablets comprising of 
gum arabic were prepared using a shorter freeze drying cycles than those with Gelatin. 
Inclusion of matrix supporting/disintegrating enhancing agents further enhanced the tablet 
characteristics.   
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Formulation Design and Optimization of Lyophilised 
ODTs Incorporating Hydrophilic and Hydrophobic Drugs 
Using Gum Arabic as a Binder 
 
7.1. Introduction and Aims 
Despite recent advances in the formulation of lyophilised ODTs, the number of products on the 
market is limited by type and dose of active drugs. The limitation is primarily due to the 
multiple factors associated with incorporating new active ingredients that influence the 
manufacturing process as well as the quality and performance of the lyophilised ODTs. Our 
previous results showed that incorporation of amino acids, even at low concentration, 
drastically affected the porosity, wettability and intermolecular bonding of the tablets and 
consequently the freeze drying cycle, disintegration time and mechanical properties (chapter 
3). Similarly, incorporating active drugs is expected to influence all aspects of the formulation. 
Moreover, inclusion of high doses of hydrophobic drugs is an additional challenge, due to 
difficulties in keeping the drug particles suspended before freezing the formulation, as the 
presence of high concentration of hydrophobic drug in aqueous environment increases the 
chance of drug particle aggregation and sedimentation (Frenkel et al., 2005), which affects the 
homogeneity of the formulation in liquid state and consequently the consistency of drug 
content within the batch. Adding suspending agents and surfactant to address this challenge 
may complicate the formulation process and optimisation. For hydrophilic drugs, a limitation 
in the maximum dose is imposed by the plasticising effect of the drug molecules on the matrix 
system that lowers the glass transition temperature or eutectic melting temperature and 
consequently lowers the collapse temperature which necessitates longer freeze drying regimes 
at lower temperatures to produce intact products (Seager, 1998). However, the use of gum 
arabic and alanine as the main excipients in the formulation of lyophilized ODTs can offer 
numerous advantages that can overcome the limitations and facilitate the formulation. The 
self emulsifying (Li et al., 2010) and suspending (Lu et al., 2003)  properties of gum arabic can 
be useful in increasing the dose of hydrophobic drugs that can be incorporated without 
compromising the consistency of drug content, disintegration time and dissolution profile of 
the tablets. On the other hand, alanine, due to its tendency to crystallise in the frozen state 
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(chapter 3), can facilitate the freeze drying process through concealing the plasticising effect of 
active drugs, and consequently increases the dose of hydrophilic drugs that can be 
incorporated in lyophilised dosage forms (Seager, 1998). 
Successful development of new pharmaceutical formulations requires extensive and 
comprehensive research to determine significant factors in formulation, understand their 
effects (individually and collectively), and optimise them to obtain high quality products. For 
lyophilised ODTs, traditional experimentation approach can be time and material consuming 
and consequently is associated with high cost, due to the existence of multiple factors that 
influence the formulation performance and manufacturing process. Recently, factorial design 
of experiment (DoE) supported by statistical software has been reported as an efficient and 
powerful tool in the development and optimization of pharmaceutical dosage forms (Nagarwal 
et al., 2009). Factorial design evaluates the influence of various formulation parameters and 
their interaction with the lowest number of experiments, hence reducing the cost and time of 
the work (Bhavsar et al., 2006). Moreover, factorial design of experiment is considered an 
essential part of quality by design paradigm (QbD) which is recommended by the FDA as a new 
regulatory requirement for approval of generic drugs (Yu, 2008).     
The main objective of the current study was to investigate the feasibility of incorporating 
therapeutics doses of active drugs in lyophilised ODTs based on gum arabic and alanine. To 
achieve this aim, full factorial design (3²) was adapted to evaluate the influence of 
concentration of two independent variables, alanine and the active drug, on five crucial 
responses, disintegration time, Tg’, hardness, friability and drug content. Quantitative 
estimation of the significant model terms (linear, polynomial and interactive) was used to build 
statistical model for each response that can describe the relationship between the dependant 
and independent variables. These models were used to optimise the concentration of alanine 
and the drug to maximize the quality of the formulation. Further, ODTs containing therapeutic 
doses of the drugs were prepared based on the optimised formulations, their short term 
stability was assessed and their dissolution profiles were compared to commercially available 
products. 
Four drugs with varied physicochemical and therapeutic properties were selected for the 
study, namely 5,5-diphenylhydantoin, ranitidine HCl, ibuprofen and loperamide HCl. The 
formulation of these drugs as ODTs, in addition to improving patient compliance, 
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demonstrates potential pharmaceutical benefits, such as enhancing the dissolution profile of 
the drugs and providing rapid onset of action.  
5,5-diphenylhydantoin (phenytoin) is a white crystalline powder which is practically insoluble 
in water with a molecular weight of 206.3 g/mol (BP, 2005). 5,5-diphenylhydantoin is an 
antiepileptic drug which is used in the treatment of epilepsy. It is available in parental, 
suspension, capsule, and chewable tablet formulations which are indicated for the control of 
generalized tonic-clonic and complex partial seizures (Katzung., 2007).  
Ranitidine HCl is supplied as white to pale yellow granular substance that is freely soluble in 
water with a molecular weight of 350.87 g/mol (BP, 2005). It is a histamine H2 receptor 
antagonist that is used to relieve and prevent heart burn associated with acid indigestion and 
sour stomach, and as short term treatment of active duodenal ulcer. Ranitidine HCl works by 
inhibiting H2 receptor at the parietal cell that is lining the stomach lumen, hence fast 
dissolution of the formulation in the stomach is necessary to exhibit its therapeutics response. 
The drug is available as immediate release formulations including conventional and 
effervescent tablets, capsules, and solution formulations (Katzung., 2007).  
Ibuprofen (MW of 350.87 g/mol) is a white crystalline powder that is practically insoluble in 
water (BP, 2005). Ibuprofen is a nonsteroidal anti-inflammatory drug that possesses analgesic 
and antipyretic properties. It is available as conventional and chewable tablets, capsule, ODT 
and suspension formulations (Katzung., 2007).  
Loperamide HCl (MW of 350.87 g/mol) is a white powder that is slightly soluble in water (BP, 
2005). It is indicated for the control and symptomatic relief of acute nonspecific diarrhoea 
(Katzung., 2007). 
 
7.2. Materials 
Gum Arabic, alanine, ranitidine HCl, 5,5-diphenylhydantoin, ibuprofen, loperamide HCl, 
sodium-octansulphonate, triethylamine, ammonium hydroxide, sodium-octansulphonate, 
triethylamine, and sodium lauryl sulphate were purchased from Sigma-Aldrich Chemicals (Pool, 
UK). Tris(hydroxymethyl)amino-methane was supplied from ICN Biomedicals (Ohio, USA). 
Nurofen Meltlets (200 mg ibuprofen), Zantac™ Relief (75mg ranitidine HCl), Epanutin® Infatabs 
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(50mg phenytoin), and Imodium® Instant (2mg loperamide HCl) were obtained from a local 
pharmacy. All the chemicals were of analytical grade. 
 
7.3. Methods 
7.3.1. Full factorial design 
The statistical experimental design in this study was performed using MODDE software version 
8 (Umetrics Inc., NJ, USA). For each drug (ranitidine HCl, 5,5-diphenylhydantoin, ibuprofen, 
loperamide HCl), a 3² randomised full factorial design of experiment was used to study the 
influence of 2 factors, each at 3 levels, and experimental trials were performed in triplicate at 
all 9 possible combinations (27 experimental runs in total). The concentration of alanine (X1) 
and the drug (X2) were selected as independent variables. The three factorial levels for each 
independent factors, low, medium and high, were coded as -1, 0 and 1, respectively. The 
disintegration time (Y1), Tg’ (Y2), hardness (Y3), friability (Y4) and drug content (Y5) were 
investigated as dependant variables (responses). 
 
7.3.2. Preparation of ODTs for factorial design experiments 
To prepare the stock solution, the binder (gum arabic) was dissolved in double distilled water 
at room temperature to obtain a concentration of 15 % w/w. Alanine was added to the 
solution at the designated concentration as a percentage of the dissolved gum Arabic. With 
constant stirring on a magnetic stirrer, the active drug was added slowly at the designated 
concentration, as a percentage of the dissolved gum arabic. The resulted formulation was 
subjected to shear homogenisation at 5000 rpm for 10 min to obtain uniform solution (in case 
of ranitidine HCl) or suspension (in case of 5,5-diphenylhydantoin, ibuprofen and loperamide 
HCl). A constant mass of 1.10 g of the homogenised formulation was poured in a tablet mould 
with internal diameter of 13.50 mm, frozen at -80 °C for about 60 minutes, annealed in -20 oC a 
pre-cooled freezer for 12 hours and then transferred back to the -80 oC freezer. The frozen 
formulation was freeze-dried (ADVANTAGE Freeze-dryer, VIRTIS) according to an optimized 
regime (primary drying for 16 hours at shelf temperature of -35 °C and secondary drying for 1 
hour at shelf temperature of 10 °C and vacuum of 50 mTorr).  
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The optimised formulation for each drug was formulated by the same method and the 
observed (experimental) and the predicted (from the model) values for the responses were 
compared to evaluate the validity of the model. 
 
7.3.3. Preparation of ODTs for the dissolution and stability studies 
Based on the optimised formulation for each drug, lyophilised ODTs containing therapeutic 
dose of the drugs were formulated to carry out dissolution and stability studies. 50 mg 5,5-
diphenylhydantoin ODTs was prepared in 18 mm diameter tablet mould, 75 mg ranitidine HCl 
in 20 mm mould, 200 mg ibuprofen in 20 mm mould, and 2 mg loperamide HCl in 13.5 mm 
mould. Accurate mass of the homogenised formulation required to obtain the therapeutic 
dose was poured in the designated tablet mould. The samples were subjected to the same 
protocol of freezing and freeze drying as above. 
 
7.3.4. Differential scanning calorimetry studies 
Differential scanning calorimetry (Pyris Diamond DSC and Intracooler 2P: Perkin Elmer, 
Wellessey, USA) was used to determine the glass transition temperature (Tg) and 
crystallisation event of the formulation in its frozen state (before freeze drying). 10-15mg of 
the liquid formulation were loaded into aluminium pans, cooled to -65 °C and then heated to 
20 °C at 5 °C/min with a nitrogen purge of 20ml/min. To determine the glass transition 
temperature of the maximally freeze concentrate sample (Tg’), after initial cooling to -65 °C, 
annealing step for 15 min at -15  °C was performed before carrying out the above method. An 
empty aluminium pan was used as reference for all measurements.  
The resulting plots were analysed by Pyris manager software. Tg and Tg' values were 
determined from the intersection of relative tangents to the baseline. All the measurements 
were done in triplicate from independently prepared samples. 
The DSC was calibrated for temperature and heat flow using standard samples of indium 
(melting point: 156.6 ˚C, ∆Hm: 28.42 J/g) and Zinc (melting point: 419.5 ˚C, ∆Hm: 108.26 J/g). 
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7.3.5. Disintegration time 
The disintegration time of the tablets was measured using a USP disintegration tester (Erweka, 
ZT3). Distilled water (800 ml) kept at 37 °C was used as a medium and the basket was raised 
and lowered at a fixed frequency of 30 cycles/min. One tablet was tested at a time. 
  
7.3.6. Mechanical properties of the tablets 
The hardness of the lyophilized tablets was investigated with a texture analyzer (QTS 25: 
Brookfield, Essex, UK) equipped with a 25 kg load cell. The instrument was calibrated with 
standard weight of 500 g and 5 kg. The tablet was placed in a holder with a cylindrical hole and 
the hardness was taken as the peak force after 1mm penetration of 5mm diameter probe at a 
speed of 6 mm/min. 
Friability of the tablets was evaluated by tumbling a sample of 5 tablets in a USP friabilator 
(Sotax, model F2, Basel, Switzerland) for 4 minutes at 25 rpm. The tablets were brushed gently, 
reweighed and the friability was calculated as a percentage of weight loss to the initial weight. 
Friability= (W₀ - W)/ W₀ x 100% 
 
7.3.7. Moisture content 
The moisture content of the freeze-dried tablets was determined by thermogravimetric 
analysis (TGA) (Pyris 1 TGA: Perkin-Elmer, Waltham, USA). The TGA was calibrated for 
temperature, furnace and weight using standard calibrants of Alume and Nickel. The tablets 
were cut into small pieces, loaded onto TGA platinum pan and placed into the pre-equilibrated 
furnace at 30 °C. After equilibration at this temperature, the samples were heated at a rate of 
10 ˚C/min to 150 °C and held isothermally at this temperature for 1 minute.  
 
7.3.8. Drug content 
For 5,5-diphenylhydantoin ODTs, after complete disintegration in 10 mL double distilled water 
in a 500mL beaker, 400 mL of an extraction solvent, a mixture of acetonitrile/water (80:20, 
v/v), was  added gradually with constant stirring on a magnetic stirrer. The solution was 
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transferred to 500mL volumetric flask and the extraction solvent was added to make up the 
volume. After good shaking, the solution was filtered through a 0.45 µm nylon filter 
(CHROMACOL LTD, Herts, UK) in autosampler vials for HPLC assay.  
Ranitidine HCl tablets was dissolved in 1 L double distilled water, shaken for 30 min, and 
filtered through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) in autosampler vials for 
HPLC assay. 
For ibuprofen, the tablet disintegrated by adding 10 mL double distilled water in a 100mL 
beaker, 80 mL of an extraction solvent, a mixture of methanol/water (80:20, v/v), was  added 
gradually with constant stirring on a magnetic stirrer. The solution was transferred to 100mL 
volumetric flask and the extraction solvent was added to make up the volume. After good 
shaking, the solution was filtered through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) 
in autosampler vials for HPLC assay. 
For loperamide HCl, the tablet disintegrated by adding 5 mL double distilled water in a 100mL 
beaker, 80 mL of the mobile phase (see HPLC method) was added gradually with constant 
stirring on a magnetic stirrer. The solution was transferred to 100mL volumetric flask and the 
mobile phase was added to make up the volume. After good shaking, the solution was filtered 
through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) in autosampler vials for HPLC 
assay. 
 
7.3.9. HPLC analysis 
HPLC analysis of the selected drugs was carried out using Reverse phase HPLC (Dionex AS 50 
autosampler with GP50 gradient pump HPLC System: Dionex, UK) at room temperature using a 
Gemini 5 µm, 4.6 x 150 mm, column (Phenomenex La Luna: Phenomenex, Torrance, USA). 
5,5-diphenylhydantoin was analysed using acetonitrile: water (90:10. v/v) as a mobile phase at 
a flow rate of 1.0 mL/min, with a sample injection volume of 5 µL and UV detection at 213 nm 
(Gupta and Myrdal, 2005). Under these HPLC conditions the retention time for 5,5-
diphenylhydantoin was 1.94 minutes. The concentration of 5,5-diphenylhydantoin in the 
tablets was determined by reference to a calibration curve constructed by diluting a stock 
solution (1mg/mL) of 5,5-diphenylhydantoin  using the mobile phases to obtain serial 
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concentrations in a range from 1.0 to 100.0 µg/ml. The calibration curve was performed in 
triplicate and resulted in a linear correlation in the studied concentration range (r²=0.99). 
Ranitidine HCl was analysed using a mobile phase consisting of acetonitrile: phosphate buffer 
(20:80, v/v). The buffer prepared as 10 mM phosphate and adjusted to pH 7.1 with 0.1 N 
sodium hydroxide (Shah et al., 2006). The mobile phase flow rate was 1 ml/min, the injection 
volume was 20 µl and the UV absorbance was at 230 nm. The retention time was 4.78 min. 
The concentration of ranitidine HCl in the tablets was determined by reference to a calibration 
curve constructed from dilutions of a stock solution (1mg/mL), using the mobile phases, in a 
concentration range between 10 to 100 µg/mL. The calibration curve was performed in 
triplicate and resulted in a linear correlation in the studied concentration range (r²=0.99). 
Ibuprofen was analysed using a mixture of methanol: water (80:20. v/v) as a mobile phase at a 
flow rate of 1.0 mL/min, with a sample injection volume of 5 µL and UV detection at 230 nm. 
Under these HPLC conditions the retention time for Ibuprofen was 2.47 minutes. The 
concentration of the drug in the tablets was determined by reference to a calibration curve 
constructed from dilutions of stock solution (1mg/mL) in a range between 100 and 500 µg/ml. 
The calibration curve was performed in triplicate and resulted in a linear correlation in the 
studied concentration range (r²=0.99). 
Loperamide HCl was analysed using a mobile phase consisting of an aqueous solution of 0.1% 
sodium-octansulphonate, 0.05% triethylamine and 0.1% ammonium hydroxide: acetonitrile 
(45:55, v/v) at a flow rate of 1.5 mL/min, with a sample injection volume of 20 µL and UV 
detection at 226 nm (Savic et al., 2009). Under these HPLC conditions the retention time was 
2.07 minutes. The concentration of the drug in the tablets was determined by reference to a 
calibration curve constructed from dilutions of stock solution (1mg/mL) in a range between 10 
and 100 µg/ml. The calibration curve was performed in triplicate and resulted in a linear 
correlation in the studied concentration range (r²=0.99). 
 
7.3.10. Dissolution studies 
The dissolution profiles of the prepared ODTs that contained therapeutic doses of the drugs 
and the commercial products were evaluated in a USP dissolution apparatus II (Erweka DT 600, 
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Heusenstamm, Germany). The dissolution conditions and dissolving medium for each drug 
were as prescribed in the USP. 
For 5,5-diphenylhydantoin (phenytoin)  tablets (50 mg), the dissolution medium was 0.05 M 
tris buffer (900ml, 37 ˚C), which was prepared by dissolving 60.5 g of 
tris(hydroxymethyl)amino-methane in 10 liters of double distilled  water, adjusting the pH to 
9.0 by phosphoric acid, and dissolving 100 g of sodium lauryl sulphate. The dissolution 
experiment was for 2 hours at rotational speed of 100rpm (USP, 2003). At fixed time intervals, 
5 ml samples were withdrawn and replaced with fresh medium (37 ˚C). The concentration of 
the drug in the filtered samples was analysed using HPLC assay (see HPLC method) and the 
cumulative drug release was calculated. 
For ranitidine HCl tablets (75 mg), the dissolution was performed in 900 mL deionised water 
(37 ˚C) for 45 minutes and at rotational speed of 50rpm (USP, 2003). At fixed time intervals, 5 
ml samples were withdrawn and replaced with fresh medium (37 ˚C). The samples were 
filtered through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) and diluted with water, 
when necessary. The amount of drug dissolved was analysed by Jenway 6405 UV/Vis 
spectrophotometer (Bibby Scientific Limited, Staffordshire, UK) at the wavelength of maximum 
absorbance (314 nm) and the cumulative drug release was calculated.  
For ibuprofen tablets (200 mg) the dissolution was performed in 900 mL phosphate buffer (pH 
7.2, 37 ˚C) for 60 minutes and at rotational speed of 50rpm (USP, 2003). At fixed time intervals, 
5 ml samples were withdrawn and replaced with fresh medium (37 ˚C). The samples were 
filtered through a 0.45 µm nylon filter (CHROMACOL LTD, Herts, UK) and diluted with the 
medium (phosphate buffer), when necessary. The amount of drug dissolved was analysed by 
Jenway 6405 UV/Vis spectrophotometer (Bibby Scientific Limited, Staffordshire, UK) at the 
wavelength of maximum absorbance (221 nm) and the cumulative drug release was 
calculated. 
For loperamide HCl, the dissolution was performed in 900 mL of 0.01 N hydrochloric acid (37 
˚C) for 30 minutes and at rotational speed of 50 rpm (USP, 2003). At fixed time intervals, 5 ml 
samples were withdrawn and replaced with fresh medium (37 ˚C). The concentration of the 
drug in the filtered samples was analysed using HPLC assay (see HPLC method) and the 
cumulative drug release was calculated. 
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7.3.11. Stability studies 
Short term stability studies were performed on the optimised ODTs that contain therapeutic 
dose of the drugs. The tablets were stored in air-tight amber glass bottles with a tight lid and 
were kept in a climatic cabinet (Firlabo, model SF BVEHF, Meyzieu, France) with a storage 
condition of 40 ˚C and 75% RH. After 3 months, the samples were evaluated for moisture 
content, disintegration time, mechanical properties and drug content. 
 
7.4. Results and discussion 
7.4.1. Factorial design 
The formulation of lyophilised orally disintegrating tablets (ODTs) consists of a water soluble 
binder, which gives shape and provides mechanical strength to the tablets.  Matrix supporting/ 
disintegration enhancing agents to fortify the porous framework provided by the water soluble 
polymer and accelerate the disintegration of the ODT.   Preliminary screening studies (chapter 
6) were conducted to select and optimise the choice and concentration of the binder and the 
matrix supporting/disintegration enhancing agent. The results suggested that gum arabic has a 
superior profile as a binder, whereas alanine and mannitol showed  favourable performance as 
matrix supporting/disintegration enhancing agents over a concentration range of 20- 50 % 
(w/w). The concentration of gum arabic was fixed at 15% (w/w) as this concentration provides 
elegant tablets in a very short freeze drying cycle and achieves the best balance between 
mechanical property and disintegration time (the highest lyophilised tablet index). Alanine and 
active drug concentrations were further investigated in this study as independent factors for 
their influence on ODT characteristics using a 3² randomised full factorial design of 
experiment. For each active drug, three levels of alanine (X1) and the active drug (X2) 
concentrations were defined depending on the physicochemical characteristics of the drug and 
the required dose (see below). Five crucial responses in the development of ODTs were 
evaluated for each formulation including disintegration time (Y1), Tg’ (Y2), hardness (Y3), 
friability (Y4) and drug content (Y5). A quadratic statistical model incorporating all main, 
interactive and polynomial terms was used to evaluate the influence of the studied factors 
(independent factors) on the responses (dependent variables). 
Yi = b0 + b1 X1 + b2 X2 + b12 X1X2 + b11 X1² + b22 X2²,    (1) 
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Where Yi is the response (dependent variable), b0 is the arithmetic mean response of the 27 
trials, and b1 and b2 are the estimated coefficient for the factors X1 and X2, respectively. The 
main effects (X1 and  X2) represent the average result of changing one factor at a time from its 
low to high value while keeping the other factor at its centre point. The interaction terms 
(X1X2) show the change in the response when both factors are varied simultaneously. The 
polynomial terms (X1² and X2²) express non linear correlations with the response.  
 
7.4.2. ODTs of 5,5-diphenylhydantoin 
7.4.2.1. Experimental design 
To optimise the properties of lyophilised ODTs that contain 50 mg of 5,5-diphenylhydantoin, 
three concentration levels of  drug, low (10%w/w) medium (20%w/w) and high (30%w/w), and 
three concentration levels of alanine, low (20%w/w) medium (30%w/w) and high (40%w/w), 
were used in the factorial design experiment. These concentrations of 5,5-diphenylhydantoin 
were designed to allow the production of lyophilised ODTs with size range comparable to the 
standard tablets sizes. The designed dimensions (diameter × thickness) of lyophilised tablets 
containing 50 mg 5,5-diphenylhydantoin are 18.00mm × 21.13 mm, 18.00 mm × 10.57 mm and 
18.00 mm × 7.05 mm for 10, 20 and 30% (w/w) formulations, respectively.  
Based on a 3² randomised full factorial design, 9 formulations were prepared in triplicates (27 
experiments (9*3) in total). The design and the results from the 27 experiments are presented 
in Table 7.1. The results showed that the disintegration time of the tablets  varied from 2 to 9 
s, the Tg’ of the formulation was between -24.82 to -14 ˚C, the hardness  varied from 2.8 to 
6.98 N, friability  from 6.01 to 19.78 % and drug content from 95.12 to 106.95 %. The results 
showed that disintegration time, Tg’, hardness and friability showed wide variations in 
responses (Figure 7.1) suggesting that these responses are strongly dependent on the selected 
independent factors. In case of drug content, the results seem to be unsystematic and random 
and might be explained as experimental errors. 
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Table 7.1 Full factorial design worksheet for 5,5-diphenylhydantoin study. The concentrations (%w/w) of 5,5diphenylhydantoin and alanine are percentages 
of the mass of gum arabic dissolved in the stock solution.   
 
 
Exp Name Run order 5,5-diphenylhydantoin 
(%) 
Alanine  
(%) 
Disintegration time  
(s) 
Tg’ 
(˚C) 
Hardness  
(N) 
Friability (%) Drug recovery  
(%) 
N1 16 10 20 7 -24.82 2.80 9.59 99.84 
N2 23 30 20 5 -23.82 3.37 19.78 98.10 
N3 1 10 40 3 -15.04 5.29 7.62 102.69 
N4 13 30 40 6 -14.81 6.00 10.44 104.85 
N5 18 10 30 2 -15.42 3.49 7.12 103.30 
N6 21 30 30 3 -15.08 4.95 10.35 104.78 
N7 11 20 20 4 -24.50 4.42 16.78 103.81 
N8 19 20 40 4 -14.09 5.80 12.57 101.45 
N9 5 20 30 7 -15.55 4.23 15.58 95.29 
N10 2 10 20 8 -24.17 3.32 8.46 104.93 
N11 27 30 20 3 -23.90 3.54 16.45 95.12 
N12 24 10 40 2 -15.31 4.34 6.33 98.43 
N13 8 30 40 6 -14.56 6.44 10.36 100.39 
N14 22 10 30 2 -15.32 4.58 6.20 103.44 
N15 10 30 30 2 -15.27 5.27 11.57 101.24 
N16 4 20 20 4 -24.37 3.38 15.42 101.40 
N17 14 20 40 6 -14.21 5.57 10.98 104.77 
N18 6 20 30 9 -15.47 4.57 13.51 99.94 
N19 3 10 20 5 -24.46 3.24 9.02 105.97 
N20 9 30 20 4 -24.12 4.02 17.38 96.55 
N21 26 10 40 3 -15.27 4.83 6.01 99.71 
N22 20 30 40 7 -14.82 6.98 10.97 99.11 
N23 15 10 30 3 -15.08 3.84 7.46 101.55 
N24 7 30 30 2 -14.85 5.57 12.52 103.88 
N25 12 20 20 5 -24.29 3.81 15.63 106.95 
N26 25 20 40 4 -14.00 5.02 11.12 103.43 
N27 17 20 30 5 -15.68 3.97 13.44 97.13 
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Figure 7.1 Replicate plots of the responses.  The values of the response are plotted vs. experimental runs displaying the variation in the response for 
replicated experiments. 
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7.4.2.2. Analysis of variance (ANOVA)  
Analysis of variance (ANOVA) was performed to evaluate the significance of the quadratic 
models (linear, interactive and polynomial) on the responses and to establish their quantitative 
effects. Table 7.2 summarises the effects of the model terms and associated p values for all 
five responses. At a 95% confident level, a model was considered significant if the p value 
<0.05. The results indicate that the disintegration time of the tablets was significantly affected 
only by the interactive model between 5,5-diphenylhydantoin and alanine (X1X2), whereas the 
rest of the model terms had no significant contribution in determining the disintegration time 
(p>0.05). This can be explained as alanine and 5,5-diphenylhydantoin concentrations 
simultaneously affect the factors that control the disintegration of the ODTs in an interactive 
way. The total concentration of both materials influences the porosity of the tablets which 
controls the diffusion of the disintegrating media into the tablets (Bi et al., 1999). At the same 
time, alanine by itself, because of its high wettability property (chapter 3), enhances the 
disintegration by wicking mechanism of disintegration (Fukami et al., 2006) whereas, 5,5-
diphenylhydantoin provides the hydrophobic moiety inside the tablet and therefore promotes 
the disintegration by the repulsive mechanism (Guyot-Hermann and  Ringard, 1981). The 
results therefore indicate that the interactive terms were the most significant factors in the 
disintegration time and accordingly the shortest disintegration time can be achieved by 
balancing both concentrations simultaneously.  
 
Table 7.2 The quantitative factor effects and associated p value for the responses. 
Term Y1 Y2 Y3 Y4 Y5 
Effect P value Effect P value Effect P value Effect P value Effect P value 
X2 0.1500 0.6465 0.1709 0.0191 0.4799 <0.0001 2.3928 <0.0001 -0.7601 0.2351 
X1 -0.1933 0.5552 3.9898 <0.0001 0.8501 <0.0001 -1.9381 <0.0001 0.1205 0.8482 
X2² -0.8630 0.0773 -0.0660 0.5035 0.0102 0.9353 -2.4227 <0.0001 -0.2248 0.8044 
X1² 0.5921 0.2164 -2.8927 <0.0001 0.0500 0.6899 0.7697 0.0266 0.3033 0.7384 
X1X2 1.1076 0.0029 -0.0087 0.9004 0.1942 0.0375 -0.8613 0.0011 1.3846 0.0404 
 
  
Chapter 7 – Formulation Design of Lyophilised ODTs Incorporating Model Drugs    
190 
 
In case of the Tg’, X1, X2 and X1² are significant model terms. X1 (alanine concentration) has a 
large positive coefficient (3.9898) suggesting that increasing alanine concentration significantly 
increases the Tg’ value, which can be explained by the tendency of high concentrations of 
alanine to crystallise in the frozen formulation (Figure 7.2). X2 (5,5-diphenylhydantoin 
concentration) has a smaller positive coefficient (0.1709) suggesting that increasing 5,5-
diphenylhydantoin concentration significantly increases the Tg’ but to a lower extent than 
alanine. This antiplastcising effect might be a result of the low solubility (hydrophobic) nature 
of 5,5-diphenylhydantoin in the hydrophilic environment of the tablet mixture (Mao et al., 
2008). On the other hand, the polynomial terms X1² (alanine concentration) has a large 
negative coefficient which reflects the inability of alanine to crystallise at low concentration 
and consequently shows plasticising behaviour in the system (lower Tg’) (Figure 7.2). The 
interactive term (X1X2) appears to have no significant effect on the Tg’, possibly due to the 
limited solubility of 5,5-diphenylhydantoin. 
 
 
 
Figure 7.2 Overlaid DSC heating scans of frozen formulations based on high (N8), medium (N9) 
and low (N7) alanine concentration with medium concentration of 5,5-diphenylhydantoin. 
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For the third response Y3 (hardness) linear terms X1 (alanine concentration) and X2 (5,5-
diphenylhydantoin concentration) were identified as the most significant factors with p value < 
0.00001, whereas the interactive term X1X2 was less significant with p value (0.0375) just below 
the significant level (p<0.05). The quantitative estimation (Table 7.2) of the significant terms 
indicated that increasing alanine concentration was the most effective way to enhance the 
hardness of the ODTs with a positive coefficient of 0.8501, which confirms the role of alanine 
as a matrix supporting agent (chapter 3). Increasing 5,5-diphenylhydantoin concentration (X2), 
also, enhances the hardness but to a lesser extent than alanine, as indicated with the smaller 
positive coefficient (0.4799). Minimal degree of improvement was seen as a result of 
interaction between alanine and 5,5-diphenylhydantoin. These results can be explained in 
terms of intermolecular bonding force and contact points between the excipients within the 
tablets (Adolfsson and Nyström, 1996). The high degree of improvement in the hardness 
associated with increasing alanine concentration in the tablet might be a result of 
enhancement of both factors; the intermolecular bonding force, possibly through initiating 
hydrogen bonds with the binder (gum arabic) as both contain hydrogen bond donors and 
acceptors, and contact points between the excipients, as a result of decreasing the porosity. 
Increasing 5,5-diphenylhydantoin may increase the contact point within between the 
excipients but it is not expected to make strong bonds due to its high hydrophobic nature. 
Therefore, the improvement in the hardness associated with increasing 5,5-diphenylhydantoin 
concentration was smaller than alanine. 
Significant influence for response Y4 (friability) was exhibited by X1 (p<0.0001), X2 (p<0.0001),  
X1X2 (p<0.01), X1² (p<0.05) and X2² (p<0.0001), suggesting that all these  model terms affect the 
friability but by varied significant levels depending on p value. The factor which had the most 
detrimental effect on the friability (increasing the friability) was X2 (5,5-diphenylhydantoin 
concentration) as suggested by its large positive coefficient, suggesting that incorporation of 
high concentration of 5,5-diphenylhydantoin concentration increased the friability of the 
ODTs. However, this effect seemed to be dependent on the concentration of 5,5-
diphenylhydantoin as indicated by the negative coefficient of the polynomial term of 5,5-
diphenylhydantoin concentration (X2²). The study also indicated that increasing alanine 
concentration (X1) was an efficient way to reduce the friability of the tablet, as X1 had high 
negative coefficient (-1.9381) which further confirms its role as matrix supporting agent. 
However, the significant influence of X1² (polynomial term of alanine concentration) with 
positive coefficient limits the reduction of the friability by increasing alanine concentration to a 
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certain level.  The interactive terms X1X2 had a negative coefficient of -0.8613, suggesting a 
reduction in the friability which might be due to increase in the contact points between the 
excipients inside the tablets (alanine and 5,5-diphenylhydantoin).       
ANOVA results (Table 7.2) indicated that all the model terms including linear, interactive and 
polynomial, had no significant influence on the drug content (p>0.05) suggesting that the 
results were randomly distributed and the variation was only  due to experimental errors in 
formulation and/or detection. 
   
7.4.2.3. Revised model and surface response plots 
After analysing the influence of all the quadratic model terms on the dependent variables 
(responses), the insignificant terms were omitted to generate a revised model that included 
only model terms that have a significant influence. The resulting equations for all five 
responses, Y1 (disintegration time), Y2 (Tg’), Y3 (hardness), Y4 (friability) and Y5 (drug content), 
are presented below: 
Y1 = + 4.742 + 1.108 X1X2  
Y2 = -15.235+ 3.990 X1 + 0.171 X2 -2.893 X1² 
Y3 = +4.48426+ 0.850X1 + 0.480X2 + 0.194X1X2  
Y4 = +13.172 + -1.938 X1 + 2.393 X2 -0.861 X1X2 + 0.770 X1² - 2.423 X2² 
Y5 = 101.334 
The results for testing the validity of the model are summarised in Table 7.3. P values for all 
the simulated responses were below the significant level (<0.05) suggesting that all the revised 
models were significant in predicting their response values. The high value of correlation 
coefficient (R²) for Tg’, hardness and friability indicate a good fit to the revised model. Low 
correlation coefficient were noticed for the disintegration time possibly due to the qualitative 
nature of the test that depends on the visual evaluation in addition to the fact that few 
seconds' inaccuracy in evaluating the disintegration time can cause huge error, as the 
disintegration time is very short. 
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Table7.3 Summary of results for testing validity of the revised models. DF indicates: degrees of 
freedom; SS: sum of squares; MS: mean of square; F: Fischer’s ratio; p: probability; R2: 
regression coefficient. 
Disintegration time 
 DF SS MS (variance) F p R
2
 
Regression 5 45.988 9.198 3.403 0.021 0.448 
Lack of Fit 3 36.086 12.029 10.477   
 
Tg’ 
 DF SS MS (variance) F p R
2
 
Regression 5 519.451 103.890 881.505 < 0.0001 0.995 
Lack of Fit 3 1.9121 0.637 20.382   
 
Hardness 
 DF SS               MS (variance) F p R
2
 
Regression 5 25.756 5.151 26.901 < 0.0001 0.865 
Lack of Fit 3 0.844 0.281 1.593   
 
Friability 
 DF SS MS (variance) F p R
2
 
Regression 5 346.007 69.201 53.041 <0.0001 0.927 
Lack of Fit 3 10.388 3.463 3.664   
 
 
Based on the revised equations, the software was used to generate response surface plots 
(three dimensional) that simulate the influence of the independent factors on each response 
individually. The graphs for disintegration time, Tg’, hardness and friability are presented in 
Figures 7.3, 7.4, 7.5 and 7.6, respectively. These plots can provide uninterrupted visual 
assessment of the change in the response surface as a function of varying the independent 
factors, individually and simultaneously, which is valuable to further understand the system 
and optimise the formulation. 
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Figure 7.3 Surface response plot showing the influence of varying alanine and 5,5-
diphenylhydantoin concentration on the disintegration time of the ODT.  
 
 
Figure 7.4 Surface response plot showing the influence of varying alanine and 5,5-
diphenylhydantoin concentration on the Tg’.  
Disintegration time
Investigation: Diphenylhydantoin (PLS, comp.=4)
Response Surface Plot
MODDE 8 - 25/06/2010 16:09:01
MODDE 8 - 25/11/2010 20:03:22
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Figure 7.5 Surface response plot showing the influence of varying alanine and 5,5-
diphenylhydantoin concentration on the hardness of the ODT.  
 
 
Figure 7.6 Surface response plot showing the influence of varying alanine and 5,5-
diphenylhydantoin concentration on the friability of the ODT. 
Hardness
Investigation: Diphenylhydantoin (PLS, comp.=4)
Response Surface Plot
MODDE 8 - 25/06/2010 16:14:43
Friability
Investigation: Diphenylhydantoin (PLS, comp.=4)
Response Surface Plot
MODDE 8 - 25/06/2010 16:17:13
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7.4.2.4. Optimum ODTs formulation 
Based on the response surface plots, the software performed hot spot analysis to determine 
the optimum formulation variables (alanine and 5,5-diphenylhydantoin concentration) to 
produce ODTs with short disintegration time, high Tg’, high hardness and low friability. The 
optimal formulation was determined as 40% (w/w) alanine and 30 % (w/w) 5,5-
diphenylhydantoin concentration. The observed response values of the optimised formulation 
compared to the predicted values are presented in Table 7.4. The characterisation results 
were verified experimentally and only small differences were found between the experimental 
(observed) and calculated (predicted) values. 
 
7.4.2.5. Formulation of 50 mg 5,5-diphenylhydantoin lyophilised ODTs 
Based on the optimised formulation, lyophilised ODTs containing 50 mg dose of 5,5-
diphenylhydantoin were prepared using 18 mm diameter mould. The characterisation 
summary of the tablets is presented in Table 7.5. As expected, the tablets showed instant 
disintegration using the USP apparatus (less than 6 seconds) without leaving any lumps or 
gritty particles in the disintegration vessel.  The mechanical properties of the tablets suggest 
the need for specialised packaging to provide the tablets with extra protection against possible 
mechanical stresses during storage and handling by patients. The average thickness of the 
dried tablets was 7.45 mm (SD=0.31, n=6).  
 
Table 7.4 Observed and predicted (from the revised model) responses and residual values for 
the optimised formulation. The observed results are means, n=3. 
Response Observed Predicted Residual 
Disintegration time (s) 5 5.90 -0.90 
Tg’ (˚C) -14.6 -14.52 0.08 
Hardness (N) 6.52 6.45 0.07 
Friability (%) 9.82 10.09 -0.27 
Drug content (%) 101.52 102.68 -0.94 
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Table 7.5 Characterisation of the prepared lyophilised ODTs after 0 and 3 months at 40 ˚C and 
75% RH. Results are means ± SD, n=3. 
Parameters Time interval (months) 
0 3 
Moisture content (%) 2.04 ± 0.47 2.25 ± 0.32 
Disintegration time (s) 5 ± 1 6 ± 1 
Hardness (N) 6.41 ± 0.56 6.28 ± 0.42 
Friability (%) 10.45 ± 2.75 9.2 ± 1.83 
Drug content (%) 101.24 ± 3.89 99.12 ± 4.02 
 
 
7.4.2.6. Dissolution studies 
The dissolution profiles of the prepared lyophilised tablets and commercial chewable tablets 
(Epanutin® Infatabs) that contain 50 mg 5,5-diphenylhydantoin (phynetoin) are presented in 
Figure 7.7. According to the US Pharmacopeia, not less than 70% of the dose should be 
dissolved within 120 min under the prescribed dissolution conditions. The results showed that 
both products satisfied the USP criteria by far and showed fast dissolution rate with around 
60% of drug release in less than 5 min, which might be explained as a consequence of crushing 
the chewable tablets (Epanutin Infatabs) to fine powder before performing the dissolution test 
and the instant disintegration of the lyophilised tablets. However, the lyophilised tablets 
showed higher dissolution efficiency with complete drug release in about 10 min (Figure 7.7). 
This can possibly be attributed to the intrinsic emulsifying properties of gum arabic (Yadav et 
al., 2007) that enhanced the extent and rate of dissolution.            
 
7.4.2.7. Stability studies 
The lyophilised ODTs of 5,5-diphenylhydantoin were subject to short term stability studies. 
There was no change noticed in appearance or smell.   The results (Table 7.5) indicated that no 
significant change in moisture content, disintegration time, drug content and mechanical 
properties were observed suggesting that the formulation were chemically and physically 
stable.    
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Figure 7.7 Dissolution profiles of commercially available chewable tablets (Epanutin Infatabs) 
and formulated lyophilised orally disintegrating tablets (LODT) of 5,5-diphenylhydantoin. 
Results are means ± SD, n=3. 
 
7.4.3. ODTs of ranitidine HCl 
7.4.3.1. Experimental design 
To optimise the properties of lyophilised ODTs that contain 75 mg of ranitidine HCl, three 
concentration levels of the drug, low (10% w/w) medium (25% w/w) and high (40% w/w), and 
three concentration levels of alanine, low (20% w/w) medium (40% w/w) and high (60% w/w), 
were used in the factorial design experiment. These concentrations of ranitidine HCl were 
designed to allow the production of lyophilised ODTs in size comparable to standard tablet. 
The dimensions (diameter × thickness) of lyophilised tablets containing 75 mg ranitidine HCl 
were 20.00mm × 13.54 mm, 20.00 mm × 5.41 mm and 20.00 mm × 3.38 mm for 10, 25 and 45 
% (w/w) formulations, respectively.  
The studied alanine concentration range (up to 60% w/w)  was higher than the concentration 
range required for finding the best balance between disintegration time and mechanical 
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properties (as in the case of incorporating hydrophobic drugs). This is mainly due to the high 
water solubility of ranitidine HCl that is expected to exhibit a plasticising effect on the system 
and consequently lower the collapse temperature of the formulation in a concentration 
dependant matter (higher concentration lower collapse temperature). Therefore, alanine 
crystallization in the frozen state is necessary to give stability to the formulation, protect 
against possible collapse and produce elegant lyophilised products (chapter 3). Our previous 
research showed that the crystallisation of alanine might be retarded by the presence of highly 
soluble moiety in the system (chapter 4) and higher concentration of alanine was required to 
crystallise. Accordingly the influence of alanine on the formulation characteristics was 
investigated at high concentration.   
Based on a 3² randomised full factorial design, 9 formulations were prepared in triplicates (27 
experiments (9*3) in total). The design and the results from the 27 experiments are presented 
in Table 7.6. The results showed that the disintegration time of the tablets varied from 3 to 8 s, 
the Tg’ of the various formulations was between -33.65 to -14.05 ˚C, the hardness varied from 
1.53 to 9.00 N, friability  from 1.62 to 22.87 % and drug content from 88.38 to 102.57 %. The 
results showed that disintegration time, Tg’, hardness and friability showed wide variations 
(Figure 7.8) suggesting that these responses were strongly dependent on the selected 
independent factors. In case of drug content, the results seem to be unsystematic and random 
suggesting independency from the studied factors and therefore the variation might be 
explained as experimental errors. 
 
7.4.3.2. Analysis of variance (ANOVA)  
Analysis of variance (ANOVA) was performed to evaluate the significance of the quadratic 
models (linear, interactive and polynomial) on the responses and to establish quantitative 
values of their effects. Table 7.7 summarises the effects of the model terms and associated p 
values for all five responses. At a 95% confident level, a model was considered significant if the 
p value <0.05. The results indicate that the disintegration time of the tablets was significantly 
affected only by alanine concentration in a linear way (X1) and ranitidine HCl concentration in a 
polynomial way (X2²), whereas the rest of the model terms had no significant contribution in 
determining the disintegration time (p>0.05). Alanine concentration has a positive coefficient 
(+0.4304) suggesting that increasing the concentration of alanine increases the disintegration 
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Table 7.6 Full factorial design worksheet for ranitidine HCl study. The concentrations (%w/w) of ranitidine HCl and alanine are percentages of the 
mass of gum arabic dissolved in the stock solution.   
Exp Name Run Order Ranitidine HCl (%) Alanine (%) Disintegration time (s) Tg’ (˚C) Hardness (N) Friability (%) Drug recovery ( %) 
N1 1 10 20 5 -26.29 3.29 10.77 101.06 
N2 22 40 20 4 -27.58 3.95 21.75 100.16 
N3 26 10 60 4 -14.12 3.65 14.57 88.38 
N4 7 40 60 5 -18.5 2.89 17.54 102.57 
N5 11 10 40 5 -14.25 8.60 2.58 99.75 
N6 20 40 40 5 -33.37 1.53 15.47 90.76 
N7 13 25 20 6 -26.25 4.28 18.02 101.58 
N8 9 25 60 8 -17.33 6.50 12.84 99.60 
N9 4 25 40 7 -17.48 6.86 14.54 94.46 
N10 12 10 20 5 -26.24 3.82 11.25 91.96 
N11 17 40 20 3 -28.27 3.63 19.24 95.54 
N12 18 10 60 5 -14.05 2.79 11.45 99.86 
N13 19 40 60 5 -18.29 2.50 19.21 91.81 
N14 2 10 40 5 -14.54 6.67 2.02 95.85 
N15 6 40 40 4 -33.65 1.72 13.45 102.12 
N16 14 25 20 4 -26.72 3.90 16.23 92.83 
N17 24 25 60 6 -17.41 6.76 10.54 90.34 
N18 10 25 40 6 -17.74 8.43 16.89 90.76 
N19 15 10 20 5 -25.93 3.75 9.84 98.07 
N20 8 40 20 4 -28.81 3.36 22.87 97.59 
N21 3 10 60 4 -14.51 3.21 14.29 95.43 
N22 23 40 60 5 -19.02 3.14 21.54 94.85 
N23 21 10 40 5 -14.67 7.48 1.62 102.52 
N24 25 40 40 5 -32.83 1.87 19.54 97.02 
N25 27 25 20 5 -26.41 4.30 17.73 97.57 
N26 16 25 60 8 -17.52 6.91 13.98 92.86 
N27 5 25 40 5 -17.37 9.00 21.54 94.09 
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Figure 7.8 Replicate plots of the responses.  The values of the response are plotted vs. experimental runs displaying the variation in the response for 
replicated experiments. 
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time. This is in line with our previous research studying the influence of alanine concentration 
on placebo lyophilised tablets (chapter 3), where a parabolic relation between disintegration 
time and alanine concentration between 20 and 40 % (w/w) was followed by steady increase 
at higher concentrations. However, the parabolic relation was not observed in this study as no 
alanine concentration was investigated between 20 and 40% (w/w) and therefore the 
polynomial terms of alanine concentration (X1²) showed no significant effect. On the other 
hand, negative coefficient of polynomial term for ranitidine HCl suggested that a very short 
disintegration time could be achieved at low (10%w/w) and high (40%w/w) concentrations of 
ranitidine HCl whereas the intermediate concentration (25%w/w) was associated with 
significant increase in the disintegration time. At low concentration of ranitidine HCl, the 
lyophilised tablets have higher porosity and consequently fast diffusion of the disintegrating 
medium and short disintegration time, whereas at high concentration, the presence of high 
concentration of highly soluble moiety (ranitidine HCl) might be the trigger for fast 
disintegration. 
In case of Tg’ of the formulation, the results showed that both alanine and ranitidine HCl had 
significant linear influences (X1 and X2, consequently) (Table7. 7). X1 (alanine concentration) 
has a positive coefficient (+2.3154) suggesting that increasing alanine concentration 
significantly increases the Tg’ value, which could be explained by the tendency of high 
concentrations of alanine to crystallise in the frozen formulation (Figure 7.9). X2 (ranitidine HCl 
concentration) has a negative coefficient (-3.6864) suggesting that increasing ranitidine HCl  
 
Table 7.7 The quantitative factor effects and associated p value for the responses. 
Term Y1 Y2 Y3 Y4 Y5 
Effect P value Effect P value Effect P value Effect P value Effect P value 
X2 -0.1377 0.4053 -3.6864 0.0008 -0.7962 0.0371 4.2209 <0.0001 0.0453 0.9589 
X1 0.4304 0.0148 2.3154 0.0231 0.7809 0.0406 -1.0925 0.1496 -0.5833 0.5092 
X2² -1.0722 0.0002 -2.4891 0.0817 -1.3371 0.0170 -1.5877 0.1463 1.6103 0.2123 
X1² -0.1474 0.5351 -2.1090 0.1363 -0.5115 0.3325 2.1040 0.0417 0.1365 0.9142 
X1X2 0.1161 0.4900 0.4633 0.6353 0.1807 0.6252 -0.0826 0.9127 -0.1651 0.8538 
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Figure 7.9 Overlaid DSC heating scans of frozen formulations based on high (N6), medium (N9) 
and low (N5) ranitidine HCl concentration with medium concentration of alanine. 
 
concentration in the formulation significantly lowered the Tg’ value. The large degree of 
negative influence of ranitidine HCl to reduce the Tg’ of the formulation drastically could be 
attributed to its high aqueous solubility that retards or prevents crystallisation of alanine in the 
frozen formulation (Figure 7.9) and to a lesser extent, exhibits its own plasticising effect in the 
system. Moreover, the DSC results also confirmed the need for high concentrations of alanine 
(>40% w/w) to stabilise formulations (increase their collapse temperature) that contain high 
concentrations of ranitidine HCl (40% w/w). 
For the third response Y3 (hardness), ANOVA results suggested that increasing alanine 
concentration (X1) in the formulation enhanced the hardness of the tablets significantly, as the 
linear terms X1 showed a positive coefficient with p value >0.05 (Table 7.7). However, this 
enhancement was highly dependent on the incorporated concentration of ranitidine HCl, 
which was found to influence the hardness in linear (X2) and polynomial (X2²) patterns. The 
linear term (X2) had a negative coefficient suggesting that incorporating higher concentration 
of ranitidine HCl in the formulation decreased the hardness of the tablets. However, this 
behaviour was suspended at optimum concentration (around 25% w/w) as indicated by the 
large negative coefficient of the polynomial term (X2²) suggesting a higher value for hardness 
at this concentration (Table 7.7). 
Tg’ 
Tg’ 
Tg’ 
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In term of friability, ranitidine concentration X2 was identified as the most significant factor 
with p value < 0.0001. The large positive coefficient value (+4.2209) of this linear term (Table 
7.7) indicated that a substantial deterioration in the friability (increasing the friability) was 
associated with increasing the concentration of ranitidine HCl in the formulation. Alanine on 
the other hand was able to protect the tablet against friability but only in a polynomial pattern 
(X1²), which suggested that an optimum concentration of alanine was required to achieve the 
lowest possible friability (around 40% w/w).  
The results of the mechanical properties (hardness and friability) can be explained by the 
various factors that influence hardness of the tablet including intermolecular bonding forces 
and contact points between the excipients within the tablets (Adolfsson and Nyström, 1996). 
The improvement in the mechanical properties that were associated with increasing alanine 
concentration in the tablet might be a result of synergism in both factors; the intermolecular 
bonding force, possibly through initiating hydrogen bonds with the binder (gum Arabic) as 
both contain hydrogen bond donors and acceptors, and contact points between the excipients, 
as a result of decreasing the porosity.  
ANOVA results (Table 7.7) indicated that all the model terms including linear, interactive and 
polynomial, had no significant influences on the drug content (p>0.05) suggesting that the 
results were randomly distributed and the variation was due to experimental errors in 
formulation and/or analysis.   
 
7.4.3.3. Revised model and surface response plots 
After analysing the influence of all the quadratic model terms on the dependent variables 
(responses), the insignificant terms were omitted to generate a revised model that included 
model terms which have significant influence. The resulting equations for all five responses, Y1 
(disintegration time), Y2 (Tg’), Y3 (hardness), Y4 (friability) and Y5 (drug content), are presented 
below: 
Y1 = +6.2855 +0.4304 X1 - 1.0722 X2² 
Y2 = -17.3926 + 2.3154 X1 - 3.6864 X2  
Y3 = +6.4020 + 0.7809 X1 - 0.7962 X2 - 1.3371 X2² 
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Y4 = +13.9958 + 4.2209 X2 + 2.1040 X1²  
Y5 = 94.5923 
The results of testing the validity of the model are summarised in Table 7.8. P values for all the 
simulated responses were below the significant level (<0.05) suggesting that all the revised 
models were significant in predicting their response values. The high value of correlation 
coefficient (R²) for Tg’, hardness and friability indicated a good fit to the revised model. Lower 
correlation coefficient was obtained for the disintegration time possibly due to the qualitative 
nature of the test that depends on the visual evaluation in addition to the fact that few 
seconds’ inaccuracy in evaluating the disintegration time can cause huge error. 
Based on the revised equations, the software generated response surface graphs that simulate 
the influence of the independent factors on each response individually for each factor 
including disintegration time Tg’, hardness and friability are presented in Figures 7.10, 7.11, 
7.12 and 7.13, respectively.  
 
Table 7.8 Summary of results for testing validity of the revised models. DF indicates: degrees of 
freedom; SS: sum of squares; MS: mean of square; F: Fischer’s ratio; p: probability; R2: 
regression coefficient. 
Disintegration time 
 DF SS MS (variance) F p R
2
 
Regression 5 21.6666 4.3333 6.9999 0.001 0.625 
Lack of Fit 3 4.3333 1.4444 3   
 
Tg’ 
 DF SS MS (variance) F p R
2
 
Regression 5 814.856 162.971 11.2691 <0.0001 0.782 
Lack of Fit 3 301.812 100.604 960.103   
 
Hardness 
 DF SS MS (variance) F p R
2
 
Regression 5 78.2386 15.6477 6.5128 0.001 0.688 
Lack of Fit 3 44.9559 14.9853 49.0529   
 
Friability 
 DF SS MS (variance) F p R
2
 
Regression 5 606.545 121.309 9.5754 <0.0001 0.695 
Lack of Fit 3 190.996 63.6655 15.2698   
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Figure 7.10 Surface response plot showing the influence of varying alanine and ranitidine HCl 
concentration on the disintegration time of the ODT. 
 
 
Figure 7.11 Surface response plot showing the influence of varying alanine and ranitidine HCl 
concentration on the Tg’.  
Disintegration time
Investigation: RanitidineHCl (MLR)
Response Surface Plot
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Figure 7.12 Surface response plot showing the influence of varying alanine and ranitidine HCl 
concentration on the hardness of the ODT.  
 
 
Figure 7.13 Surface response plot showing the influence of varying alanine and ranitidine HCl 
concentration on the friability of the ODT. 
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7.4.3.4. Optimum ODTs formulation 
Based on the response surface plots, the software was used to perform hot spot analysis to 
obtain  optimum formulation variables (alanine and ranitidine HCl concentrations) to produce 
ODTs with short disintegration time, high Tg’, high hardness and low friability. The optimal 
formulation was determined as 40% (w/w) alanine and 15 % (w/w) ranitidine HCl. The 
observed response values of the optimised formulation compared to the predicted values are 
presented in Table 7.9. The closeness of the actual (observed) and calculated (predicted) 
values verified the established statistical models experimentally. 
 
7.4.3.5. Formulation of 75 mg ranitidine HCl lyophilised ODTs 
Based on the optimised formulation, lyophilised ODTs containing 75 mg dose of ranitidine HCl 
were prepared using 20 mm diameter mould. Characterisation summary of the tablets is 
presented in Table 7.10. As expected, the tablets showed instant disintegration using the USP 
apparatus (less than 4 seconds) without leaving any lumps or gritty particles in the 
disintegration vessel.  The mechanical properties of the tablets suggest the need for 
specialised packaging to withstand possible external mechanical stresses during storage and 
handling by patients. 
 
Table 7.9 Observed and predicted (from the revised model) responses and residual values for 
the optimised formulation. The observed results are means, n=3. 
Response Observed Predicted Residual 
Disintegration time (s) 4.00 5.50 -1.50 
Tg’ (˚C) -14.87 -15.72 0.85 
Hardness (N) 7.09 6.13 0.96 
Friability (%) 3.85 8.55 -4.70 
Drug content (%) 96.57 95.51 1.06 
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Table 7.10 Characterisation of the prepared lyophilised ODTs after 0 and 3 months at 40 ˚C and 
75% RH. Results are means ± SD, n=3. 
Parameters Time interval (months) 
0 3 
Moisture content (%) 1.85 ± 0.51 2.21 ± 0.42 
Disintegration time (s) 5 ± 1 6 ± 1 
Hardness (N) 7.41 ± 0.70 6.88 ± 0.52 
Friability (%) 4.45 ± 2.75 2.98 ± 1.83 
Drug content (%) 97.24 ± 2.93 96.18 ± 4.24 
 
 
7.4.3.6. Dissolution studies 
The dissolution profiles of the prepared lyophilised tablets and commercial compressed tablets 
(Zantac™ Relief) that contain 75 mg ranitidine HCl are presented in Figure 7.14. According to 
the USP, not less than 80% of the drug should dissolve within 45 min under the prescribed 
dissolution conditions. The results showed that both products satisfied the USP criteria with 
complete dissolution in less than 45 min. However, the lyophilised tablets showed faster 
dissolution rate with 100% drug release in about 5 min compared to 20 min for the 
compressed tablets (Figure 7.14) Due to the high solubility of ranitidine HCl in the aqueous 
media, the slow dissolution rate of the compressed tablets could be attributed to their slow 
disintegration (about 13 min) compared to instant disintegration of the lyophilised tablet. 
 
7.4.3.7. Stability studies 
Short term stability studies of the lyophilised ODTs of ranitidine HCl are summarised in Table 
7.10. The results indicated no significant change in appearance, moisture content, 
disintegration time, drug content and mechanical properties, suggesting that the formulation 
was chemically and physically stable.   
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Figure 7.14 Dissolution profiles of commercially available compressed tablets (Zantac 75mg) 
and formulated lyophilised orally disintegrating tablets (LODT) of ranitidine HCl. Results are 
means ± SD, n=3.  
 
7.4.4. ODTs of ibuprofen 
7.4.4.1. Experimental design 
To optimise the properties of lyophilised ODTs containing 200 mg of ibuprofen, three 
concentration levels of drug, low (10% w/w) medium (25% w/w) and high (40% w/w), and 
three concentration levels of alanine, low (20% w/w) medium (30% w/w) and high (40% w/w), 
were used in the factorial design experiment. These concentrations of ibuprofen were 
designed to allow the production of lyophilised ODTs in tablet size ranges comparable to the 
standard tablet sizes. The designed dimensions (diameter × thickness) of lyophilised tablets 
containing 200 mg ibuprofen are 20.00mm × 36.00 mm, 20.00 mm × 14.44 mm and 20.00 mm 
×9.00 mm for 10, 25 and 40% (w/w) formulations, respectively.  
Based on a 3² randomised full factorial design, 9 formulations were prepared in triplicates (27 
experiments (9*3) in total). The design and results from the 27 experiments are presented in 
Table 7.11.  
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Table 7.11 Full factorial design worksheet for ibuprofen study. The concentrations (%w/w) of ibuprofen and alanine are percentages of the mass of 
gum arabic dissolved in the stock solution.   
Exp Name Run Order Ibuprofen (%) Alanine (%) Disintegration time Tg’ Hardness Friability Drug recovery % 
N1 22 10 20 3 -25.27 1.87 13.84 108.00 
N2 9 40 20 5 -25.19 3.60 13.12 98.037 
N3 13 10 40 9 -15.91 3.62 18.55 101.15 
N4 12 40 40 16 -15.90 3.93 14.41 99.38 
N5 24 10 30 7 -16.13 3.51 25.19 103.55 
N6 14 40 30 4 -16.28 3.33 32.15 103.62 
N7 3 25 20 11 -25.22 3.11 27.42 102.35 
N8 6 25 40 8 -15.54 3.56 20.68 106.12 
N9 21 25 30 10 -17.06 2.60 30.47 103.17 
N10 20 10 20 3 -25.18 2.32 11.92 107.15 
N11 11 40 20 6 -25.28 4.37 10.38 95.91 
N12 23 10 40 12 -15.73 3.01 19.54 100.01 
N13 10 40 40 18 -15.50 4.92 13.27 99.38 
N14 5 10 30 6 -16.08 3.53 23.66 104.69 
N15 19 40 30 4 -16.17 3.11 33.47 103.32 
N16 27 25 20 12 -24.99 2.52 25.45 103.64 
N17 16 25 40 7 -15.28 3.70 18.94 102.47 
N18 4 25 30 9 -16.94 2.32 31.61 105.25 
N19 18 10 20 4 -24.52 1.98 14.39 103.61 
N20 8 40 20 6 -25.37 3.23 8.75 100.08 
N21 25 10 40 10 -15.51 2.86 16.31 103.55 
N22 1 40 40 12 -15.69 3.94 17.00 101.06 
N23 7 10 30 6 -15.99 3.01 25.19 101.42 
N24 17 40 30 5 -16.61 3.87 32.15 102.76 
N25 2 25 20 12 -25.43 3.16 27.42 102.18 
N26 26 25 40 9 -15.42 4.27 20.68 105.07 
N27 15 25 30 7 -17.22 2.11 29.39 104.96 
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Figure 7.15 Replicate plots of the responses.  The values of the response are plotted vs. experimental runs displaying the variation in the response for 
replicated experiments. 
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The results (Table 7.11 ) showed that the disintegration time of the tablets varied from 3 to 18 
s, the Tg’ of the formulation was between -25.43 to -15.28 ˚C, the hardness varied from 1.87 to 
4.92 N, friability  from 8.75 to 33.47 % and drug content from 95.91 to 108.00 %. The variation 
and repeatability (Figure 7.15) of the disintegration time, Tg’, hardness and friability of the 
formulations suggest that these responses were considerably dependent on the selected 
independent factors. In case of drug content, the results seem to be unsystematic and random 
possibly due to experimental errors. 
 
7.4.4.2. Analysis of variance (ANOVA)   
Analysis of variance (ANOVA) was performed to evaluate the significance of the quadratic 
models (linear, interactive and polynomial) on the responses and to estimate their quantitative 
effects. Table 7.12 summarises the effects of the model terms and associated p values for all 
five responses. At a 95% confidence level, a model was considered significant if the p value 
<0.05. The results indicate that the disintegration time of the tablets was significantly affected 
by the linear, polynomial models of alanine concentration(X1 and X1², respectively) and the 
polynomial model of ibuprofen concentration (X2²). The positive coefficients of both models 
for alanine concentration suggested a parabolic relationship with the disintegration time, 
which is typical for such disintegrating enhancing agent as a balance between porosity and 
wettability properties of the lyophilised tablets achieves the shortest disintegration time 
(chapter 3). Increasing alanine concentration in the formulation decreases the porosity of the 
tablets but, at the same time, enhances the wettability suggesting the need for concentration 
optimisation to achieve fast disintegration of the tablets (chapter 3).  
Ibuprofen concentration showed significant influence on the disintegration time only through 
its polynomial model (X2²). The negative coefficient of X2² might suggest that incorporation of 
ibuprofen in the formulation retards the disintegration only at intermediate concentration at 
around 30% w/w (Table 7.11), whereas incorporation of low and high concentration promotes 
disintegration. This could be explained as incorporation of low concentration of ibuprofen 
(20% w/w) had minimum influence on tablets’ properties that control the disintegration 
(wettability and porosity) and therefore the disintegration seemed to be controlled only by 
alanine concentration. Incorporation of higher concentration (30% w/w) decreased the 
porosity and increased the hydrophobicity inside the tablets which together resulted in an 
increase in disintegration time. However, increasing the concentration of ibuprofen to 40%  
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Table 7.12 The quantitative factor effects and associated p value for the responses. 
Term Y1 Y2 Y3 Y4 Y5 
Effect P value Effect P value Effect P value Effect P value Effect P value 
X2 0.7977 0.1169 -0.0193 0.7836 0.3628 0.0031 0.2799 0.7292 -1.4650 0.0611 
X1 2.3439 <0.0001 3.9605 <0.0001 0.3616 0.0032 0.3098 0.7017 -0.1048 0.7894 
X2² -2.1855 0.0053 0.1947 0.0656 0.1775 0.2700 -4.6493 0.0006 -1.3719 0.1228 
X1² 2.2438 0.0044 -2.7165 <0.0001 0.2146 0.1854 -8.2485 <0.0001 -0.9698 0.0971 
X1X2 0.5714 0.2632 0.1631 0.0617 -0.1646 0.1522 -0.1098 0.8938 0.9610 0.0840 
 
 
(w/w) showed faster disintegration, possibly due to the emergence of additional repulsive 
forces between the hydrophobic (ibuprofen) and hydrophilic (alanine) molecules inside the 
tablets that promote disintegration (Guyot-Hermann and Ringard, 1981).  
The Tg’ of the formulation was significantly influenced by the linear (X1) and polynomial (X1²) 
models of alanine concentration. X1 (alanine concentration) has a large positive coefficient 
(3.9618) suggesting that increasing alanine concentration drastically increases the Tg’ value of 
the formulation, which could be explained by the tendency of high concentrations of alanine 
to crystallise in the frozen formulation (Figure 7.16). The polynomial terms X1² (alanine 
concentration) has a negative large coefficient (-2.7165) which can be attributed to the 
inability of alanine to crystallise at low concentration and consequently resulting in plasticising 
the system (lower Tg’). On the other hand, both models of ibuprofen (linear and polynomial) 
and its interactive model with alanine (X1X2) showed no significant effect on the Tg’, possibly 
due to the very low aqueous solubility of ibuprofen. 
For the third response Y3 (hardness), the significant independent factors were identified as the 
linear terms of alanine concentration(X1) and ibuprofen concentration(X2) with a respective p 
value of 0.0031and  0.0025 (Table 7.12). Both models had positive coefficient suggesting that 
increasing the concentration of alanine and/or ibuprofen in the formulation enhanced the 
hardness of the tablets. The results can be explained by the various factors that influence the 
hardness of the tablet including intermolecular bonding force and contact points between the 
excipients within the tablets. The high degree of improvement in the hardness associated with 
increasing alanine concentration in the tablet might be a result of additive effect of both  
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Figure 7.16 Overlaid DSC heating scans of frozen formulations based on high (N8), medium 
(N9) and low (N7) alanine concentrations with medium concentration of ibuprofen. 
 
factors; intermolecular bonding force, possibly through hydrogen bonds with the binder (gum 
arabic) as both contain hydrogen bond donors and acceptors, and contact points between the 
excipients, as a result of decrease in the porosity (chapter 3). However increasing ibuprofen 
concentration improved the hardness possibly as a result of increase in the contact points 
between the excipients. 
In terms of friability of the tablets, only the polynomial model of alanine (X1²) and ibuprofen 
(X2²) concentrations showed significant influence with p value <0.0001and 0.0006, respectively 
(Table 7.12). The high level of significant influence and the large negative coefficient (-8.2485) 
of X1² (alanine concentration) suggested that optimising alanine concentration was the most 
effective way to reduce the friability of the tablets. However, this protection against friability 
was not linear (polynomial) as a consequence of high friability values that were recorded for 
tablets with intermediate concentration of alanine (30% w/w). Similarly, ibuprofen 
concentration influenced the friability in a negative polynomial way, as tablets with low (20%) 
and high (40%) concentration had lower friability than tablets containing intermediate 
concentration (30%).   
Tg’ 
Tg’ 
Tg’ 
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 ANOVA results (Table 7.12) indicated that all alanine and ibuprofen concentration models 
including linear, interactive and polynomial, had no significant influence on the drug content 
(p>0.05) suggesting that the results were randomly distributed and the variation was possibly 
due to experimental errors in formulation and/or detection.  
  
7.4.4.3. Revised model and surface response plots 
After analysing the influence of all the quadratic model terms on the dependent variables 
(responses), the insignificant terms were omitted to generate a revised model that included 
model terms with significant influence. The resulting equations for all five responses, Y1 
(disintegration time), Y2 (Tg’), Y3 (hardness), Y4 (friability) and Y5 (drug content), are presented 
below: 
 
Y1 = + 8.5735 + 2.3440 X1 + 2.2438 X1² - 2.1855 X2²  
Y2 = - 16.6609 + 3.9605 X1 - 2.7165 X1²  
Y3 = + 2.8580 + 0.3616 X1 + 0.3628 X2  
Y4 = + 33.7294 - 8.2485 X1² + -4.6493 X2² 
Y5 = + 104.9170 
 
The results for testing the validity of the model are summarised in table 13. P values for all the 
simulated responses were below the significant level (<0.05) suggesting that all the revised 
models were significant in predicting their response values. The high value of correlation 
coefficient (R²) for the disintegration time, Tg’ and friability indicate a good fit to the revised 
model.  
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Table 7.13 Summary of results for testing validity of the revised models. DF indicates: degrees 
of freedom; SS: sum of squares; MS: mean of square; F: Fischer’s ratio; p: probability; R2: 
regression coefficient. 
Disintegration time 
 DF SS MS (variance) F p R
2 
Regression 5 290.386 58.077 9.3882 <0.001 0.691 
Lack of Fit 3 96.577 32.192 17.3838   
 
Tg’ 
 DF SS MS (variance) F p R
2 
Regression 5 501.347 100.269 797.576 <0.001 0.995 
Lack of Fit 3 1.84301 0.614335 13.8734   
 
Hardness 
 DF SS MS (variance) F p R
2 
Regression 5 8.51981 1.70396 5.58357 0.002 0.571 
Lack of Fit 3 3.51459 1.17153 7.28648   
 
Friability 
 DF SS MS (variance) F p R
2 
Regression 5 1127.16 225.432 13.6202 <0.001 0.764 
Lack of Fit 3 311.884 103.961 52.427   
 
 
Based on the revised equations, the software was used to generate response surface graphs 
that simulated the influence of the independent factors on each response individually. The 
graphs for disintegration time Tg’, hardness and friability are presented in Figures 7.17, 7.18, 
7.19 and 7.20, respectively.    
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Figure 7.17 Surface response plot showing the influence of varying alanine and ibuprofen 
concentration on the disintegration time of the ODT. 
 
 
Figure 7.18 Surface response plot showing the influence of varying alanine and ibuprofen 
concentration on the Tg’.  
Disintegration time
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Figure 7.19 Surface response plot showing the influence of varying alanine and ibuprofen 
concentration on the hardness of the ODT.  
 
 
Figure 7.20 Surface response plot showing the influence of varying alanine and ibuprofen 
concentration on the friability of the ODT. 
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7.4.4.4. Optimum ODTs formulation 
Based on the response surface plots, the software was used to perform hot spot analysis to 
find the optimum formulation variables (alanine and ibuprofen concentrations) to produce 
ODTs with optimum characteristics such as short disintegration time, high Tg’, high hardness 
and low friability. The optimal formulation was determined as 40% (w/w) alanine and 40 % 
(w/w) ibuprofen concentration. The observed values of the responses of the optimised 
formulation compared to the predicted values are presented in Table 7.14. The 
characterisation results verified, experimentally, the established statistical models, as only 
small differences were observed between the actual (observed) and calculated (predicted) 
values.  
 
7.4.4.5. Formulation of 200 mg ibuprofen lyophilised ODTs 
Based on the optimised formulation, lyophilised ODTs containing 200 mg dose of ibuprofen 
were prepared using 18 mm diameter mould. The characterisation summary of the tablets is 
presented in Table 7.15. As expected, the tablets showed instant disintegration using the USP 
apparatus (less than 16 seconds) without leaving any lumps or gritty particles in the 
disintegration vessel. The average thickness of the dried tablets was 9.12 mm (SD=0.27, n=6). 
  
Table 7.14 Observed and predicted (from the revised model) responses and residual values for 
the optimised formulation. The observed results are means, n=3. 
Response Observed Predicted Residual 
Disintegration time (s) 15 13 2 
Tg’ (˚C) -15.64 -15.33 -0.31 
Hardness (N) 5.01 4.05 0.96 
Friability (%) 12.94 15.79 -2.85 
Drug content (%) 102.37 104.92 -2.55 
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Table 7.15 Characterisation of the prepared lyophilised ODTs after 0 and 3 months at 40 ˚C and 
75% RH. Results are means ± SD, n=3. 
Parameters Time interval (months) 
0 3 
Moisture content (%) 1.87 ± 0.42 2.27 ± 0.39 
Disintegration time (s) 16 ± 3 17 ± 3 
Hardness (N) 5.57 ± 0.61 5.08 ± 0.52 
Friability (%) 13.94 ± 3.34 11.82 ± 2.57 
Drug content (%) 97.54 ± 2.32 101.12 ± 3.05 
 
 
7.4.4.6. Dissolution studies 
The dissolution profiles of the prepared lyophilised tablets and commercial compressed ODTS 
(Nurofen Meltlets) that contain 200 mg ibuprofen are presented in Figure 7.21. According to 
the US Pharmacopeia, not less than 70% of the dose should dissolve within 120 min under the 
prescribed dissolution conditions. The results showed that both products satisfied the USP 
criteria as the required 70% release was reached in less than 10 min, which could be attributed 
to their fast disintegration in the dissolution medium.  However, the lyophilised tablets 
showed faster dissolution rate with around 90% drug release after 5 min compared to around 
50% in case of compressed ODTs (Figure 7.21). The quicker disintegration of the lyophilised 
tablets could not fully explain their faster dissolution rate, as the difference was only about 30 
seconds. Therefore, the results might be attributed to the presence of gum Arabic in the 
lyophilised tablets which has intrinsic emulsifying properties that can enhance the extent and 
rate of dissolution of hydrophobic drugs (Yadav et al., 2007).  
 
7.4.4.7. Stability studies 
The results from short term stability studies of the lyophilised ODTs are summarised in Table 
7.15.  The results indicated that no significant change in appearance, moisture content, 
disintegration time, drug content and mechanical properties was observed, which may 
suggests that the formulation were chemically and physically stable.    
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Figure 7.21 Dissolution profiles of commercially available compressed ODTs (Nurofen Meltlets) 
and formulated lyophilised orally disintegrating tablets (LODT) of ibuprofen. Results are means 
± SD, n=3. 
 
 
7.4.5. ODTs of loperamide HCl 
7.4.5.1. Experimental design 
To optimise the properties of lyophilised ODTs containing 2 mg of loperamide HCl , three 
concentration levels of the drug, low (1 %w/w) medium (2 %w/w) and high (3 %w/w), and 
three concentration levels of alanine, low (20 %w/w) medium (30 %w/w) and high (40 %w/w), 
were used in the factorial design experiment. These concentrations of loperamide HCl were 
designed to allow the production of lyophilised ODTs in tablet with sizes comparable to the 
standard tablets. The designed dimensions (diameter × thickness) of lyophilised tablets 
containing 2 mg loperamide HCl are 13.50mm × 7.91 mm, 13.50 mm × 3.96 mm and 13.50 mm 
× 2.64 mm for 1, 2 and 3% (w/w) formulations, respectively.  
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Based on a 3² randomised full factorial design, 9 formulations were prepared in triplicates (27 
experiments (9*3) in total). The design and the results from the 27 experiments are presented 
in Table 7.16. The results showed that the disintegration time of the tablets was between 3 to 
6 s, the Tg’ of the formulation was between -25.04 to -13.06 ˚C, the hardness varied from 1.71 
to 5.52 N, friability from 7.32 to 26.80 % and drug content from 94.10 to 109.76 %. The 
variation and repeatability (Figure 7.22) of the Tg’, hardness and friability of the formulations 
suggest that these responses were considerably dependent on the selected independent 
factors. In case of disintegration time and drug content, the results seem to be unsystematic 
and random possibly due to experimental errors. 
 
7.4.5.2. Analysis of variance (ANOVA)  
Analysis of variance (ANOVA) was performed to evaluate the significance of the quadratic 
models (linear, interactive and polynomial) on the responses and to establish their quantitative 
effects. Table 7.17 summarises the effects of the model terms and associated p values for all 
five responses. At a 95% confident level, a model was considered significant if the p value 
<0.05. 
The results indicate that the disintegration time of the tablets was independent from the 
studied concentration ranges of alanine and loperamide HCl, as all the model terms showed no 
significant influence on the disintegration time (p>0.05). This could be attributed to the instant 
disintegration of all the prepared tablets (3 to 6 seconds) as a result of using a pre-optimised 
concentrations of the binder (gum arabic) and disintegrating enhancing agent (alanine). 
Additionally low concentrations of loperamide HCl were incorporated in the formulation which 
did not affect the disintegration time. Moreover, the qualitative nature of the disintegration 
test which depends on the visual evaluation in addition to the fact that few seconds’ 
inaccuracy in evaluating the disintegration time may cause huge error. 
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Table 7.16 Full factorial design worksheet for loperamide HCl. The concentrations (%w/w) loperamide HCl and alanine are percentages of the mass of 
gum arabic dissolved in the stock solution.   
Exp Name Run Order Loperamide HCl (%) Alanine (%) Disintegration time Tg’ Hardness Friability Drug recovery % 
N1 6 1 20 4 -24.11 1.71 19.42 103.39 
N2 22 3 20 5 -24.96 2.30 15.84 95.67 
N3 10 1 40 5 -13.06 5.16 14.12 97.91 
N4 16 3 40 5 -14.71 3.18 9.29 94.95 
N5 19 1 30 5 -15.04 3.79 14.89 101.13 
N6 11 3 30 4 -15.24 2.84 25.84 104.00 
N7 21 2 20 3 -24.75 3.06 20.82 100.25 
N8 18 2 40 4 -14.06 4.17 9.70 100.71 
N9 1 2 30 6 -15.15 2.95 22.80 103.72 
N10 5 1 20 3 -24.22 1.81 18.87 99.13 
N11 24 3 20 6 -25.04 2.05 14.95 97.49 
N12 27 1 40 4 -13.27 5.52 13.20 109.76 
N13 12 3 40 3 -14.74 3.66 8.97 99.01 
N14 20 1 30 4 -15.11 4.71 17.43 99.94 
N15 2 3 30 3 -15.31 2.54 26.80 100.10 
N16 3 2 20 5 -24.68 3.56 19.59 103.09 
N17 9 2 40 3 -14.12 3.90 10.11 95.43 
N18 15 2 30 4 -15.17 3.29 21.76 97.68 
N19 14 1 20 4 -24.18 2.36 20.8 102.16 
N20 25 3 20 4 -24.99 2.71 17.52 97.07 
N21 23 1 40 4 -13.12 5.03 11.19 96.58 
N22 13 3 40 5 -14.65 3.82 7.32 94.10 
N23 26 1 30 4 -15.02 3.92 15.44 98.36 
N24 4 3 30 4 -15.30 2.89 25.41 97.16 
N25 7 2 20 4 -24.69 2.76 18.84 102.27 
N26 8 2 40 3 -14.15 3.54 10.97 102.74 
N27 17 2 30 4 -15.19 2.52 23.19 96.08 
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Figure 7.22 Replicate plots of the responses.  The values of the response are plotted vs. experimental runs displaying the variation in the response for 
replicated experiments. 
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In case of Tg’ of the formulation, the results showed that both independent factors (alanine 
and loperamide HCl concentrations) had significant influence (Table 7.17). The linear model of 
alanine concentration (X1) had a large positive coefficient (4.4282) suggesting that increasing 
alanine concentration in the formulation drastically increases the Tg’ value, which could be 
explained by the tendency of high concentrations of alanine to crystallise in the frozen 
formulation (Figure 7.23). However, upon increasing the concentration of alanine above a 
threshold level, the minimum concentration required to initiate crystallisation, the increase in 
Tg’ is limited as indicated from the negative effect of the polynomial term of alanine 
concentration (-2.8572). Moreover, the negative coefficient of polynomial terms of alanine 
concentration (X1²) could be attributed to the inability of alanine to crystallise at low 
concentration and consequently showed plasticising behaviour in system (lower Tg’). 
Loperamide HCl concentration appeared to influence the Tg’ significantly only by its linear 
model (X2) with a negative coefficient of -0.347082, suggesting that increasing loperamide HCl 
concentration in the formulation significantly lowers the Tg’. Compared to ranitidine HCl (see 
above), loperamide HCl showed less plasticising effects on the system possibly due to its lower 
aqueous solubility or to the fact that a smaller concentration  was used in the experiments. 
 
Table 7.17 The quantitative factor effects and associated p value for the responses. 
Term Y1 Y2 Y3 Y4 Y5 
Effect P value Effect P value Effect P value Effect P value Effect P value 
X2 0.0969 0.6549 -0.3471 <0.0001 -0.3752 0.0062 0.2874 0.7129 -1.3139 0.1344 
X1 -0.0916 0.6725 4.4282 <0.0001 0.7230 <0.0001 -3.3212 0.0003 -0.4284 0.6170 
X2² 0.1361 0.7169 0.0153 0.8688 0.0373 0.8632 -0.6350 0.6390 -0.6903 0.6416 
X1² -0.0751 0.8413 -2.8572 <0.0001 0.0520 0.8101 -4.8378 0.0016 -0.1712 0.9079 
X1X2 -0.2347 0.3801 -0.1374 0.0463 -0.3555 0.0284 -0.1093 0.9088 -0.1165 0.9113 
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Figure 7.23 Overlaid DSC heating scans of frozen formulations based on high (N8), medium 
(N9) and low (N7) alanine concentrations with medium concentration of loperamide HCl. 
 
For hardness (Y3), linear terms of alanine concentration (X1) and loperamide concentration (X2) 
were identified as the only significant factors with p value < 0.0001 and 0.0062, respectively. 
The quantitative estimation (Table 7.17) of the significant terms indicated that increasing 
alanine concentration was an effective way to enhance the hardness of the ODTs as suggested 
by its positive coefficient (+ 0.7230), which confirms the role of alanine as a matrix supporting 
agent (chapter 3). This enhancement was dependent on the incorporated concentration of 
loperamide HCl, which was found to reduce the hardness significantly in a linear way (X2), 
suggesting that increasing loperamide concentration in the formulation decreased that 
hardness of the tablets. However, the results suggested minimal quantitative deterioration in 
hardness as a results of incorporating loperamide HCl possibly due to its low concentration in 
the formulation and the small negative coefficient of its linear model (-0.3752). 
 For the fourth response Y3 (friability), alanine concentration (X1) was the only factor that 
showed significant effect. The results suggested (Table 7.17) that increasing alanine 
concentration was an efficient way to reduce the friability of the tablet, as X1 had high negative 
coefficient (-3.3212) which confirms its role as matrix supporting agent. However, the 
Tg’ 
Tg’ 
Tg’ 
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significant influence of X1² (polynomial term of alanine concentration) with negative coefficient 
indicated that reducing the friability of the tablets can be achieved only at high concentrations 
of alanine (> 30% w/w). 
The results for the mechanical properties (hardness and friability) can be explained by various 
factors that influence the hardness of the tablet, which include intermolecular bonding force 
and contact points between the excipients within the tablets. The improvement in the 
mechanical properties associated with increasing alanine concentration in the tablet might be 
a result of both the factors; the intermolecular bonding force, possibly through hydrogen 
bonds with the binder (gum arabic) as both contain hydrogen bond donors and acceptors, and 
contact points between the excipients, as a result of decrease in the porosity (chapter 3).  
ANOVA results (Table 7.17) indicated that all the model terms including linear, interactive and 
polynomial, had no significant influences on the drug content (p>0.05) suggesting that the 
results were randomly distributed and the variation was only a matter of experimental errors 
in formulation and/or analysis. 
 
7.4.5.3. Revised model and surface response plots 
After analysing the influence of all the quadratic model terms on the dependent variables 
(responses), the insignificant terms were omitted to generate a revised model that only 
included model terms with significant influence. The resulting equations for all five responses, 
Y1 (disintegration time), Y2 (Tg’), Y3 (hardness), Y4 (friability) and Y5 (drug content), are 
presented below: 
Y1 = + 4.08942 
Y2 = - 15.1904 + 4.42822 X1  - 0.347082 X2 - 2.85724 X1²  
Y3 = + 3.23817 + 0.723033X1 - 0.375224X2   
Y4 = + 22.1249 - 3.32121 X1 - 4.83781 X1²  
Y5 = + 100.455 
The results for testing the validity of the model are summarised in Table 7.18. P values for all 
the simulated responses were below the significant level (<0.05) suggesting that all the revised 
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models were significant in predicting their response values. The high value of correlation 
coefficient (R²) for Tg’, hardness and friability indicated a good fit to the revised model.  
Based on the revised equations, the software was used to generate response surface graphs 
that simulate the influence of the independent factors on each response individually. The 
graphs for disintegration time Tg’, hardness and friability are presented in Figures 7.24, 7.25 
and 7.26, respectively.  
 
Table 7.18 Summary of results for testing validity of the revised models. DF indicates: degrees 
of freedom; SS: sum of squares; MS: mean of square; F: Fischer’s ratio; p: probability; R2: 
regression coefficient. 
Disintegration time 
 DF SS MS (variance) F p R
2
 
Regression 4 1.8519 0.4630 0.5802 0.680 0.110 
Lack of Fit 4 4.8889 1.2222 1.7368   
 
Tg’ 
 DF SS MS (variance) F p R
2
 
Regression 4 615.629 153.9070 3146.98 <0.0001 0.998 
Lack of Fit 4 1.02367 0.2559 88.1353   
 
Hardness 
 DF SS MS (variance) F p R
2
 
Regression 4 20.4683 5.1171 19.592 <0.0001 0.781 
Lack of Fit 4 3.5365 0.8841 7.20245   
 
Friability 
 DF SS MS (variance) F p R
2
 
Regression 4 581.169 145.292 13.8735 <0.0001 0.724 
Lack of Fit 4 209.773 52.4432 45.7677   
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Figure 7.24 Surface response plot showing the influence of varying alanine and loperamide HCl 
concentration on the Tg’. 
 
 Figure 7.25 Surface response plot showing the influence of varying alanine and loperamide 
HCl concentration on the hardness of the ODT. 
MODDE 8 - 25/11/2010 20:22:28
Hardness
Investigation: LoperamideHCl (PLS, comp.=4)
Response Surface Plot
MODDE 8 - 26/06/2010 10:56:03
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Figure 7.26 Surface response plot showing the influence of varying alanine and loperamide HCl 
concentration on the friability of the ODT. 
 
 
7.4.5.4. Optimum ODTs formulation 
Based on the response surface plots, the software was used to perform hot spot analysis to 
find the optimum formulation variables (alanine and loperamide HCl concentration s) for 
formulating ODTs with optimum characteristics such as high Tg’, high hardness and low 
friability. The optimal formulation was determined as 40% (w/w) alanine and 1 % (w/w) 
loperamide HCl. The observed response values of the optimised formulation compared to the 
predicted values are presented in Table 7.19. The characterisation results verified, 
experimentally, the established statistical models, as only small differences were observed 
between the actual (observed) and calculated (predicted) values.  
 
 
Friability
Investigation: LoperamideHCl (PLS, comp.=4)
Response Surface Plot
MODDE 8 - 26/06/2010 11:04:08
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7.4.5.5. Formulation of 2 mg loperamide HCl lyophilised ODTs 
Based on the optimised formulation, lyophilised ODTs containing 50 mg dose of loperamide 
HCl were prepared using 13.5 mm diameter mould. Characterisation summary of the tablets is 
presented in Table 7.20. As expected, the tablets showed instant disintegration (less than 4 
seconds) without leaving any lumps or gritty particles in the disintegration vessel. The average 
thickness of the dried tablets was 7.95 mm (SD=0.27, n=6).  
 
Table 7.19 Observed and predicted (from the revised model) responses and residual values for 
the optimised formulation. The observed results are means, n=3. 
Response Observed Predicted Residual 
Disintegration time (s) 3 4 -1 
Tg (˚C) -13.15 -13.33 0.18 
Hardness (N) 5.62 5.12 0.50 
Friability (%) 11.41 10.50 0.91 
Drug content (%) 98.75 100.46 -1.71 
 
 
Table 7.20 Characterisation of the prepared lyophilised ODTs after 0 and 3 months at 40 ˚C and 
75% RH. Results are means ± SD, n=3. 
Parameters Time interval (months) 
0 3 
Moisture content (%) 1.58 ±  0.34 1.87 ± 0.42 
Disintegration time (s) 3 ± 1 3 ± 1 
Hardness (N) 5.89 ± 0.49 5.68 ± 0.71 
Friability (%) 11.94 ± 2.23 10.04 ± 2.07 
Drug content (%) 98.78 ± 2.74 97.38 ± 3.32 
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7.4.5.6. Dissolution studies 
The dissolution profiles of the prepared lyophilised tablets and commercial lyophilised ODTs 
(Imodium® Instant) that contain 2 mg loperamide HCl are presented in Figure 7.27. According 
to the US Pharmacopeia, not less than 80% of the dose should dissolve within 30 min under 
the prescribed dissolution conditions. 
All the tested ODTs from both formulations showed instant disintegration in the dissolution 
medium.  Our lyophilised ODTs showed faster dissolution rate with around 70% drug release in 
just 2 min, and achieved the mandatory drug release (80%) within 10 min. On the other hand, 
the commercial lyophilised ODTs showed huge variation in their dissolution rate, especially in 
the first 6 min, and required 25 min for 80% dose release. Moreover, the prepared ODTs 
displayed efficient dissolution with cumulative drug release of more than 90% at the end of the 
experiment compared to a maximum cumulative release of 80% for the commercial ODTs. The 
superior dissolution profile of the prepared ODTs might be attributed to the emulsifying 
properties of arabic gum that facilitate the dissolution of the drug and/or, simply, due to larger 
size of our tablets (13.50mm × 7.91 mm) compared to the commercial one (Imodium® Instant), 
which may allow better dispersion of the drug inside the dry tablets, and consequently provide 
faster and more consistent dissolution profile. 
 
7.4.5.7. Stability studies  
The short term stability studies of the prepared ODTs are summarised in Table 7.20. The 
results indicated that no significant change in appearance, moisture content, disintegration 
time, drug content and mechanical properties was observed suggesting that the formulation 
was chemically and physically stable. 
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Figure 7.27 Dissolution profiles of commercially available lyophilised ODTs (Imodium Instant) 
and formulated lyophilised orally disintegrating tablets (LODT) of loperamide HCl. Results are 
means ± SD, n=3. 
  
7.5. Conclusion 
The application of 3² factorial design illustrated the influence of varying the selected 
formulation factors individually and simultaneously on the quality of ODTs. The results of 
analysis of variance (ANOVA) led to a statistical model and three dimensional plots that 
described adequately the relationship between the dependent and independent variables. The 
revised model showed high degree of reliability and therefore succeeded to generate ODT 
formulations with optimised properties. Compared to commercial products, our formulations 
showed faster, more efficient and reproducible dissolution profiles. The formulation of 
lyophilised ODTs based on gum arabic and alanine showed capability to deliver diverse range 
of drugs with advantages over commercial products.  
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Summary and Implications of Research Findings  
 
8.1. Summary of research findings 
This thesis describes a systematic development strategy for lyophilised orally disintegrating 
tablets as a novel solid oral dosage form that improves patient compliance along with 
providing pharmaceutical advantages for the active drug. Investigating the formulation factors 
that control the preparation process and performance of ODTs based on the common 
excipients revealed the need for alternative materials to be used in the formulation. 
Accordingly, the research was performed to explore and optimise new advantageous material 
as matrix forming agents.  As a result of this research, two novel systems that can address 
limitations and widen the application of lyophilised ODTs were studied.  
 
8.1.1. Formulation and optimisation of lyophilised ODTs based on gelatin 
and saccharide 
Successful development of fast disintegrating tablets by lyophilisation technique requires 
careful optimisation of formulation parameters in order to obtain an optimal balance between 
the tablet properties, namely: thermal properties, primary drying time, mechanical properties 
and disintegration time. 
The results showed that disintegration time of the tablets dramatically decreased by 
decreasing the concentration and bloom strength of gelatin in the stock solution, whereas the 
mechanical properties of the tablets were influenced by the concentration of gelatin rather 
than the bloom strength. Enhancing the mechanical properties of the freeze-dried tablets by 
increasing gelatin concentration inversely influenced their disintegration time. On the other 
hand, increasing gelatin concentration in the formulation decreased the sublimation rate 
significantly, which results in longer primary drying time to formulate ODT from high 
concentration of gelatin. Accordingly, low bloom strength gelatin with stock solution 
concentration between 2-5% (w/w) was most suitable for developing lyophilised orally 
disintegrating tablets. 
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Mannitol crystallised during freeze drying and consequently produced elegant tablets. Xylitol, 
glucose, trehalose and maltotriose were more resistant to crystallisation and therefore they 
may act as lyoprotectants in the formulation. The disintegration time profiles of 
gelatin/saccharide systems were parabolic with different dip values (shortest disintegration 
time) at distinctive concentrations for each saccharide. High concentration of trehalose, 
maltotriose and mannitol (equal or higher than 40% w/w) significantly enhanced the 
mechanical properties of the tablets. Mannitol at concentration between 30 to 40 % w/w (of 
total solid material) achieved the greatest balance between the disintegration time and 
hardness as demonstrated by the LTI value. The optimised ODT formulation in this study was 
able to deliver therapeutic dose of clonidine HCl efficiently. 
 
8.1.2. Investigation of amino acids as matrix forming agent in the 
development of saccharide free ODTs 
Formulation of saccharide free lyophilised ODTs will enable their use for the treatment of long 
term chronic conditions and also for multiple dose medications, especially for children, 
diabetic and obese patients who have limitations on daily intake of saccharides. Naturally 
occurring amino acids are prospective candidates because of their versatility in terms of 
physicochemical properties, high safety profile and availability. Replacement of saccharide 
requires excipients that fulfill stringent characteristics such as reasonable drying time, stability 
during and after freeze-drying process as well as formation of elegant tablets with short 
disintegration time and adequate mechanical properties. 
The crystallisation behaviour of alanine, glycine, cysteine and serine in the frozen state at high 
concentration increased the stability of the formulation during the freeze drying process and, 
although, arginine, histidine, threonine, asparagine, phenylalanine and methionine did not 
show tendency to crystallise they displayed relatively high Tg’, suggesting their suitability as 
freeze drying excipients. Proline formulations (≥ 30% w/w) were difficult to freeze dry due to 
their low glass transition temperature. The characterisation of the ODTs suggested that high 
concentration of amino acids is required to enhance the mechanical properties, whereas only 
optimum concentrations promote faster disintegration. The mechanisms of disintegration of 
the ODTs depend on the physicochemical properties of the amino acid. The highly wettable 
amino acids promote disintegration by enhancing the overall wettability of the ODT, which was 
highly dependent on the wetting time of the amino acid and the total porosity of the tablet. 
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Therefore, parabolic relationships between the disintegration time and the concentration of 
these amino acids were noticed. On the other hand, poorly wettable amino acids generate 
intermolecular repulsive forces within the hydrophilic matrix that encourage the 
disintegration. Depending on the lyophilised tablet index values, 30% alanine formulation 
achieved the best balance between the hardness and disintegration time.  
 
 8.1.3. Investigation of formulation and process of lyophilised ODTs using 
novel amino acid combinations 
The use of amino acids individually to replace the saccharide in the formulation of lyophilised 
ODTs showed varied capability to fulfil all the required characteristics. For instance, proline 
showed complete wettability in water (disintegrating medium) with short wetting time, which 
is expected to improve the disintegration of ODTs; however, its inclusion in freeze dried 
formulations was limited due to the extremely low glass transition temperatures and 
consequently resulting in the collapse of the prepared formulations. On the other hand, serine 
based formulations displayed higher collapse temperature and produced elegant tablets even 
at high concentration, due to its tendency to crystallise in the frozen state, but was 
characterised by long disintegration time, which was explained by serine's partial wetting 
property, as the measured contact angle (θ) with water was 0˚ < θ < 90˚.  
Inclusion of optimised combinations of serine and proline in the formulation of lyophilised 
orally disintegrating tablets verified our hypothesis to combine the benefits of high wettability 
and stability of proline and serine, respectively, and resulted in the formation of tablets with 
superior properties over that of individual amino acids. 
Studying the influence of freezing protocol revealed that annealing induces morphological 
changes in the ODTs that not only allow faster sublimation rate but also shorter disintegration 
time. 
 
8.1.4. Formulation of multiparticulate systems as lyophilised ODTs 
To formulate multiparticulate systems (pellets) as lyophilised ODTs, the stock solution of the 
matrix forming agents should be viscous enough to keep the pellets stable and suspended 
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throughout and after the formulation process, exhibit adequate mechanical strength in the dry 
state and disintegrate quickly upon hydration. 
Gelatin, carrageenan and alanine as matrix forming agents was selected as independent 
variables and their influences on the crucial responses of the formulation (disintegration time, 
hardness, viscosity and pH) were studied by applying on a central composite face centered 
(CCF) design. The disintegration time and viscosity were controlled by the associative 
interaction between gelatine and carrageenan upon hydration which forms a strong complex 
that increases the viscosity of the stock solution and forms tablet with more resistant to 
disintegration in aqueous medium. Therefore, the levels of carrageenan, gelatin and their 
interaction in the formulation were the significant factors. In terms of hardness, increasing 
gelatin concentration was the most effective way to improve the hardness, due to the 
formation of extensive 3D networks of gelatin fibres. To lesser extent, increasing alanine 
concentration also enhanced the hardness significantly. Accordingly, optimum concentrations 
of these excipients were needed to find the best balance that fulfilled all formulation 
requirements. The revised model showed high degree of predictions and optimisation 
reliability and therefore succeeded to find an ODT formulation with optimised properties that 
were able deliver  enteric coated multiparticulate of omeprazole without compromising their 
functionality.     
  
8.1.5. Investigation of alternative binders for the formulation of 
lyophilised ODTs 
Gum arabic was found to have an outstanding potential to be used as a binder in the 
formulation of lyophilised ODTs. Gum arabic showed immediate dispersion in either cold or 
hot water to form low viscosity solutions, which allowed the use of high concentrations and 
simplified the formulation process at the same time. Formulations with high concentration of 
gum arabic was found to provide elegant freeze dried tablets with rapid disintegration time 
and sufficient mechanical strength to withstand manual handling. Tablets based on 15% w/w 
gum arabic achieved the best balance between hardness the disintegration time. Compared to 
gelatin formulation, the tablets based on gum arabic showed superior performance in term of 
disintegration time and hardness. Moreover, tablets comprising of gum arabic were prepared 
using a shorter freeze drying cycles than those with Gelatin. Inclusion of matrix 
supporting/disintegrating enhancing agents further enhanced the tablet characteristics.  
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8.1.6. Formulation design and optimization of lyophilised ODTs 
incorporating hydrophilic and hydrophobic drugs using gum arabic as a 
binder 
The application of gum arabic as a binder in the formulation of lyophilised ODTs showed an 
outstanding potential to improve the formulation, production process and performance of the 
tablet and consequently expand their use. However, the actual incorporation of active drugs 
can have multiple consequences on the manufacturing process as well as the quality and 
performance of the lyophilised ODTs. Accordingly, the feasibility of incorporating therapeutics 
doses of active drugs was investigated using full factorial design (3²) studies that evaluated the 
influence two formulation variables, alanine and active drugs concentrations, on five crucial 
responses, disintegration time, Tg’, hardness, friability and drug content. The design of 
experiment (DoE) and the range of formulation excipients were different for each drug 
depending on its therapeutic dose and hydrophilicity. Highly soluble drugs (ranitidine HCl) 
required a high concentration of alanine to conceal the low collapse temperature of the 
system at high concentration of the drug and consequently allow the production of intact 
tablets. In case of poorly and slightly soluble drugs (5,5diphenylhydantoin, ibuprofen and 
loperamide HCl), the level of alanine was decided mainly to allow the optimisation of the 
disintegration time and the mechanical properties due to the minimal influence of these drugs 
on the collapse temperature.  
The application of 3² factorial design of experimental succeeded to reveal the influence of 
varying the selected formulation factors individually and simultaneously on the quality of the 
ODTs, which led to a statistical model and three dimensional plots that described adequately 
the relationship between the dependent and independent variables.  
Optimisation results showed that a concentration of 40% w/w alanine achieved the required 
balance between the thermal properties, disintegration time and mechanical strength. 
Whereas, the optimised level of the active drug was different in each case, which can be 
attributed to their differences in the physicochemical properties. 
The formulation of lyophilised ODTs based on gum arabic and alanine showed capability to 
deliver diverse range of drugs with advantages over commercial products in terms of providing 
faster, more efficient and reproducible dissolution profiles. Moreover, short term stability 
studies of the prepared lyophilised ODTs indicated no significant changes in appearance, 
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moisture content, disintegration time, drug content and mechanical properties, suggesting 
that the formulations were chemically and physically stable.  
 
8.2. Future directions 
The studies carried out in this thesis have introduced two platform technologies that showed 
excellent in-vitro potential to add significant advances to the field of lyophilised orally 
disintegrating tablets. Some extended work is underway to explore the clinical performance of 
these ODTs in terms of patient acceptance, manual handling, mouth feeling upon 
disintegration and other in vivo data such as sites of absorption, GIT residence time and blood 
level curve. In term of process development, determination the effect of the shape and size of 
the tablets on the freeze drying regime as well as ODT characteristics would be of interest.      
The studies carried out in this thesis reveal that further advances in the development of 
lyophilised ODTs can be achieved by exploring new materials, innovative formulation 
processes and novel applications. The future prospects of this dosage form would rely on:    
i. Development of a novel lyophilised ODT formulation with mechanical properties 
comparable to the conventional compressed tablet and accordingly avoids the need of 
specialised packaging. This is a challenging task because of the highly porous nature of 
the lyophilised ODTs which compromises the mechanical properties.  
ii. Employment of excipients coprocessing technology to create multifunctional 
excipients that combined the benefits of the incorporated excipients and minimize 
their drawbacks (Saha & Shahiwala, 2009). Basically, the coprocessed excipients should 
dissolve quickly in water to allow easy formulation, possess high wettability in aqueous 
medium to allow fast disintegrating in the mouth and form elegant tablet with 
adequate mechanical strength in short freeze drying cycle. Other advantageous 
characteristics can be added such as suspending, bioadhesive and emulsifying 
properties.   
iii. Development of a new disintegration test method to assess the disintegration time, 
texture and taste of the ODTs which can simulate the disintegration nature in the oral 
cavity and provide reasonable in vitro in vivo correlation (IVIVC). Although several 
methods have been proposed using texture analyser (Abdelbary et al., 2005; El-Arini 
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and Clas, 2002) rotary shaft (Narazaki et al., 2004) or E-tongue (Murray et al., 2004), 
none of them has been officially recognized by the regulatory authorities. 
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Appendix I  
 
 
Figure: Preliminary experiments to study the viscosity of different solution of gelatine (3, 4 and 
5%) before and after the addition of 0.2, 0.5 and 0.8% carrageenan. The results show 
substantial increase in the solution viscosity after addition of small concentration of 
carrageenan as a result of their associative interaction. Addition of 0.2% carrageenan to for 5% 
gelatine solution increased the viscosity by more than 100 fold, from 1.5 ± 0.1 mPa.s for 5% 
gelatine alone to 165.8 ± 13.7 mPa.s upon addition of 0.2% carrageenan. Results are mean ± 
SD, n=3. 
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